[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3559227A1 - Protease variants and uses thereof - Google Patents

Protease variants and uses thereof

Info

Publication number
EP3559227A1
EP3559227A1 EP17832644.3A EP17832644A EP3559227A1 EP 3559227 A1 EP3559227 A1 EP 3559227A1 EP 17832644 A EP17832644 A EP 17832644A EP 3559227 A1 EP3559227 A1 EP 3559227A1
Authority
EP
European Patent Office
Prior art keywords
amino acid
variant
acid sequence
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17832644.3A
Other languages
German (de)
French (fr)
Inventor
Lilia Maria Babe
Lydia Dankmeyer
David A. Estell
Frits Goedegebuur
Thijs Kaper
Harm Mulder
Sina Pricelius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco US Inc filed Critical Danisco US Inc
Publication of EP3559227A1 publication Critical patent/EP3559227A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)

Definitions

  • Another embodiment is directed to one or more subtilisin variant comprising an amino acid sequence comprising one or more amino acid substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1C/H/K/L/T/Y, 38D/E/G/H/I/K/L/M/P, 40C/F/M, 48C/G/I/M/N/Q/T/W/Y, 58I/P, 76A/C/F/P, 87A/D, 87L/M/T, 89C/F/G/M/N/Q/S, 101E/H/N, 116E/F/H/I/N/S/V/W, 128F/M, 130C/G/H/M/N/P/R/S/T, and 248C/S; (ii) I S, 38D/E/N/P/V, 40A/C/D/E/I/M/P/R, 58S/V,
  • Another embodiment is directed to a method of cleaning a creme brulee stain comprising contacting a surface or an item in need of cleaning with an effective amount of one or more subtilisin variant or composition containing one or more subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1, 21, 38, 40, 48, 58, 76, 82, 87, 89, 101, 116, 128, 129, 130, and 248; (ii) 1C/D/E/F/H/I/K/L/M/N/P/R/S/T/VAV/Y, 21 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
  • Figure 1 provides a CLUSTALW alignment of the mature amino acid sequence of B. amyloliquefaciens subtilisin BPN' (SEQ ID NO: 17) with the mature amino acid sequences of: B. lentus subtilisin GG36 (SEQ ID NO: 1), B. licheniformis subtilisin AprL (SEQ ID NO: 15), B. gibsonii subtilisin Bgi02446 (SEQ ID NO: 11), and B. gibsonii subtilisin BgiDSM14391 (SEQ ID NO: 13).
  • protease refers to an enzyme that has the ability to break down proteins and peptides.
  • a protease has the ability to conduct “proteolysis,” by hydrolysis of peptide bonds that link amino acids together in a peptide or polypeptide chain forming the protein.
  • proteolytic activity This activity of a protease as a protein-digesting enzyme is referred to as "proteolytic activity.”
  • proteolytic activity may be ascertained by comparative assays that analyze the respective protease' s ability to hydrolyze a suitable substrate.
  • expression refers to the transcription and stable accumulation of sense (mRNA) or anti-sense RNA, derived from a nucleic acid molecule of the disclosure. Expression may also refer to translation of mRNA into a polypeptide. Thus, the term “expression” includes any step involved in the "production of the polypeptide” including, but not limited to, transcription, post-transcriptional modifications, translation, post-translational modifications, secretion and the like.
  • operably linked DNA sequences are contiguous. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers may be used in accordance with conventional practice.
  • Recombination and “recombining” of polynucleotides or nucleic acids refer generally to the assembly or combining of two or more nucleic acid or polynucleotide strands or fragments to generate a new polynucleotide or nucleic acid.
  • mature form of a protein, polypeptide, or peptide refers to the functional form of the protein, polypeptide, or peptide without the signal peptide sequence and propeptide sequence.
  • homologous proteins or “homologous proteases” refers to proteins that have distinct similarity in primary, secondary, and/or tertiary structure. Protein homology can refer to the similarity in linear amino acid sequence when proteins are aligned. Homology can be determined by amino acid sequence alignment, e.g., using a program such as BLAST, MUSCLE, or CLUSTAL. Homologous search of protein sequences can be done using BLASTP and PSI-BLAST from NCBI BLAST with threshold (E-value cut-off) at 0.001.
  • nucleic acids or polypeptides generally denotes a nucleic acid or polypeptide that is essentially free from other components as determined by analytical techniques well known in the art (e.g., a purified polypeptide or polynucleotide forms a discrete band in an electrophoretic gel, chromatographic eluate, and/or a media subjected to density gradient centrifugation).
  • a nucleic acid or polypeptide that gives rise to essentially one band in an electrophoretic gel is "purified.”
  • a purified nucleic acid or polypeptide is at least about 50% pure, usually at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5%, about 99.6%, about 99.7%, about 99.8%) or more pure (e.g., percent by weight on a molar basis).
  • tripolyphosphate Some embodiments are directed to cleaning compositions or detergent compositions that do not contain any phosphate (e.g., phosphate salt or phosphate builder).
  • any phosphate e.g., phosphate salt or phosphate builder.
  • subtilisin variant useful for cleaning applications and in methods of cleaning, as well as in a variety of industrial applications.
  • one or more isolated, recombinant, substantially pure, or non-naturally occurring subtilisin variant is disclosed herein.
  • one or more subtilisin variant described herein is useful in cleaning applications and can be incorporated into cleaning compositions that are useful in methods of cleaning an item or a surface in need thereof.
  • An even further embodiment is directed to one or more subtilisin variant described herein, wherein said variant comprises an amino acid sequence with (i) 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%), 99% or less than 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13; (ii) 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%), 99%) or less than 100%) amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13; (iii) 94%, 95%, 96%, 97%, 98%, 99%, or less than 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: l 1 or 13.
  • Described herein is one or more isolated, non-naturally occurring, or recombinant polynucleotide comprising a nucleic acid sequence that encodes one or more subtilisin variant described herein, or recombinant polypeptide or active fragment thereof.
  • One or more nucleic acid sequence described herein is useful in recombinant production (e.g., expression) of one or more subtilisin variant described herein, typically through expression of a plasmid expression vector comprising a sequence encoding the one or more subtilisin variant described herein or fragment thereof.
  • One embodiment provides nucleic acids encoding one or more subtilisin variant described herein, wherein the variant is a mature form having proteolytic activity.
  • a variety of methods are known in the art that are suitable for generating modified polynucleotides described herein that encode one or more subtilisin variant described herein, including, but not limited to, for example, site-saturation mutagenesis, scanning mutagenesis, insertional mutagenesis, deletion mutagenesis, random mutagenesis, site-directed mutagenesis, and directed-evolution, as well as various other recombinatorial approaches.
  • a polynucleotide construct encoding one or more subtilisin variant described herein is present on an integrating vector that enables the integration and optionally the amplification of the polynucleotide encoding the variant into the host chromosome. Examples of sites for integration are well known to those skilled in the art.
  • transcription of a polynucleotide encoding one or more subtilisin variant described herein is effectuated by a promoter that is the wild-type promoter for the parent subtilisin.
  • the promoter is heterologous to the one or more subtilisin variant described herein, but is functional in the host cell.
  • Methods known in the art to transform Bacillus cells include such methods as plasmid marker rescue transformation, which involves the uptake of a donor plasmid by competent cells carrying a partially homologous resident plasmid ⁇ See, Contente et al., Plasmid 2:555-571 (1979); Haima et al., Mol. Gen. Genet. 223 : 185-191 (1990); Weinrauch et al., J. Bacteriol. 154: 1077-1087 (1983); and Weinrauch et al., J. Bacteriol. 169: 1205-1211 (1987)).
  • the incoming donor plasmid recombines with the homologous region of the resident "helper" plasmid in a process that mimics chromosomal transformation.
  • a boron-free composition is a composition that contains less than 2.5% boron. In even further embodiments, a boron-free composition is a composition that contains less than 1.5% boron. In another embodiment, a boron-free composition is a composition that contains less than 1.0% boron. In still further embodiments, a boron-free composition is a composition that contains less than 0.5% boron. In other embodiments, the composition is a composition free or substantially-free of enzyme stabilizers or peptide inhibitors.
  • the composition described herein comprises one or more subtilisin variant described herein and one or more additional enzyme.
  • the one or more additional enzyme is selected from acyl transferases, alpha-amylases, beta-amylases, alpha- galactosidases, arabinosidases, aryl esterases, beta-galactosidases, carrageenases, catalases, cellobiohydrolases, cellulases, chondroitinases, cutinases, endo-beta-1, 4-glucanases, endo-beta- mannanases, esterases, exo-mannanases, galactanases, glucoamylases, hemicellulases, hyaluronidases, keratinases, laccases, lactases, ligninases, lipases, lipoxygenases, , mannanases, metalloproteases,
  • the acidifying particle can comprise any acid, including organic acids and mineral acids.
  • Organic acids can have one or two carboxyls and in some instances up to 15 carbons, especially up to 10 carbons, such as formic, acetic, propionic, capric, oxalic, succinic, adipic, maleic, fumaric, sebacic, malic, lactic, glycolic, tartaric and glyoxylic acids.
  • the acid is citric acid.
  • Mineral acids include hydrochloric and sulphuric acid.
  • the acidifying particle is a highly active particle comprising a high level of amino carboxylic builder. Sulphuric acid has also been found to further contribute to the stability of the final particle.
  • the cleaning composition is a liquid or gel detergent, which is not unit dosed, that may be aqueous, typically containing at least 20% and up to 95% water by weight, such as up to about 70% water by weight, up to about 65% water by weight, up to about 55% water by weight, up to about 45% water by weight, or up to about 35% water by weight.
  • aqueous liquid or gel detergent may contain from 0-30%) organic solvent.
  • a liquid or gel detergent may be non-aqueous.
  • the term "animal” includes all non-ruminant and ruminant animals.
  • the animal is a non-ruminant animal, such as a horse and a mono-gastric animal.
  • mono-gastric animals include, but are not limited to, pigs and swine, such as piglets, growing pigs, sows; poultry such as turkeys, ducks, chicken, broiler chicks, layers; fish such as salmon, trout, tilapia, catfish and carps; and crustaceans such as shrimps and prawns.
  • cereals such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS) (particularly corn based Distillers Dried Grain Solubles (cDDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola, fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; and e) minerals and vitamins.
  • DDGS Distillers Dried Grain Solubles
  • cDDGS corn based Distillers Dried Grain Solubles
  • sources such as so
  • the egg-yolk cleaning performance of the B. gibsonii-clade subtilisins and variants thereof is set forth in Table 4, expressed as PI values versus parent subtilisin.
  • the BMI cleaning performance of the B. gibsonii-clade subtilisins and variants thereof is set forth in Tables 5, expressed as PI values versus parent subtilisin.
  • the stability of the B. gibsonii-dadt subtilisins and variants thereof is set forth in Table 6, expressed as PI values versus parent subtilisin.
  • the PI values were calculated as described above in Example 2, where the parent of the Bgi02446 variants is the wild-type Bgi02446 subtilisin (SEQ ID NO: l 1), and the parent of the

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)

Abstract

Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability and/or soil removal compared to one or more reference subtilisin.

Description

PROTEASE VARIANTS AND USES THEREOF
[001] Disclosed herein is one or more subtilisin variant, nucleic acid encoding same, and compositions and methods related to the production and use thereof, including one or more subtilisin variant that has improved stability and/or soil removal compared to one or more reference subtilisin.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[002] The content of the sequence listing electronically submitted with the application as an ASCII text file (Name: NB41172WOPCT_ST25; Size: 26KB; Created: December 19, 2017) forms part of the application and is hereby incorporated herein by reference in its entirety.
[003] A protease (also known as a proteinase) is an enzyme protein that has the ability to break down other proteins. A protease has the ability to conduct proteolysis, which begins protein catabolism by hydrolysis of peptide bonds that link amino acids together in a peptide or polypeptide chain forming the protein. This activity of a protease as a protein-digesting enzyme is termed a proteolytic activity. Many well-known procedures exist for measuring proteolytic activity (Kalisz, "Microbial Proteinases," In: Fiechter (ed.), Advances in Biochemical
Engineering/Biotechnology, (1988)). For example, proteolytic activity may be ascertained by comparative assays which analyze the respective protease' s ability to hydrolyze a commercial substrate. Exemplary substrates useful in the analysis of protease or proteolytic activity, include, but are not limited to, di-methyl casein (Sigma C-9801), bovine collagen (Sigma C-9879), bovine elastin (Sigma E-1625), and bovine keratin (ICN Biomedical 902111). Colorimetric assays utilizing these substrates are well known in the art (see, e.g., WO 99/34011 and U.S. Pat. No. 6,376,450, both of which are incorporated herein by reference).
[004] Serine proteases are enzymes (EC No. 3.4.21) possessing an active site serine that initiates hydrolysis of peptide bonds of proteins. Serine proteases comprise a diverse class of enzymes having a wide range of specificities and biological functions that are further divided based on their structure into chymotrypsin-like (trypsin-like) and subtilisin-like. The
prototypical subtilisin (EC No. 3.4.21.62) was initially obtained from Bacillus subtilis.
Subtilisins and their homologues are members of the S8 peptidase family of the MEROPS classification scheme (Rawlings, N.D. et al (2016) Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 44, D343-D350).
Members of family S8 have a catalytic triad in the order Asp, His and Ser in their amino acid sequence. Although a number of useful variant proteases have been developed for cleaning applications, there remains a need for improved protease variants.
[005] One embodiment is directed to one or more subtilisin variant comprising an amino acid sequence comprising one or more amino acid substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1A/C/D/E/G/H/I/K/M/N/R/S/T/V, 9R, 15T, 21 A/ C/D/E/F/ G/H/K/L/M/N/P/ Q/R/ S/T/V/W / Y, 38A/C/D/E/F/G/H/I/L/M/N/P/Q/R/V, 40A/C/D/E/F/G/M/N/P/Q/R/T/Y, 48C/D/E/I/K/M/N/P/Q/R/S/T/V/Y,
58C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/VAV/Y, 76 A/C/D/E/F/G/H/I/K/L/M/Q/T/V/Y,
82 A/ C/E/F/ G/H/K/L/M/N/P/ Q/R/ S/T/W /Y, 87A/C/D/E/F/G/H/I/L/M/Q/T/V/W,
89A/C/D/F/G/H/L/M/N/P/Q/R/S/V/W, 99A D/G/S,
101A D/E/F/G/H/I/K/L/M/N/Q/S/T/VAV/Y, 1 16A/C/D/E/F/G/H/K/L/M/N/Q/R/S/V, 1 18D/R, 128A/D/E/H/I/L/M/N/Q/T/V/Y, 129C/E, 130A/C/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 163 S, 170S, 194P, 2051, 206C/L, 218D, 245R, 248A/C/E/F/G/H/I/K/L/M/Q/S/T/V/W/Y, and 255R; (ii) I S, 21E/F/G/M/N/P/Q/R/S/T, 38C/D/F/G/L/P, 40A/C/D/G/M/N, 48P/Q/T, 58C/D/F/M/Q/R, 76A/D/F/G/H/I/K/L/M/Q/T/V/Y, 82C/M/R/T/Y, 87D/Q, 89C/R, 101D/E/M, 1 16D/E/H/N/R, 128D/E/N/Q/V, 129C, 130D/E/G/V, and 248T; (iii) 1D/E/M/N/S,
21 A/ C/D/F/ G/L/M/N/P/ Q/R/S/V/W/ Y, 38A/D/F/G/L/M/N/P/Q/R, 40A/C/D/F/G/M/N/P/Q/R, 48K, 58L/M/P/Q/R/S/W/Y, 76A/D/F/K/M/Q, 82A/C/F/K/M/N/R/T/Y, 87A/C/D/E/F/G/H/M/Q, 89C/F/H/L/N/P/Q/R/S/V/W, 101M, 1 16A/C/D/E/F/H/M/N/R, 128A, 129E, 130G, and
248A/F/H/Q/T; (iv) 21F/M/N/P/Q/R/S, 38D/F/G/P, 40G/M, 58R, 76A/D/F, 82M/R, 89C/R, and 1 16H/N/R; (v) 1C/E/S/T/V, 21E/G/Q/S/T/V, 38C/D/E/G/H/I/L/V, 40A/C/D/E/G/N/Q/T/Y, 48C/D/E/I/N/P/Q/S/T/V/Y, 58C/D/E/F/G/I/K/M/Q/V, 76A/C/D/E/F/G/H/I/L/M/T/V/Y, 82C/E/ G/H/N/P/ Q/R/ S/T/W /Y, 87A C/D/I/L/M/Q/T/V/W, 89C,
101A/D/E/G/H/I/K/L/M/N/Q/S/T/V, 1 16C/D/E/G/H/N/V, 128D/E/H/L/M/N/Q/T/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V/Y, and 248A/C/E/G/Q/S/T/V; (vi) 21E/T, 38C/D/G/L, 40D/G, 48P/Q/T, 58D/F, 76D/G/H/I, 82T/Y, 87D/Q, 89C, 101D/E, 1 16D/E/H/N,
128D/E/N/Q/V, 129C, 130D/E/G/V, and 248T; (vii) lC/D/E/F/I/K/L/M/N/P/V/Y,
21 A I G/H/K/L/M/N/P/ S/T/V/W / Y, 38C/D/E/H/I/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/G/H/I/T/Y, 58A/C/D/E/F/G/H/I/K/M/S/V, 76A/C/D/E/G/H/I/K/L/M/P/S/T/VAV/Y, 82A/C/E/G/H/K/M/N/P/Q/R/S/T/W/Y, 87A/C/D/F/H/I/K/L/M/P/Q/T/V/W/Y, 89C/H/K/N/P/V, 101D/E/F/I/K/L/M/N/Q/T/V/Y, 1 16A/C/D/E/G/K/L/N/R/S/V, 128A/D/F/H/I/K/L/M/N/Q/T/V/W/Y, 129C, 130D/E/G/H/I/K/M/N/Q/S/T/W/Y, and 248A/E/G/L/Q/T/V; (viii) IK, 21K/M/T, 38D/V, 58G/K/V, 76C/I/K, 82G/M/P/S/T/Y, 87C, 89C, 116A/D, 128A/D/I/K/L/N/Q/V, 129C, and 130E/S/T; (ix) 1C/D/E/I/L/M/T/Y,
21 A/C/D/E/G/L/M/N/R/W/Y, 38 A/C/D/E/G/H/I/L/M/N/P/S/T/VAV/Y,
40A/C/D/E/G/I/K/L/M/T/V/W/Y, 48C/D/E/G/H/I/M/N/P/Q/S/T/V/Y,
58 A/C/D/E/G/I/K/L/M/N/P/Q/R/S/V/Y, 76 A/C/D/E/G/H/L/M/P/Q/S/T/V/Y,
82C/D/E/F/H/K/L/M/N/P/Q/S/T/V/Y, 87A/C/D/E/F/G/H/K/L/M/N/P/Q/S/TA^/W/Y,
89A/C/D/E/M/N/Y, 101 A/D/E/F/G/H/I/K/L m/Q/S/T/V/Y,
116A/C/D/E/G/H/I/K/L/M/N/Q/S/V/Y, 128A/D/K/N/Q/T/W/Y, 129C,
130C/D/E/G/H/I/K/L/M/N/P/Q/S/T/VAV/Y, and 248A/C/D/E/G/H/I/K/L/Q/S/T/V/Y; (x) IT, 21C/D/E/L, 38C/D/E/G/I/L/M/V, 40D/E/I/L/V, 48C/D/E/P/V/Y, 58C/D/G/I/K/V/Y,
76C/D/E/P/T/Y, 82S/T/V/Y, 87C/D/E/G/P, 89C, 101A/D/E/L/M/N/T/V, 116A/D/E/H/I/L/N/Y, 128D/T, 129C, 130/D/E/G/L/Q/S/T/V, and 248G/T; (xi) 1C/D/E, 21C/D/E/R,
38C/D/E/G/I/M/S/T, 40C/D/E/L, 48C/D/E/I/S/V/Y, 58A/C/D/E/K, 76A/C/D/E/T, 82E/S, 87C/D/E/N, 89C, 101A/D/E/G/H/I/L/M/N/Q/S/T/V, 116A/C/D/E, 128D/T/W/Y, 129C,
130C/D/E/G/H/I/K/L/N/S/T/V/W/Y, and 248C/D/E/G/H/I/K/L/Q/T/V/Y; (xii) 21D, 38C/D/E, 40D, 48E, 58C, 76D/E/T, 87C/D, 89C, 101D/E, 116D/E, and 130D/E/G; (xiii) 1C/H/K/L/S/T/Y, 38D/E/G/H/I/K/L/M/N/P/V, 40A/C/D/E/F/I/M/P/R, 48C/G/I/M/N/Q/T/W/Y, 58I/P/S/V, 76A/C/D/F/P/Q/S, 87A/C/D/L/M/T, 89C/F/G/M/N/Q/S, 101C/E/F/H/M/N/P/S/T,
116D/E/F/G/H/I/L/N/S/VAV/Y, 128F/I/M, 129C, 130C/D/E/G/H/M/N/P/Q/R/S/T/V, and 248C/D/G/L/S/W; (xiv) 38D/E/P, 40C/M, 76P, 89C/G/M, 101E/N, 116H/I, 128M, and 130G; (xv) 21E/L, 38C/D/E/G/H/V, 40D, 48C/E, 58K, 76A/C/D/E/G/T, 82S, 87C, 89C, 101D/e/M/N, 116A/C/D/E, 128K/T/W/Y, 130D/G/H/I/K/L/N/S/Y, and 248E/G/I/K/Q/T/Y; (xvi) 87C, 89C, 116A/D, and 130G; (xvii) 38D/E/G/H, 48C, 76A/C, 87C, 89C, 101D/E/N, 116D/E, 130G, 130H, 130N, 130S, and 248G; (xviii) 38D/E/G/I/M, 40C/D/E, 48C, 76A/C/D, 87C/D, 89C,
101E/M/N/S/T, 116D/E, 128T, 130C/D/E/G /H/N/S/T, and 248C; or (xix) combination of (i) to (xviii); wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
[006] Another embodiment is directed to one or more subtilisin variant comprising an amino acid sequence comprising one or more amino acid substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1C/H/K/L/T/Y, 38D/E/G/H/I/K/L/M/P, 40C/F/M, 48C/G/I/M/N/Q/T/W/Y, 58I/P, 76A/C/F/P, 87A/D, 87L/M/T, 89C/F/G/M/N/Q/S, 101E/H/N, 116E/F/H/I/N/S/V/W, 128F/M, 130C/G/H/M/N/P/R/S/T, and 248C/S; (ii) I S, 38D/E/N/P/V, 40A/C/D/E/I/M/P/R, 58S/V, 76D/P/Q/S, 87C, 89C/G/M, 101C/E/F/ /N/P/ST, 116D/G/H/I/L/Y, 128I/M, 130D/E/G/Q/V, and 248D/G/L/W; (iii) IK, 76D, 82L, 87D/E, 116E, 206C/L; (iv) 1C/E, 21E/T, 38C/D/G, 40C/D/G/N, 48D/E/I/P/S/T, 58C/D/F/G/I/K/Q/V, 76C/D/E/F/G/H/I/L/T/V/Y, 82G/H/N/P/Q/R/S/T/W/Y, 87C/D/L/Q/T/V, 89C, 101D/E, 116C/D/E/H/N, 128D/E/L/Q/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V, and 248A/E/Q/T/V; (v) 1 S/T/V, 21E/G/Q/S/T, 38C/D/E/G/I/L/V, 40D/E/G/T, 48P/T/V, 58C/D/E, 76D/G/H/I, 82 Y, 87D, 89C, 101A/D/E/G/H/I/K/L/M/N/Q/S/T/V, 116D/E/G/N,
128D/E/N/Q/T/V, 129C, 130D/E/G/V, and 248G/S/T; (vi) 1G/I, 15T, 21D/E/F/G/H/M/P/Q/S/Y, 48E/M, 58D/E/H/K/Q/W, 76D, 87C/D/E, 101E/G/M/N/Q, 116D/F/S, 128L, 130A/I/N/Q/S/T, 159S, 170S, 218D, and 248C/E/I/Q/S/T; (vii) 21E, 58D, 76D, 87D, 101E, 116D, and 248T; (viii) 1D/E/N/S, 21F/G/L/M/N/P/Q/R/SA^/W/Y, 38D/F/G/L/N/P/Q, 40D/G/M/Q, 58P/R,
76A/D/F/K/M, 82K/M/N/R/T/Y, 87A/C/D/F/G/H/M/Q, 89C/H/L/R/W, 101M,
116A/C/D/E/F/H/N/R, 128A, 129E, 130G, and 248A/F/H/Q/T; (ix) 1M,
21A/C/D/F/M/N/P/Q/R/S, 38A/D/F/G/M/P/R, 40A/C/F/G/M/N/P/R, 48K, 58L/M/Q/R/S, 58W, 58Y, 76 A, 76D, 76F, 76Q, 82 A, 82C, 82F, 82M, 82R, 87E, 89C, 89F, 89N, 89P, 89Q, 89/S/V, and 116H/M/N/R; (x) 1A/G/K/M/R, 9R, 21M/N/P, 48M/R, 58I/Q, 87A/C, 89A/H/M/N/Q/S/W, 101N, 116A/F/K/N/S, 128L, 130Q/R, 194P, 245R, 248Q, and 255R; (xi) 21M/N/P and 116N; (xii) 1C/D/E/F/I/K/L/M/N/V/Y, 21 A/E/ G/H/K/L/M/N/P/ S/T/V/W / Y, 38C/D/H/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/H/I/T/Y, 58C/F/G/I/K/M/V,
76A/C/D/E/G/I/K/L/M/P/T/V/W/Y, 82E/G/H/K/M/N/P/Q/R/S/TAV/Y,
87A/C/D/F/H/I/K/L/M/T/V/W/Y, 89C/H/N, 101D/E/F/I/K/L/M/N/Q/T/V/Y,
116A/C/D/E/G/K/L/N/R/S/V, 128A/D/I/K/L/M/N/Q/V/W, 129C,
130D/E/G/H/I/K/M/N/S/T/W/Y, and 248A/E/L/Q/TV; (xiii) 1K/P, 21K/M/Q/T, 38D/E/I/V, 48G, 58A/D/E/G/H/K/S/V, 76C/H/I/K/S, 82A/C/G/M/P/S/T/Y, 87C/P/Q, 89C/K/P/V, 116A/D, 128A/D/F/H/I/K/L/N/Q/T/V/Y, 129C, 130E/Q/S/T, and 248 G; (xiv) 1A/HZK/MZR/V, 15T, 21D/G/H/K/L/M/T/W, 48K/M/V, 58E/I/N/P/S, 76D, 87C/D, 89G/N/W,
101E/F/I/K/L /N/Q/V/W/Y, 116D/K/L/N/Q/S, 128I/L/T, 129E,
130A/H/I/K/L/N/Q/R/S/T/V/Y, 248K/M, 159S, and 218D; (xv) IK, 21K/M/T, 87C, 116D, 128I/L, and 130S/T; (xvi) 1T/Y, 21C/D/E/L/R, 38C/D/E/G/H/I/L/M/S/T/V/W, 40D/E/I/K/L/T/V/W, 48C/D/E/M/N/P/Q/V/Y, 58A/C/D/G/I/K/M/N/P/Q/R/S/V/Y, 76A/C/D/E/L/M/P/T/V/Y, 82C/D/E/K/M/N/P/Q/S/T/V/Y,
87A/C/D/E/F/G/H/K/L/M/P/S/T/V/W/Y, 89A/C/D/M/N/Y, 101A/D/E/L/M/N/T/V/Y,
116A/C/D/E/H/I/K/L/N/S/V/Y, 128D/K/T/W/Y, 129C, 130C/D/E/G/H/I/K/L/N/P/Q/S/T/V/W/Y, and 248A/C/D/E/G/H/I/K/L/Q/T/V/Y; (xvii) 1C/D/E/I/L/M/T, 21 A/C/D/E/ G/L/M/N/W / Y, 38A/C/D/E/G/I/L/M/N/P/V/Y, 40A/C/D/E/G/I/L/M/V/Y, 48C/D/E/G/H/I/P/S/T/V/Y,
58C/D/E/G/I/K/L/V/Y, 76C/D/E/G/H/P/Q/S/T/Y, 82F/H/L/S/T/V/Y, 87C/D/E/G/N/P/Q, 89C/E, lOlA/D/E/F/G/H/I/K/L/M/N/Q/S/T/V, 116A/D/E/G/H/I/L/M/N/Q/Y, 128A/D/N/Q/T, 129C, 130D/E/G/L/M/Q/S/T/V, and 248G/S/T; (xviii) 1M, 21A/C/D/E/H/M/N/P/Y, 48D/E/M/N/Q, 58C/D/E/I/K/M/N/Q/S, 76D, 82L, 87A/C/D/E/M/V, 89A/D/M/N, 101E/L/M/N,
116A/D/E/L/M/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, 170S, 2051, 206C/L, 218D, and 248C/E/G/H/I/L/S/T/V/W/Y; (xix) 21C/D/E, 48D/E, 58C/D/I/K, 76D, 87C/D/E,
101E/L/M/N, 116A/D/E/L/N, 130L/Q/S/T/V, and 248G/T; (xx) 1Y, 21E/L, 38C/D/H/L/V, 40D/I/T/V, 48E/Y, 58C/G/I/K/M/V, 76A/C/D/E/L/M/P/T/V/Y, 82E/K/M/N/P/Q/S/T/Y,
87A/C/D/F/H/K/L/M/T/V/W/Y, 89C/N, 101D/E/L/M/N/T/V/Y, 116A/C/D/E/K/L/N/S/V, 128D/K/W, 129C, 130D/E/G/H/I/K/N/S/T/W/Y, and 248A/E/L/Q/T/V; (xxi) 21M, 38D/E/I/V, 48G, 58D/E/G/K/V, 76C/H/S, 82S/T/Y, 87C/P/Q, 89C, 116A/D, 128A/D/N/Q/T, 129C,
130E/Q/S/T, and 248G; (xxii) 1M, 21D/H/M, 48M, 58E/I/N/S, 76D, 87C/D, 89N, 101E/L/M/N, 116D/L/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, and 218D; (xxiii) 87C, 116D, and 130S/T; (xxiii) 1Y, 38D/H/L, 48Y, 581, 76A/C/P, 87A/D/L/M/T, 89C/N, 101E/N, 116E/N/S/V, and 130G/H/N/S/T; (xxv) 38D/E/V, 58V, 76S, 87C, 89C, 116D, 130E/Q, and 248G; (xxvi) 76D and 87D; (xxvii) 1T/Y, 38D/E/G/H/I/L/M, 48C/M/N/Q/Y, 58I/P, 76A/C/P, 87A/D/L/M/T, 89C/M/N, 101E/N, 116E/H/I/N/S/V, 130C/G/H/N/P/S/T, and 248C; (xxviii) 38D/E/N/P/V, 40A/C/D/E/I/M, 58V, 76D/P/Q/S, 87C, 89C, 101E/F/M/N/S/T, 116D/G/H/I/L/Y,
130D/E/G/Q/V, and 248G; or (xxix) 76D, 82L, 87D/E, 116E, and 206C/L, where the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
[007] Another embodiment is directed to a method of cleaning a creme brulee stain comprising contacting a surface or an item in need of cleaning with an effective amount of one or more subtilisin variant or composition containing one or more subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1, 21, 38, 40, 48, 58, 76, 82, 87, 89, 101, 116, 128, 129, 130, and 248; (ii) 1C/D/E/F/H/I/K/L/M/N/P/R/S/T/VAV/Y, 21 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
38 A/C/D/E/F/G/H/I/L/M/N/P/Q/R/S/T/V/W/Y, 40A/C/D/E/F/G/H/I/K/L/M/N/Q/R/S/T/VAV/Y, 48C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 58 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y, 76A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
82A/C/D/E/F/H/I/K/L/M/N/P/Q/R/S/T/V/W/Y,
87A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
89A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/T/VAV/Y, 101 A/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 116A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/V/Y, 128A/C/D/E/F/H/I/K/L/M/N/Q/S/T/VAV/Y, 129 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
130A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y, and
248A/C/D/E/F/G/H/I/K/L/M/P/Q/R/S/T/VAV/Y; (iii) II/M/N/T/Y, 21A/C/D/E/L/M/N/R/W/Y, 38 A/C/D/E/G/H/I/L/M/N/P/Q/V/W/Y, 40A/D/G/H/I/K/L/S/T/V/Y,
48C/D/E/F/G/I/M/N/P/Q/V/Y, 58 A/C/D/G/I/K/M/Q/S/V/Y,
76C/D/E/F/G/H/L/M/P/Q/S/T/V/W/Y, 82F/K/M/T/V/Y, 87C/D/E/F/ G/H/L/M/N/P/ Q/T/V/W / Y, 89A/C/D/M/N, 101A/D/E/F/G/L/M/N/Q/T/V, 116A/C/D/E/G/H/I/K/L/M/N/Q/Y, 128D/N/T, 129C/M, 130A/D/E/G/K/L/M/N/P/Q/T/V, and 248G/T; (iv) IT, 21A/C/M/N/W,
38A/H/I/L/M/V/Y, 40D/I/L/V, 48C/D/E/M/V/Y, 58C/D/G/K/V, 76C/E/M/Q/S/T/V/Y, 82K/Y, 87C/D/E/M/N/P, 89C, 101A/D/E/M/N/T, 116A/C/D/I/M/N/Q, 128T, 129C, and 130G/L; (vi) 38I/L/V, 401, 48V, 76T, 89C, 101 A/N, and 130G; or (vii) combinations of (i) to (vi); wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17. A still further embodiment is directed to a method of cleaning a creme brulee stain comprising contacting a surface or an item in need of cleaning with an effective amount of one or more subtilisin variant or composition containing one or more subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1C/D/E/F/K/H/T/V/W, 21C/D/E/F/H/K/R, 38C/D/E/F/G/H/I/M/N/P/R/S/T,
40C/D/E/F/G/H/I/K/L/R/S, 48C/D/E/I/M/R/S/V/Y, 58A/C/D/E/K,
76A/C/D/E/F/G/K/M/N/R/T/W, 82E/K/M/R/S, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V,
89A/C/D/F/K/M/N/P/Q/R, 101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 116A/C/D/E/F/M/N/P/Q/R, 128A/D/H/N/Q/S/T/W/Y, 129C/D/E/G/M/Q/R, 130C/D/E/G/H/I/K/L m/P/R/S/T/V/W/Y, and 248C/D/E/G/H/I/K/L/Q/T/V/Y; (ii) 21, 38, 40, 48, 76, 87, 89, 101, 116, 128, 129, and 130; (iii) 21C/D/E/F/H/K/R, 38C/D/E/F/G/H/I/M/N/P/R/S/T, 40C/D/E/F/G/H/I/K/L/R/S,
48C/D/E/I/M/R/S/V/Y, 76 A/C/D/E/F/ G/K/M/N/R/T/W, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V, 89A/C/D/F/K/M/N/P/Q/R, 101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 116A/C/D/E/F/M/N/P/Q/R, 128A/D/H/N/Q/S/T/W/Y, 129C/D/E/G/M/Q/R, and 130C/D/E/G/H/I/K/L/M/N/P/R/S/T/VAV/Y; (iv) 48, 76, 87, 89, 101, 116, and 130; (v) 48C/D/E/I/M/R/S/V/Y,
76A/C/D/E/F/G/K/M/N/R/T/W, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V,
89A/C/D/F/K/M/N/P/Q/R, 101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 116A/C/D/E/F/M/N/P/Q/R, and 130C/D/E/G/H/I/K/L/M/N/P/R/S/T/VAV/Y; (vi) 38E, 40D, 48E, 76C/E, 87C/D/M/N, 89C, 101D/E/M/N, 116C/D/E/M, and 130D/G; (vii) 76E, 89C, and 130G; (viii) IK, 38D/E/G/I/M/T, 40C/D/E, 48C/I, 58D, 76A/C/D/E, 87C/D/E/L/M/Q/R, 89A/C/K/M, 101A/D/E/K/M/N/Q/R/S/T, 116D/E/P, 128Q/S/T, 129C/D/E, 130C/D/E/G/H/N/R/S/T, and 248C/D/E/H; (ix) 38E, 89C, and 130G; or (x) combinations of (i) to (ix); wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
[008] Some further embodiments are directed to a composition comprising one or more subtilisin variant described herein. Further embodiments are directed to a method of cleaning comprising contacting a surface or an item in need of cleaning with an effective amount of one or more subtilisin variant described herein or one or more composition described herein. In yet a still further embodiment, one or more subtilisin variant described herein has an increase in creme brulee stain cleaning activity when compared to the creme brulee stain cleaning activity of a protease with the amino acid sequence of SEQ ID NO: 1, 11, 13, 15, 17 and/or Bgi02446-S39E. Bgi02446-S39E refers to a sequence of SEQ ID NO: 11, having an E at position 39. In yet another embodiment, one or more subtilisin variant described herein has an increase in egg yolk stain cleaning activity when compared to the egg yolk stain cleaning activity of a protease with the amino acid sequence of Bgi02446-S39E. In still another embodiment, one or more subtilisin variant described herein has an increase in BMI stain cleaning activity when compared to the BMI stain cleaning activity of a protease with the amino acid sequence of Bgi02446-S39E.
[009] Still other embodiments are directed to a method for producing a variant described herein, comprising stably transforming a host cell with an expression vector comprising a polynucleotide encoding one or more subtilisin variant described herein. Still further embodiments are directed to a polynucleotide comprising a nucleic acid sequence encoding one or more subtilisin variant described herein.
DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 provides a CLUSTALW alignment of the mature amino acid sequence of B. amyloliquefaciens subtilisin BPN' (SEQ ID NO: 17) with the mature amino acid sequences of: B. lentus subtilisin GG36 (SEQ ID NO: 1), B. licheniformis subtilisin AprL (SEQ ID NO: 15), B. gibsonii subtilisin Bgi02446 (SEQ ID NO: 11), and B. gibsonii subtilisin BgiDSM14391 (SEQ ID NO: 13).
[0011] Unless otherwise indicated herein, one or more subtilisin variant described herein can be made and used via conventional techniques commonly used in molecular biology, microbiology, protein purification, protein engineering, protein and DNA sequencing, recombinant DNA fields, and industrial enzyme use and development. Terms and abbreviations not defined should be accorded their ordinary meaning as used in the art. Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Any definitions provided herein are to be interpreted in the context of the specification as a whole. As used herein, the singular "a," "an" and "the" includes the plural unless the context clearly indicates otherwise. Unless otherwise indicated, nucleic acid sequences are written left to right in 5' to 3' orientation; and amino acid sequences are written left to right in amino to carboxy orientation. Each numerical range used herein includes every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.
[0012] As used herein in connection with a numerical value, the term "about" refers to a range of +/- 0.5 of the numerical value, unless the term is otherwise specifically defined in context. For instance, the phrase a "pH value of about 6" refers to pH values of from 5.5 to 6.5, unless the pH value is specifically defined otherwise.
[0013] The nomenclature of the amino acid substitutions of the one or more subtilisin variants described herein uses one or more of the following: position; positiomamino acid substitution(s); or starting amino acid(s):position:amino acid substitution(s). Reference to a "position" (i.e. 5, 8, 17, 22, etc) encompasses any starting amino acid that may be present at such position, and any substitution that may be present at such position. Reference to a "position: amino acid substitution(s)" (i.e. 1 S/T/G, 3G, 17T, etc) encompasses any starting amino acid that may be present at such position and the one or more amino acid(s) with which such starting amino acid may be substituted. Reference to a position can be recited several forms, for example, position 003 can also be referred to as position 3. Reference to a starting or substituted amino acid may be further expressed as several starting, or substituted amino acids separated by a foreslash ("/"). For example, D275S/K indicates position 275 is substituted with serine (S) or lysine (K) and P/S197K indicates that starting amino acid proline (P) or serine (S) at position 197 is substituted with lysine (K). Reference to an X as the amino acid in a position, refers to any amino acid at the recited position.
[0014] The position of an amino acid residue in a given amino acid sequence is numbered by correspondence with the amino acid sequence of SEQ ID NO: 17. That is, the amino acid sequence of BPN' shown in SEQ ID NO: 17 serves as a reference sequence. For example, the amino acid sequence of one or more subtilisin variant described herein is aligned with the amino acid sequence of SEQ ID NO: 17 in accordance with Figure 1 using an alignment algorithm as described herein, and each amino acid residue in the given amino acid sequence that aligns (preferably optimally aligns) with an amino acid residue in SEQ ID NO: 17 is conveniently numbered by reference to the numerical position of that corresponding amino acid residue.
Sequence alignment algorithms, such as, for example, described herein will identify the location where insertions or deletions occur in a subject sequence when compared to a query sequence.
[0015] The terms "protease" and "proteinase" refer to an enzyme that has the ability to break down proteins and peptides. A protease has the ability to conduct "proteolysis," by hydrolysis of peptide bonds that link amino acids together in a peptide or polypeptide chain forming the protein. This activity of a protease as a protein-digesting enzyme is referred to as "proteolytic activity." Many well-known procedures exist for measuring proteolytic activity. For example, proteolytic activity may be ascertained by comparative assays that analyze the respective protease' s ability to hydrolyze a suitable substrate. Exemplary substrates useful in the analysis of protease or proteolytic activity, include, but are not limited to, di-methyl casein (Sigma C- 9801), bovine collagen (Sigma C-9879), bovine elastin (Sigma E-1625), and bovine keratin (ICN Biomedical 902111). Colorimetric assays utilizing these substrates are well known in the art (See e.g., WO99/34011 and US 6,376,450). The pNA peptidyl assay (See e.g., Del Mar et al., Anal Biochem, 99:316-320, 1979) also finds use in determining the active enzyme concentration. This assay measures the rate at which p-nitroaniline is released as the enzyme hydrolyzes a soluble synthetic substrate, such as succinyl-alanine-alanine-proline-phenylalanine-p-nitroanilide (suc-AAPF-pNA). The rate of production of yellow color from the hydrolysis reaction is measured at 410 nm on a spectrophotometer and is proportional to the active enzyme
concentration. In addition, absorbance measurements at 280 nanometers (nm) can be used to determine the total protein concentration in a sample of purified protein. The activity on substrate divided by protein concentration gives the enzyme specific activity.
[0016] The phrase "composition(s) substantially-free of boron" or "detergent(s)
substantially-free of boron" refers to composition(s) or detergent(s), respectively, that contain trace amounts of boron, for example, less than about 1000 ppm (lmg/kg or liter equals 1 ppm), less than about 100 ppm, less than about 50 ppm, less than about 10 ppm, or less than about 5 ppm, or less than about 1 ppm, perhaps from other compositions or detergent constituents.
[0017] As used herein, "the genus Bacillus" includes all species within the genus "Bacillus," as known to those of skill in the art, including but not limited to B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. gibsonii, and B. thuringiensis. It is recognized that the genus Bacillus continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as B. stearothermophilus, which is now named "Geobacillus
stearothermophilus", or B. polymyxa, which is now "Paenibacillus polymyxa" . The production of resistant endospores under stressful environmental conditions is considered the defining feature of the genus Bacillus, although this characteristic also applies to the recently named Alicyclobacillus, Amphibacillus, Aneurinibacillus, Anoxybacillus, Brevibacillus, Filobacillus, Gracilibacillus, Halobacillus, Paenibacillus, Salibacillus, Thermobacillus, Ureibacillus, and Virgibacillus.
[0018] The term "vector" refers to a nucleic acid construct used to introduce or transfer nucleic acid(s) into a target cell or tissue. A vector is typically used to introduce foreign DNA into a cell or tissue. Vectors include plasmids, cloning vectors, bacteriophages, viruses (e.g., viral vector), cosmids, expression vectors, shuttle vectors, and the like. A vector typically includes an origin of replication, a multicloning site, and a selectable marker. The process of inserting a vector into a target cell is typically referred to as transformation. The present invention includes, in some embodiments, a vector that comprises a DNA sequence encoding a serine protease polypeptide (e.g., precursor or mature serine protease polypeptide) that is operably linked to a suitable prosequence (e.g., secretory, signal peptide sequence, etc.) capable of effecting the expression of the DNA sequence in a suitable host, and the folding and translocation of the recombinant polypeptide chain.
[0019] As used herein in the context of introducing a nucleic acid sequence into a cell, the term "introduced" refers to any method suitable for transferring the nucleic acid sequence into the cell. Such methods for introduction include but are not limited to protoplast fusion, transfection, transformation, electroporation, conjugation, and transduction. Transformation refers to the genetic alteration of a cell which results from the uptake, optional genomic incorporation, and expression of genetic material (e.g., DNA).
[0020] The term "expression" refers to the transcription and stable accumulation of sense (mRNA) or anti-sense RNA, derived from a nucleic acid molecule of the disclosure. Expression may also refer to translation of mRNA into a polypeptide. Thus, the term "expression" includes any step involved in the "production of the polypeptide" including, but not limited to, transcription, post-transcriptional modifications, translation, post-translational modifications, secretion and the like.
[0021] The phrases "expression cassette" or "expression vector" refers to a nucleic acid construct or vector generated recombinantly or synthetically for the expression of a nucleic acid of interest (e.g., a foreign nucleic acid or transgene) in a target cell. The nucleic acid of interest typically expresses a protein of interest. An expression vector or expression cassette typically comprises a promoter nucleotide sequence that drives or promotes expression of the foreign nucleic acid. The expression vector or cassette also typically includes other specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell. A recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Some expression vectors have the ability to incorporate and express heterologous DNA fragments in a host cell or genome of the host cell. Many prokaryotic and eukaryotic expression vectors are commercially available. Selection of appropriate expression vectors for expression of a protein from a nucleic acid sequence incorporated into the expression vector is within the knowledge of those of skill in the art.
[0022] As used herein, a nucleic acid is "operably linked" with another nucleic acid sequence when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a nucleotide coding sequence if the promoter affects the transcription of the coding sequence. A ribosome binding site may be operably linked to a coding sequence if it is positioned so as to facilitate translation of the coding sequence.
Typically, "operably linked" DNA sequences are contiguous. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers may be used in accordance with conventional practice.
[0023] The term "gene" refers to a polynucleotide (e.g., a DNA segment), that encodes a polypeptide and includes regions preceding and following the coding regions. In some instances a gene includes intervening sequences (introns) between individual coding segments (exons).
[0024] The term "recombinant", when used with reference to a cell typically indicates that the cell has been modified by the introduction of a foreign nucleic acid sequence or that the cell is derived from a cell so modified. For example, a recombinant cell may comprise a gene not found in identical form within the native (non-recombinant) form of the cell, or a recombinant cell may comprise a native gene (found in the native form of the cell) that has been modified and re-introduced into the cell. A recombinant cell may comprise a nucleic acid endogenous to the cell that has been modified without removing the nucleic acid from the cell; such modifications include those obtained by gene replacement, site-specific mutation, and related techniques known to those of ordinary skill in the art. Recombinant DNA technology includes techniques for the production of recombinant DNA in vitro and transfer of the recombinant DNA into cells where it may be expressed or propagated, thereby producing a recombinant polypeptide.
"Recombination" and "recombining" of polynucleotides or nucleic acids refer generally to the assembly or combining of two or more nucleic acid or polynucleotide strands or fragments to generate a new polynucleotide or nucleic acid.
[0025] A nucleic acid or polynucleotide is said to "encode" a polypeptide if, in its native state or when manipulated by methods known to those of skill in the art, it can be transcribed and/or translated to produce the polypeptide or a fragment thereof. The anti-sense strand of such a nucleic acid is also said to encode the sequence.
[0026] The terms "host strain" and "host cell" refer to a suitable host for an expression vector comprising a DNA sequence of interest.
[0027] A "protein" or "polypeptide" comprises a polymeric sequence of amino acid residues. The terms "protein" and "polypeptide" are used interchangeably herein. The single and 3 -letter code for amino acids as defined in conformity with the IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) is used throughout this disclosure. The single letter X refers to any of the twenty amino acids. It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code.
[0028] The terms "prosequence" or "propeptide sequence" refer to an amino acid sequence between the signal peptide sequence and mature protease sequence that is necessary for the proper folding and secretion of the protease; they are sometimes referred to as intramolecular chaperones. Cleavage of the prosequence or propeptide sequence results in a mature active protease. Bacterial serine proteases are often expressed as pro-enzymes. Examples of modified propeptides are provided, for example, in WO 2016/205710.
[0029] The terms "signal sequence" and "signal peptide" refer to a sequence of amino acid residues that may participate in the secretion or direct transport of the mature or precursor form of a protein. The signal sequence is typically located N-terminal to the precursor or mature protein sequence. The signal sequence may be endogenous or exogenous. A signal sequence is normally absent from the mature protein. A signal sequence is typically cleaved from the protein by a signal peptidase after the protein is transported.
[0030] The term "mature" form of a protein, polypeptide, or peptide refers to the functional form of the protein, polypeptide, or peptide without the signal peptide sequence and propeptide sequence.
[0031] The term "precursor" form of a protein or peptide refers to a mature form of the protein having a prosequence operably linked to the amino or carbonyl terminus of the protein. The precursor may also have a "signal" sequence operably linked to the amino terminus of the prosequence. The precursor may also have additional polypeptides that are involved in post- translational activity (e.g., polypeptides cleaved therefrom to leave the mature form of a protein or peptide).
[0032] The terms "wild-type" or "parent", with respect to a polypeptide, refer to a naturally- occurring polypeptide that does not include a man-made substitution, insertion, or deletion at one or more amino acid positions. Similarly, the terms "wild-type" or "parent," with respect to a polynucleotide, refer to a naturally-occurring polynucleotide that does not include a man-made substitution, insertion, or deletion at one or more nucleosides. A polynucleotide encoding a wild-type or parental polypeptide is, however, not limited to a naturally-occurring
polynucleotide, and encompasses any polynucleotide encoding the wild-type or parental polypeptide.
[0033] The term "naturally-occurring" refers to, for example, a sequence and residues contained therein (e.g., polypeptide sequence and amino acids contained therein or nucleic acid sequence and nucleic acids contained therein) that are found in nature. Conversely, the term "non-naturally occurring" refers to, for example, a sequence and residues contained therein (e.g., polypeptide sequences and amino acids contained therein or nucleic acid sequence and nucleic acids contained therein) that are not found in nature.
[0034] As used herein with regard to amino acid residue positions, "corresponding to" or "corresponds to" or "corresponds" refers to an amino acid residue at the enumerated position in a protein or peptide, or an amino acid residue that is analogous, homologous, or equivalent to an enumerated residue in a protein or peptide. As used herein, "corresponding region" generally refers to an analogous position in a related protein or a reference protein.
[0035] The terms "derived from" and "obtained from" refer to not only a protein produced or producible by a strain of the organism in question, but also a protein encoded by a DNA sequence isolated from such strain and produced in a host organism containing such DNA sequence. Additionally, the term refers to a protein which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the protein in question. To exemplify, "proteases derived from Bacillus" refers to those enzymes having proteolytic activity that are naturally produced by Bacillus, as well as to serine proteases like those produced by Bacillus sources but which through the use of genetic engineering techniques are produced by other host cells transformed with a nucleic acid encoding the serine proteases.
[0036] The term "identical" in the context of two polynucleotide or polypeptide sequences refers to the nucleic acids or amino acids in the two sequences that are the same when aligned for maximum correspondence, as measured using sequence comparison or analysis algorithms described below and known in the art.
[0037] The phrases "% identity" or percent identity" or "PID" refers to protein sequence identity. Percent identity may be determined using standard techniques known in the art. The percent amino acid identity shared by sequences of interest can be determined by aligning the sequences to directly compare the sequence information, e.g., by using a program such as BLAST, MUSCLE, or CLUSTAL. The BLAST algorithm is described, for example, in Altschul et al., J Mol Biol, 215:403-410 (1990) and Karlin et al., Proc Natl Acad Sci USA, 90:5873-5787 (1993). A percent (%) amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "reference" sequence including any gaps created by the program for optimal/maximum alignment. BLAST algorithms refer to the "reference" sequence as the "query" sequence.
[0038] As used herein, "homologous proteins" or "homologous proteases" refers to proteins that have distinct similarity in primary, secondary, and/or tertiary structure. Protein homology can refer to the similarity in linear amino acid sequence when proteins are aligned. Homology can be determined by amino acid sequence alignment, e.g., using a program such as BLAST, MUSCLE, or CLUSTAL. Homologous search of protein sequences can be done using BLASTP and PSI-BLAST from NCBI BLAST with threshold (E-value cut-off) at 0.001. (Altschul et al., "Gapped BLAST and PSI BLAST a new generation of protein database search programs", Nucleic Acids Res, Set 1;25(17):3389-402(1997)). The BLAST program uses several search parameters, most of which are set to the default values. The NCBI BLAST algorithm finds the most relevant sequences in terms of biological similarity but is not recommended for query sequences of less than 20 residues (Altschul et al., Nucleic Acids Res, 25:3389-3402, 1997 and Schaffer et al., Nucleic Acids Res, 29:2994-3005, 2001). Exemplary default BLAST parameters for a nucleic acid sequence searches include: Neighboring words threshold=l 1; E-value cutoff=10; Scoring Matrix=NUC.3.1 (match=l, mismatch=-3);Gap Opening=5; and Gap Extension=2. Exemplary default BLAST parameters for amino acid sequence searches include: Word size = 3; E-value cutoff=10; Scoring Matrix=BLOSUM62; Gap Opening=l 1; and Gap extension=l . Using this information, protein sequences can be grouped and/or a phylogenetic tree built therefrom. Amino acid sequences can be entered in a program such as the Vector NTI Advance suite and a Guide Tree can be created using the Neighbor Joining (NT) method (Saitou and Nei, Mol Biol Evol, 4:406-425, 1987). The tree construction can be calculated using Kimura's correction for sequence distance and ignoring positions with gaps. A program such as AlignX can display the calculated distance values in parenthesis following the molecule name displayed on the phylogenetic tree.
[0039] Understanding the homology between molecules can reveal the evolutionary history of the molecules as well as information about their function; if a newly sequenced protein is homologous to an already characterized protein, there is a strong indication of the new protein's biochemical function. The most fundamental relationship between two entities is homology; two molecules are said to be homologous if they have been derived from a common ancestor.
Homologous molecules, or homologs, can be divided into two classes, paralogs and orthologs. Paralogs are homologs that are present within one species. Paralogs often differ in their detailed biochemical functions. Orthologs are homologs that are present within different species and have very similar or identical functions. A protein superfamily is the largest grouping (clade) of proteins for which common ancestry can be inferred. Usually this common ancestry is based on sequence alignment and mechanistic similarity. Superfamilies typically contain several protein families which show sequence similarity within the family. The term "protein clan" is commonly used for protease superfamilies based on the MEROPS protease classification system. As used herein, the term "subtilisin" includes any member of the S8 serine protease family as described in MEROPS - The Peptidase Data base (Rawlings, N.D., et al (2016) Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 44, D343-D350).
[0040] The CLUSTAL W algorithm is another example of a sequence alignment algorithm (See, Thompson et al., Nucleic Acids Res, 22:4673-4680, 1994). Default parameters for the CLUSTAL W algorithm include: Gap opening penalty=10.0; Gap extension penalty=0.05;
Protein weight matrix=BLOSUM series; DNA weight matrix=IUB; Delay divergent sequences %=40; Gap separation distance=8; DNA transitions weight=0.50; List hydrophilic
residues=GPSNDQEKR; Use negative matrix=OFF; Toggle Residue specific penalties=ON; Toggle hydrophilic penalties=ON; and Toggle end gap separation penalty=OFF. In CLUSTAL algorithms, deletions occurring at either terminus are included. For example, a variant with a five amino acid deletion at either terminus (or within the polypeptide) of a polypeptide of 500 amino acids would have a percent sequence identity of 99% (495/500 identical residues x 100) relative to the "reference" polypeptide. Such a variant would be encompassed by a variant having "at least 99% sequence identity" to the polypeptide.
[0041] A nucleic acid or polynucleotide is "isolated" when it is at least partially or completely separated from other components, including but not limited to for example, other proteins, nucleic acids, cells, etc. Similarly, a polypeptide, protein or peptide is "isolated" when it is at least partially or completely separated from other components, including but not limited to for example, other proteins, nucleic acids, cells, etc. On a molar basis, an isolated species is more abundant than are other species in a composition. For example, an isolated species may comprise at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%), about 99%), or about 100% (on a molar basis) of all macromolecular species present.
Preferably, the species of interest is purified to essential homogeneity (i.e., contaminant species cannot be detected in the composition by conventional detection methods). Purity and homogeneity can be determined using a number of techniques well known in the art, such as agarose or polyacrylamide gel electrophoresis of a nucleic acid or a protein sample, respectively, followed by visualization upon staining. If desired, a high-resolution technique, such as high performance liquid chromatography (HPLC) or a similar means can be utilized for purification of the material.
[0042] The term "purified" as applied to nucleic acids or polypeptides generally denotes a nucleic acid or polypeptide that is essentially free from other components as determined by analytical techniques well known in the art (e.g., a purified polypeptide or polynucleotide forms a discrete band in an electrophoretic gel, chromatographic eluate, and/or a media subjected to density gradient centrifugation). For example, a nucleic acid or polypeptide that gives rise to essentially one band in an electrophoretic gel is "purified." A purified nucleic acid or polypeptide is at least about 50% pure, usually at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5%, about 99.6%, about 99.7%, about 99.8%) or more pure (e.g., percent by weight on a molar basis). In a related sense, a composition is enriched for a molecule when there is a substantial increase in the concentration of the molecule after application of a purification or enrichment technique. The term "enriched" refers to a compound, polypeptide, cell, nucleic acid, amino acid, or other specified material or component that is present in a composition at a relative or absolute concentration that is higher than a starting composition.
[0043] The term "cleaning activity" refers to a cleaning performance achieved by a serine protease polypeptide or reference subtilisin under conditions prevailing during the proteolytic, hydrolyzing, cleaning, or other process of the disclosure. In some embodiments, cleaning performance of a serine protease or reference subtilisin may be determined by using various assays for cleaning one or more enzyme sensitive stain on an item or surface (e.g., a stain resulting from food, grass, blood, ink, milk, oil, and/or egg protein). Cleaning performance of one or more subtilisin variant described herein or reference subtilisin can be determined by subjecting the stain on the item or surface to standard wash condition(s) and assessing the degree to which the stain is removed by using various chromatographic, spectrophotometric, or other quantitative methodologies. Exemplary cleaning assays and methods are known in the art and include, but are not limited to those described in WO99/34011 and US 6,605,458, as well as those cleaning assays and methods included in the Examples provided below.
[0044] The term "effective amount" of one or more subtilisin variant described herein or reference subtilisin refers to the amount of protease that achieves a desired level of enzymatic activity in a specific cleaning composition. Such effective amounts are readily ascertained by one of ordinary skill in the art and are based on many factors, such as the particular protease used, the cleaning application, the specific composition of the cleaning composition, and whether a liquid or dry (e.g., granular, tablet, bar) composition is required, etc.
[0045] The term "adjunct material" refers to any liquid, solid, or gaseous material included in cleaning composition other than one or more subtilisin variant described herein, or
recombinant polypeptide or active fragment thereof. In some embodiments, the cleaning compositions of the present disclosure include one or more cleaning adjunct materials. Each cleaning adjunct material is typically selected depending on the particular type and form of cleaning composition (e.g., liquid, granule, powder, bar, paste, spray, tablet, gel, foam, or other composition). Preferably, each cleaning adjunct material is compatible with the protease enzyme used in the composition.
[0046] Cleaning compositions and cleaning formulations include any composition that is suited for cleaning, bleaching, disinfecting, and/or sterilizing any object, item, and/or surface. Such compositions and formulations include, but are not limited to for example, liquid and/or solid compositions, including cleaning or detergent compositions (e.g., liquid, tablet, gel, bar, granule, and/or solid laundry cleaning or detergent compositions and fine fabric detergent compositions; hard surface cleaning compositions and formulations, such as for glass, wood, ceramic and metal counter tops and windows; carpet cleaners; oven cleaners; fabric fresheners; fabric softeners; and textile, laundry booster cleaning or detergent compositions, laundry additive cleaning compositions, and laundry pre-spotter cleaning compositions; dishwashing compositions, including hand or manual dishwashing compositions (e.g., "hand" or "manual" dishwashing detergents) and automatic dishwashing compositions (e.g., "automatic dishwashing detergents"). Single dosage unit forms also find use with the present invention, including but not limited to pills, tablets, gelcaps, or other single dosage units such as pre-measured powders or liquids.
[0047] Cleaning composition or cleaning formulations, as used herein, include, unless otherwise indicated, granular or powder-form all-purpose or heavy-duty washing agents, especially cleaning detergents; liquid, granular, gel, solid, tablet, paste, or unit dosage form all- purpose washing agents, especially the so-called heavy-duty liquid (HDL) detergent or heavy- duty dry (HDD) detergent types; liquid fine-fabric detergents; hand or manual dishwashing agents, including those of the high-foaming type; hand or manual dishwashing, automatic dishwashing, or dishware or tableware washing agents, including the various tablet, powder, solid, granular, liquid, gel, and rinse-aid types for household and institutional use; liquid cleaning and disinfecting agents, including antibacterial hand-wash types, cleaning bars, mouthwashes, denture cleaners, car shampoos, carpet shampoos, bathroom cleaners; hair shampoos and/or hair- rinses for humans and other animals; shower gels and foam baths and metal cleaners; as well as cleaning auxiliaries, such as bleach additives and "stain-stick" or pre-treat types. In some embodiments, granular compositions are in "compact" form; in some embodiments, liquid compositions are in a "concentrated" form.
[0048] The term "detergent composition" or "detergent formulation" is used in reference to a composition intended for use in a wash medium for the cleaning of soiled or dirty objects, including particular fabric and/or non-fabric objects or items. In some embodiments, the detergents of the disclosure comprise one or more subtilisin variant described herein and, in addition, one or more surfactants, transferase(s), hydrolytic enzymes, oxido reductases, builders (e.g., a builder salt), bleaching agents, bleach activators, bluing agents, fluorescent dyes, caking inhibitors, masking agents, enzyme stabilizers, calcium, enzyme activators, antioxidants, and/or solubilizers. In some instances, a builder salt is a mixture of a silicate salt and a phosphate salt, preferably with more silicate (e.g., sodium metasilicate) than phosphate (e.g., sodium
tripolyphosphate). Some embodiments are directed to cleaning compositions or detergent compositions that do not contain any phosphate (e.g., phosphate salt or phosphate builder).
[0049] The term "bleaching" refers to the treatment of a material (e.g., fabric, laundry, pulp, etc.) or surface for a sufficient length of time and/or under appropriate pH and/or temperature conditions to effect a brightening (i.e., whitening) and/or cleaning of the material. Examples of chemicals suitable for bleaching include, but are not limited to, for example, CIO2, H2O2, peracids, NO2, etc. Bleaching agents also include enzymatic bleaching agents such as perhydrolase and arylesterases. Another embodiment is directed to a composition comprising one or more subtilisin variant described herein, and one or more perhydrolase, such as, for example, is described in WO2005/056782, WO2007/106293, WO 2008/063400,
WO2008/106214, and WO2008/106215.
[0050] The term "wash performance" of a protease (e.g., one or more subtilisin variant described herein, or recombinant polypeptide or active fragment thereof) refers to the
contribution of one or more subtilisin variant described herein to washing that provides additional cleaning performance to the detergent as compared to the detergent without the addition of the one or more subtilisin variant described herein to the composition. Wash performance is compared under relevant washing conditions. In some test systems, other relevant factors, such as detergent composition, sud concentration, water hardness, washing mechanics, time, pH, and/or temperature, can be controlled in such a way that condition(s) typical for household application in a certain market segment (e.g., hand or manual dishwashing, automatic dishwashing, dishware cleaning, tableware cleaning, fabric cleaning, etc.) are imitated.
[0051] The phrase "relevant washing conditions" is used herein to indicate the conditions, particularly washing temperature, time, washing mechanics, sud concentration, type of detergent and water hardness, actually used in households in a hand dishwashing, automatic dishwashing, or laundry detergent market segment.
[0052] The term "disinfecting" refers to the removal of contaminants from the surfaces, as well as the inhibition or killing of microbes on the surfaces of items.
[0053] The term "compact" form of the cleaning compositions herein is best reflected by density and, in terms of composition, by the amount of inorganic filler salt. Inorganic filler salts are conventional ingredients of detergent compositions in powder form. In conventional detergent compositions, the filler salts are present in substantial amounts, typically about 17 to about 35% by weight of the total composition. In contrast, in compact compositions, the filler salt is present in amounts not exceeding about 15% of the total composition. In some
embodiments, the filler salt is present in amounts that do not exceed about 10%, or more preferably, about 5%, by weight of the composition. In some embodiments, the inorganic filler salts are selected from the alkali and alkaline-earth-metal salts of sulfates and chlorides. In some embodiments, the filler salt is sodium sulfate.
[0054] Disclosed herein is one or more subtilisin variant useful for cleaning applications and in methods of cleaning, as well as in a variety of industrial applications. Disclosed herein is one or more isolated, recombinant, substantially pure, or non-naturally occurring subtilisin variant. In some embodiments, one or more subtilisin variant described herein is useful in cleaning applications and can be incorporated into cleaning compositions that are useful in methods of cleaning an item or a surface in need thereof.
[0055] One embodiment is directed to one or more subtilisin variant comprising an amino acid sequence comprising one or more amino acid substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1A/C/D/E/G/H/I/K/M/N/R/S/T/V, 9R, 15T, 21 A/ C/D/E/F/ G/H/K/L/M/N/P/ Q/R/ S/T/V/W / Y, 38A/C/D/E/F/G/H/I/L/M/N/P/Q/R/V, 40A/C/D/E/F/G/M/N/P/Q/R/T/Y, 48C/D/E/I/K/M/N/P/Q/R/S/T/V/Y,
58C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/VAV/Y, 76 A/C/D/E/F/G/H/I/K/L/M/Q/T/V/Y,
82 A/ C/E/F/ G/H/K/L/M/N/P/ Q/R/ S/T/W /Y, 87A/C/D/E/F/G/H/I/L/M/Q/T/V/W,
89A/C/D/F/G/H/L/M/N/P/Q/R/S/V/W, 99A/D/G/S,
101A D/E/F/G/H/I/K/L/M/N/Q/S/T/VAV/Y, 116A/C/D/E/F/G/H/K/L/M/N/Q/R/S/V, 118D/R, 128A/D/E/H/I/L/M/N/Q/T/V/Y, 129C/E, 130A/C/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 163S, 170S, 194P, 2051, 206C/L, 218D, 245R, 248A/C/E/F/G/H/I/K/L/M/Q/S/T/V/W/Y, and 255R; (ii) I S, 21E/F/G/M/N/P/Q/R/S/T, 38C/D/F/G/L/P, 40A/C/D/G/M/N, 48P/Q/T, 58C/D/F/M/Q/R, 76A/D/F/G/H/I/K/L/M/Q/T/V/Y, 82C/M/R/T/Y, 87D/Q, 89C/R, 101D/E/M, 116D/E/H/N/R, 128D/E/N/Q/V, 129C, 130D/E/G/V, and 248T; (iii) 1D/E/M/N/S,
21 A/ C/D/F/ G/L/M/N/P/ Q/R/S/V/W/ Y, 38A/D/F/G/L/M/N/P/Q/R, 40A/C/D/F/G/M/N/P/Q/R, 48K, 58L/M/P/Q/R/S/W/Y, 76A/D/F/K/M/Q, 82A/C/F/K/M/N/R/T/Y, 87A/C/D/E/F/G/H/M/Q, 89C/F/H/L/N/P/Q/R/S/V/W, 101M, 116A/C/D/E/F/H/M/N/R, 128A, 129E, 130G, and
248A/F/H/Q/T; (iv) 21F/M/N/P/Q/R/S, 38D/F/G/P, 40G/M, 58R, 76A/D/F, 82M/R, 89C/R, and 116H/N/R; (v) 1C/E/S/T/V, 21E/G/Q/S/T/V, 38C/D/E/G/H/I/L/V, 40A/C/D/E/G/N/Q/T/Y, 48C/D/E/I/N/P/Q/S/T/V/Y, 58C/D/E/F/G/I/K/M/Q/V, 76A/C/D/E/F/G/H/I/L/M/T/V/Y, 82C/E/ G/H/N/P/ Q/R/ S/T/W /Y, 87A C/D/I/L/M/Q/T/V/W, 89C,
101A/D/E/G/H/I/K/L/M/N/Q/S/T/V, 116C/D/E/G/H/N/V, 128D/E/H/L/M/N/Q/T/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V/Y, and 248A/C/E/G/Q/S/T/V; (vi) 21E/T, 38C/D/G/L, 40D/G, 48P/Q/T, 58D/F, 76D/G/H/I, 82T/Y, 87D/Q, 89C, 101D/E, 116D/E/H/N,
128D/E/N/Q/V, 129C, 130D/E/G/V, and 248T; (vii) 1C/D/E/F/I/K/L/M/N/P/V/Y,
21A/E/G/H/K/L/M/N/P/S/T/V/W/Y, 38C/D/E/H/I/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/G/H/I/T/Y, 58A/C/D/E/F/G/H/I/K/M/S/V, 76A/C/D/E/G/H/I/K/L/M/P/S/T/VAV/Y, 82A/C/E/G/H/K/M/N/P/Q/R/S/T/W/Y, 87A/C/D/F/H/I/K/L /P/Q/T/V/W/Y, 89C/H/K/N/P/V, 101D/E/F/I/K/L/M/N/Q/T/V/Y, 116A/C/D/E/G/K/L/N/R/S/V,
128A/D/F/H/I/K/L/M/N/Q/TA^/W/Y, 129C, 130D/E/G/H/I/K/M/N/Q/S/T/W/Y, and
248A/E/G/L/Q/T/V; (viii) IK, 21K/M/T, 38D/V, 58G/K/V, 76C/I/K, 82G/M/P/S/T/Y, 87C, 89C, 116A/D, 128A/D/I/K/L/N/Q/V, 129C, and 130E/S/T; (ix) 1C/D/E/I/L/M/T/Y,
21 A/C/D/E/G/L/M/N/R/W/Y, 38 A/C/D/E/G/H/I/L/M/N/P/S/T/VAV/Y,
40A/C/D/E/G/I/K/L/M/T/V/W/Y, 48C/D/E/G/H/I/M/N/P/Q/S/T/V/Y,
58 A/C/D/E/G/I/K/L/M/N/P/Q/R/S/V/Y, 76 A/C/D/E/G/H/L/M/P/Q/S/T/V/Y,
82C/D/E/F/H/K/L/M/N/P/Q/S/T/V/Y, 87A/C/D/E/F/G/H/K/L/M/N/P/Q/S/TA^/W/Y,
89A/C/D/E/M/N/Y, 101 A/D/E/F/G/H/I/K/L m/Q/S/T/V/Y,
116A/C/D/E/G/H/I/K/L/M/N/Q/S/V/Y, 128A/D/K/N/Q/T/W/Y, 129C,
130C/D/E/G/H/I/K/L/M/N/P/Q/S/T/VAV/Y, and 248A/C/D/E/G/H/I/K/L/Q/S/T/V/Y; (x) IT, 21C/D/E/L, 38C/D/E/G/I/L/M/V, 40D/E/I/L/V, 48C/D/E/P/V/Y, 58C/D/G/I/K/V/Y,
76C/D/E/P/T/Y, 82S/T/V/Y, 87C/D/E/G/P, 89C, 101A/D/E/L/M/N/T/V, 116A/D/E/H/I/L/N/Y, 128D/T, 129C, 130/D/E/G/L/Q/S/T/V, and 248G/T; (xi) 1C/D/E, 21C/D/E/R,
38C/D/E/G/I/M/S/T, 40C/D/E/L, 48C/D/E/I/S/V/Y, 58A/C/D/E/K, 76A/C/D/E/T, 82E/S, 87C/D/E/N, 89C, 101A/D/E/G/H/I/L/M/N/Q/S/T/V, 116A/C/D/E, 128D/T/W/Y, 129C,
130C/D/E/G/H/I/K/L/N/S/T/V/W/Y, and 248C/D/E/G/H/I/K/L/Q/T/V/Y; (xii) 21D, 38C/D/E, 40D, 48E, 58C, 76D/E/T, 87C/D, 89C, 101D/E, 116D/E, and 130D/E/G; (xiii) 1C/H/K/L/S/T/Y, 38D/E/G/H/I/K/L/M/N/P/V, 40A/C/D/E/F/I/M/P/R, 48C/G/I/M/N/Q/T/W/Y, 58I/P/S/V, 76A/C/D/F/P/Q/S, 87A/C/D/L/M/T, 89C/F/G/M/N/Q/S, 101C/E/F/H/M/N/P/S/T,
116D/E/F/G/H/I/L/N/S/VAV/Y, 128F/I/M, 129C, 130C/D/E/G/H/M/N/P/Q/R/S/T/V, and
248C/D/G/L/S/W; (xiv) 38D/E/P, 40C/M, 76P, 89C/G/M, 101E/N, 116H/I, 128M, and 130G; (xv) 21E/L, 38C/D/E/G/H/V, 40D, 48C/E, 58K, 76A/C/D/E/G/T, 82S, 87C, 89C, 101D/e/M/N, 116A/C/D/E, 128K/T/W/Y, 130D/G/H/I/K/L/N/S/Y, and 248E/G/I/K/Q/T/Y; (xvi) 87C, 89C, 116A/D, and 130G; (xvii) 38D/E/G/H, 48C, 76A/C, 87C, 89C, 101D/E/N, 116D/E, 130G, 130H, 130N, 130S, and 248G; (xviii) 38D/E/G/I/M, 40C/D/E, 48C, 76A/C/D, 87C/D, 89C, 101E/M/N/S/T, 116D/E, 128T, 130C/D/E/G /H/N/S/T, and 248C; or (xix) combination of (i) to (xviii); wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
[0056] Another embodiment is directed to one or more subtilisin variant comprising an amino acid sequence comprising one or more amino acid substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1C/H/K/L/T/Y,
38D/E/G/H/I/K/L/M/P, 40C/F/M, 48C/G/I/M/N/Q/T/W/Y, 58I/P, 76A/C/F/P, 87A/D, 87L/M/T, 89C/F/G/M/N/Q/S, 101E/H/N, 116E/F/H/I/N/S/V/W, 128F/M, 130C/G/H/M/N/P/R/S/T, and 248C/S; (ii) I S, 38D/E/N/P/V, 40A/C/D/E/I/M/P/R, 58S/V, 76D/P/Q/S, 87C, 89C/G/M, 101C/E/F/ /N/P/ST, 116D/G/H/I/L/Y, 128I/M, 130D/E/G/Q/V, and 248D/G/L/W; (iii) IK, 76D, 82L, 87D/E, 116E, and 206C/L; (iv) 1C/E, 21E/T, 38C/D/G, 40C/D/G/N, 48D/E/I/P/S/T, 58C/D/F/G/I/K/Q/V, 76C/D/E/F/G/H/I/L/T/V/Y, 82G/H/N/P/Q/R/S/T/W/Y, 87C/D/L/Q/T/V, 89C, 101D/E, 116C/D/E/H/N, 128D/E/L/Q/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V, and 248A/E/Q/T/V; (v) 1 S/T/V, 21E/G/Q/S/T, 38C/D/E/G/I/L/V, 40D/E/G/T, 48P/T/V, 58C/D/E, 76D/G/H/I, 82 Y, 87D, 89C, 101A/D/E/G/H/I/K/L/M/N/Q/S/T/V, 116D/E/G/N,
128D/E/N/Q/T/V, 129C, 130D/E/G/V, and 248G/S/T; (vi) 1G/I, 15T, 21D/E/F/G/H/M/P/Q/S/Y, 48E/M, 58D/E/H/K/Q/W, 76D, 87C/D/E, 101E/G/M/N/Q, 116D/F/S, 128L, 130A/I/N/Q/S/T, 159S, 170S, 218D, and 248C/E/I/Q/S/T; (vii) 21E, 58D, 76D, 87D, 101E, 116D, and 248T; (viii) 1D/E/N/S, 21F/G/L/M/N/P/Q/R/S/V/W/Y, 38D/F/G/L/N/P/Q, 40D/G/M/Q, 58P/R,
76A/D/F/K/M, 82K/M/N/R/T/Y, 87A/C/D/F/G/H/M/Q, 89C/H/L/R/W, 101M,
116A/C/D/E/F/H/N/R, 128A, 129E, 130G, and 248A/F/H/Q/T; (ix) 1M,
21A/C/D/F/M/N/P/Q/R/S, 38A/D/F/G/M/P/R, 40A/C/F/G/M/N/P/R, 48K, 58L/M/Q/R/S, 58W, 58Y, 76 A, 76D, 76F, 76Q, 82 A, 82C, 82F, 82M, 82R, 87E, 89C, 89F, 89N, 89P, 89Q, 89/S/V, and 116H/M/N/R; (x) 1A/G/K/M/R, 9R, 21M/N/P, 48M/R, 58I/Q, 87A/C, 89A/H/M/N/Q/S/W, 101N, 116A/F/K/N/S, 128L, 130Q/R, 194P, 248Q, and 245R, and 255R; (xi) 21M/N/P and 116N; (xii) 1C/D/E/F/I/K/L/M/N/V/Y, 21A/E/G/H/K/L/M/N/P/S/T/VAV/Y,
38C/D/H/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/H/I/T/Y, 58C/F/G/I/K/M/V,
76A/C/D/E/G/I/K/L/M/P/T/V/W/Y, 82E/G/H/K/M/N/P/Q/R/S/TAV/Y,
87A/C/D/F/H/I/K/L/M/T/V/W/Y, 89C/H/N, 101D/E/F/I/K/L/M/N/Q/T/V/Y,
116A/C/D/E/G/K/L/N/R/S/V, 128A/D/I/K/L/M/N/Q/V/W, 129C, 130D/E/G/H/I/K/M/N/S/T/W/Y, and 248A/E/L/Q/TV; (xiii) 1K/P, 21K/M/Q/T, 38D/E/I/V, 48G, 58A/D/E/G/H/K/S/V, 76C/H/I/K/S, 82A/C/G/M/P/S/T/Y, 87C/P/Q, 89C/K/P/V, 116A/D, 128A/D/F/H/I/K/L/N/Q/T/V/Y, 129C, 130E/Q/S/T, and 248 G; (xiv) 1A/HZK/MZR/V, 15T, 21D/G/H/K/L/M/T/W, 48K/M/V, 58E/I/N/P/S, 76D, 87C/D, 89G/N/W,
101E/F/I/K/L/M/N/Q/V/W/Y, 116D/K/L/N/Q/S, 128I/L/T, 129E,
130A/H/I/K/L/N/Q/R/S/T/V/Y, 159S, 218D, and 248K/M; (xv) IK, 21K/M/T, 87C, 116D, 128I/L, and 130S/T; (xvi) 1T/Y, 21C/D/E/L/R, 38C/D/E/G/H/I/L/M/S/T/V/W,
40D/E/I/K/L/T/V/W, 48C/D/E/M/N/P/Q/V/Y, 58A/C/D/G/I/K/M/N/P/Q/R/S/V/Y,
76A/C/D/E/L/M/P/T/V/Y, 82C/D/E/K/M/N/P/Q/S/T/V/Y,
87A/C/D/E/F/G/H/K/L/M/P/S/T/V/W/Y, 89A/C/D/M/N/Y, 101A/D/E/L/M/N/T/V/Y,
116A/C/D/E/H/I/K/L/N/S/V/Y, 128D/K/T/W/Y, 129C, 130C/D/E/G/H/I/K/L/N/P/Q/S/T/V/W/Y, and 248A/C/D/E/G/H/I/K/L/Q/T/V/Y; (xvii) 1C/D/E/I/L/M/T, 21 A/C/D/E/ G/L/M/N/W / Y, 38A/C/D/E/G/I/L/M/N/P/V/Y, 40A/C/D/E/G/I/L/M/V/Y, 48C/D/E/G/H/I/P/S/T/V/Y,
58C/D/E/G/I/K/L/V/Y, 76C/D/E/G/H/P/Q/S/T/Y, 82F/H/L/S/T/V/Y, 87C/D/E/G/N/P/Q, 89C/E, lOlA/D/E/F/G/H/I/K/L/M/N/Q/S/T/V, 116A/D/E/G/H/I/L/M/N/Q/Y, 128A/D/N/Q/T, 129C, 130D/E/G/L/M/Q/S/T/V, and 248G/S/T; (xviii) 1M, 21A/C/D/E/H/M/N/P/Y, 48D/E/M/N/Q, 58C/D/E/I/K/M/N/Q/S, 76D, 82L, 87A/C/D/E/M/V, 89A/D/M/N, 101E/L/M/N,
116A/D/E/L/M/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, 170S, 2051, 206C/L, 218D, and 248C/E/G/H/I/L/S/T/V/W/Y; (xix) 21C/D/E, 48D/E, 58C/D/I/K, 76D, 87C/D/E,
101E/L/M/N, 116A/D/E/L/N, 130L/Q/S/T/V, and 248G/T; (xx) 1Y, 21E/L, 38C/D/H/L/V, 40D/I/T/V, 48E/Y, 58C/G/I/K/M/V, 76A/C/D/E/L/M/P/T/V/Y, 82E/K/M/N/P/Q/S/T/Y,
87A/C/D/F/H/K/L/M/T/V/W/Y, 89C/N, 101D/E/L/M/N/T/V/Y, 116A/C/D/E/K/L/N/S/V, 128D/K/W, 129C, 130D/E/G/H/I/K/N/S/T/W/Y, and 248A/E/L/Q/T/V; (xxi) 21M, 38D/E/I/V, 48G, 58D/E/G/K/V, 76C/H/S, 82S/T/Y, 87C/P/Q, 89C, 116A/D, 128A/D/N/Q/T, 129C,
130E/Q/S/T, and 248G; (xxii) 1M, 21D/H/M, 48M, 58E/I/N/S, 76D, 87C/D, 89N, 101E/L/M/N, 116D/L/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, and 218D; (xxiii) 87C, 116D, and 130S/T; (xxiii) 1Y, 38D/H/L, 48Y, 581, 76A/C/P, 87A/D/L/M/T, 89C/N, 101E/N, 116E/N/S/V, and 130G/H/N/S/T; (xxv) 38D/E/V, 58V, 76S, 87C, 89C, 116D, 130E/Q, and 248G; (xxvi) 76D and 87D; (xxvii) 1T/Y, 38D/E/G/H/I/L/M, 48C/M/N/Q/Y, 58I/P, 76A/C/P, 87A/D/L/M/T, 89C/M/N, 101E/N, 116E/H/I/N/S/V, 130C/G/H/N/P/S/T, and 248C; (xxviii) 38D/E/N/P/V, 40A/C/D/E/I/M, 58V, 76D/P/Q/S, 87C, 89C, 101E/F/M/N/S/T, 116D/G/H/I/L/Y, 130D/E/G/Q/V, and 248G; or (xxix) 76D, 82L, 87D/E, 116E, and 206C/L, where the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
[0057] In another embodiment, variants provided herein comprise one or more amino acids substitutions selected from the group consisting of the substitutions listed in Table 8 having a PI > 1.1 in one or more of the laundry, egg, or creme brulee assays, or having greater than 50% residual activity in EDTA.
[0058] In another embodiment, the one or more subtilisin variant provided herein comprises one or more additional substitutions, deletions, or insertions, or combinations thereof. In one example, the additional substitution that can be combined with the substitutions provided herein is selected from the group consisting of a variant having at least 90% identity with the amino acid sequence of SEQ ID NO: 11 and said variant comprising at least one substitution (using the SEQ ID NO: 17 numbering) selected from the group consisting of T3V, T9R, A15T, V68A, N76D, N99A/D/G/S, S101G/M, V104E/I, N118V/R, S128F, D129Q, F130A, G159S, Y167A, R170S, T194P, V205I, Q206C/E/I/K/T/V/W/L, Y209W, M217C, N218D, M222S/F, Q245R and T255R. In another example, the variant having one or more additional substitutions, is a variant having at least 90% identity with the amino acid sequence of SEQ ID NO: 1 and the variant comprising at least one additional substitution (using the SEQ ID NO: 17 numbering) selected from the group consisting of S3 V, S9R, A15T, V68A, N76D, S99A/D/E/G/N , S101G/M, S103A, V104E/I, G118V/R, S128F, P129Q, S130A, G159S, Y167A, R170S, A194P, V205I, Q206C/E/I/K/T/V/W/L, Y209W, L217C/M, N218D, M222S/F, Q245R and T255R.
[0059] Another embodiment is directed to one or more subtilisin variant described herein with the proviso that one or more substitutions is non-naturally occurring. Yet an even still further embodiment is directed to one or more subtilisin variant described herein wherein said variant (i) is a member of the B. gibsonii-clade; (ii) is isolated; (iii) has proteolytic activity; or (iv) comprises a combination of (i) to (iii). Still yet another embodiment is directed to one or more subtilisin variant described herein, wherein said variant is derived from a parent or reference polypeptide with (i) 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13; or (ii) 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13. In still another embodiment the parent comprises the amino acid sequence of SEQ ID NO: 11 or 13. An even further embodiment is directed to one or more subtilisin variant described herein, wherein said variant comprises an amino acid sequence with (i) 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%), 99% or less than 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13; (ii) 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%), 99%) or less than 100%) amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13; (iii) 94%, 95%, 96%, 97%, 98%, 99%, or less than 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: l 1 or 13.
[0060] In an even still further embodiment, one or more subtilisin variant described herein has one or more improved property when compared to a reference or parent subtilisin; wherein the improved property is selected from improved cleaning performance in detergents, improved stability; and combinations thereof. In another embodiment, parent subtilisin comprises an amino acid sequence of SEQ ID NO: 11 or 13. In yet another embodiment, the improved property is (i) improved cleaning performance in detergent, wherein said variant has a BMI, creme brulee and/or egg stain cleaning PI >1; and/or (ii) improved stability, wherein said variant has a stability PI > 1. In still yet another embodiment, the cleaning performance in detergent is measured in accordance with the cleaning performance in laundry (HDL) and ADW detergents assay of Example 1; and/or the stability is measured in accordance with the stability assay of Example 1.
[0061] The term "enhanced stability" or "improved stability" in the context of an oxidation, chelator, denaturant, surfactant, thermal and/or pH stable protease refers to a higher retained proteolytic activity over time as compared to a reference protease, for example, a wild-type protease or parent protease. Autolysis has been identified as one mode of subtilisin activity loss in liquid detergents. (Stoner et al, 2004 Protease autolysis in heavy-duty liquid detergent formulations: effects of thermodynamic stabilizers and protease inhibitors, Enzyme and
Microbial Technology 34: 114-125.).
[0062] The terms "thermally stable" and "thermostable" and "thermostability" with regard to a protease variant refers to a protease that retains a specified amount of enzymatic activity after exposure to identified temperatures over a given period of time under conditions (or "stress conditions") prevailing during proteolytic, hydrolysing, cleaning or other process, while being exposed to altered temperatures. "Altered temperatures" encompass increased or decreased temperatures.
[0063] In some embodiments, the variant proteases provided herein retain at least about 40%, about 50%, about 60%, about 70%, about 80%, about 85%, about 90%, about 92%, about 95%, about 96%), about 97%, about 98%, or about 99% proteolytic activity after exposure to temperatures of 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 58°C, 59°C, or 60°C over a given time period, for example, at least about 20 minutes, at least about 60 minutes, about 90 minutes, about 120 minutes, about 180 minutes, about 240 minutes, about 300 minutes, about 360 minutes, about 420 minutes, about 480 minutes, about 540 minutes, about 600 minutes, about 660 minutes, about 720 minutes, about 780 minutes, about 840 minutes, about 900 minutes, about 960 minutes, about 1020 minutes, about 1080 minutes, about 1140 minutes, or about 1200 minutes.
[0064] A further embodiment is directed a method of cleaning a creme brulee stain comprising contacting a surface or an item in need of cleaning with an effective amount of one or more subtilisin variant or composition containing one or more subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1, 21, 38, 40, 48, 58, 76, 82, 87, 89, 101, 116, 128, 129, 130, and 248; (ii) 1C/D/E/F/H/I/K/L/M/N/P/R/S/T/VAV/Y, 21 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
38 A/C/D/E/F/G/H/I/L/M/N/P/Q/R/S/T/V/W/Y, 40A/C/D/E/F/G/H/I/K/L/M/N/Q/R/S/T/VAV/Y, 48C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 58 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y, 76A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
82A/C/D/E/F/H/I/K/L/M/N/P/Q/R/S/T/V/W/Y,
87A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
89A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/T/VAV/Y, 101 A/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 116A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/V/Y, 128A/C/D/E/F/H/I/K/L/M/N/Q/S/T/VAV/Y, 129 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
130A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y, and
248A/C/D/E/F/G/H/I/K/L/M/P/Q/R/S/T/VAV/Y; (iii) 1I/M/N/T/Y, 21A/C/D/E/L/M/N/R/W/Y, 38 A/C/D/E/G/H/I/L/M/N/P/Q/VAV/Y, 40A/D/G/H/I/K/L/S/T/V/Y,
48C/D/E/F/G/I/M/N/P/Q/V/Y, 58 A/C/D/G/I/K/M/Q/S/V/Y, 76C/D/E/F/G/H/L/M/P/Q/S/T/V/W/Y, 82F/K/M/TA /Y, 87C/D/E/F/ G/H/L/M/N/P/ Q/T/ VAV / Y, 89A/C/D/M/N, 101A/D/E/F/G/L/M/N/Q/T/V, 116A/C/D/E/G/H/I/K/L/M/N/Q/Y, 128D/N/T, 129C/M, 130A/D/E/G/K/L/M/N/P/Q/T/V, and 248G/T; (iv) IT, 21A/C/M/N/W,
38 A/H/I/L/MA/ AT, 40D/I/L/V, 48C/D/E/M/V/Y, 58C/D/G/K/V, 76C/E/M/Q/S/T/V/Y, 82K/Y, 87C/D/E/M/N/P, 89C, 101A/D/E/M/N/T, 116A/C/D/I/M/N/Q, 128T, 129C, and 130G/L; (vi) 38I/L/V, 401, 48V, 76T, 89C, 101 A/N, and 130G; or (vii) combinations of (i) to (vi); wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17. A still further embodiment is directed to a method of cleaning a creme brulee stain comprising contacting a surface or an item in need of cleaning with an effective amount of one or more subtilisin variant or composition containing one or more subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from: (i) 1C/D/E/F/K/H/T/V/W, 21C/D/E/F/H/K/R, 38C/D/E/F/G/H/I/M/N/P/R/S/T,
40C/D/E/F/G/H/I/K/L/R/S, 48C/D/E/I/M/R/S/V/Y, 58A/C/D/E/K,
76A/C/D/E/F/G/K/M/N/R/T/W, 82E/K/M/R/S, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V,
89A/C/D/F/K/M/N/P/Q/R, 101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 116A/C/D/E/F/M/N/P/Q/R, 128A/D/H/N/Q/S/TAV/Y, 129C/D/E/G/M/Q/R, OC/D/E/G/H/I/K/L/M/N/P/R/S/T/VAVA^, and 248C/D/E/G/H/I/K/L/Q/T/V/Y; (ii) 21, 38, 40, 48, 76, 87, 89, 101, 116, 128, 129, and 130; (iii) 21C/D/E/F/H/K/R, 38C/D/E/F/G/H/I/M/N/P/R/S/T, 40C/D/E/F/G/H/I/K/L/R/S,
48C/D/E/I/M/R/S/V/Y, 76 A/C/D/E/F/ G/K/M/N/R/TAV, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V, 89A/C/D/F/K/M/N/P/Q/R, 101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 116A/C/D/E/F/M/N/P/Q/R, 128A/D/H/N/Q/S/TAV/Y, 129C/D/E/G/M/Q/R, and 130C/D/E/G/H/I/K/L/M/N/P/R/S/T/VAV/Y; (iv) 48, 76, 87, 89, 101, 116, and 130; (v) 48C/D/E/I/M/R/S/V/Y,
76 A/C/D/E/F/ G/K/M/N/R/TAV, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V,
89A/C/D/F/K/M/N/P/Q/R, lOlA/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 116A/C/D/E/F/M/N/P/Q/R, and 130C/D/E/G/H/I/K/L/M/N/P/R/S/T/VAV/Y; (vi) 38E, 40D, 48E, 76C/E, 87C/D/M/N, 89C, 101D/E/M/N, 116C/D/E/M, and 130D/G; (vii) 76E, 89C, and 130G; (viii) IK, 38D/E/G/I/M/T, 40C/D/E, 48C/I, 58D, 76A/C/D/E, 87C/D/E/L/M/Q/R, 89A/C/K/M, 101A/D/E/K/M/N/Q/R/S/T, 116D/E/P, 128Q/S/T, 129C/D/E, 130C/D/E/G/H/N/R/S/T, and 248C/D/E/H; (ix) 38E, 89C, and 130G; or (x) combinations of (i) to (ix); wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17. [0065] In an even further embodiment, the one or more subtilisin variant used in the method of cleaning a creme brulee stain described herein comprises an amino acid sequence with70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or less than 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1, 11, 13, 15, or 17. In yet another embodiment, the one or more subtilisin variant used in the method of cleaning a creme brulee stain described herein has a creme brulee stain cleaning PI >1 when compared to SEQ ID NO: 1, 11, 13, 15, 17 and/or Bgi02446-S39E. In still yet another embodiment, the one or more subtilisin variant used in the method of cleaning a creme brulee stain described herein has a creme brulee stain cleaning PI >1 when compared to SEQ ID NO: 1, 11, 13, 15, 17 and/or Bgi02446-S39E, wherein the creme brulee stain cleaning performance of said variant is measured in accordance with the creme brulee assay described in Example 1. Still yet another embodiment is directed to the method of cleaning a creme brulee stain described herein, with the proviso that the one or more subtilisin used in said method comprises one or more non-naturally occurring substitutions. In yet another embodiment, the one or more subtilisin variant used in the method of cleaning an egg yolk stain described herein has an egg yolk stain cleaning PI >1 when compared to Bgi02446-S39E. In still yet another embodiment, the one or more subtilisin variant used in the method of cleaning an egg yolk stain described herein has an egg yolk stain cleaning PI >1 when compared to Bgi02446-S39E, where the egg yolk stain cleaning performance of the variant is measured in accordance with the egg yolk assay described in Example 1. Still yet another embodiment is directed to the method of cleaning an egg yolk stain described herein, with the proviso that the one or more subtilisin used in said method comprises one or more non-naturally occurring substitutions. In yet another embodiment, the one or more subtilisin variant used in the method of cleaning blood-milk-ink (BMI) stain described herein has a BMI stain cleaning PI >1 when compared to Bgi02446-S39E. In still yet another embodiment, the one or more subtilisin variant used in the method of cleaning a BMI stain described herein has a BMI stain cleaning PI >1 when compared to Bgi02446-S39E, where the BMI stain cleaning performance of the variant is measured in accordance with the BMI assay described in Example 1. Still yet another embodiment is directed to the method of cleaning a BMI stain described herein, with the proviso that the one or more subtilisin used in the method comprises one or more non-naturally occurring substitutions. In a further embodiment, the one or more subtilisin variant used in the methods described herein(i) is isolated; (ii) has proteolytic activity; or (iii) comprises a combination of (i) and (ii).
[0066] In another embodiment, variants provided herein comprise one or more variants having amino acids substitutions selected from the group consisting of those listed in Tables 6, 7, 8, 9, 10, 11, 12, and 13 having a PI ^ 1.1 in one or more of the cleaning assays or stability assay, including laundry, BMI, egg, creme brulee assays or EDTA stability assay, or having greater than 40% residual activity in EDTA stability assay.
[0067] One or more subtilisin variant described herein can be subject to various changes, such as one or more amino acid insertion, deletion, and/or substitution, either conservative or non- conservative, including where such changes do not substantially alter the enzymatic activity of the variant. Similarly, a nucleic acid of the invention can also be subject to various changes, such as one or more substitution of one or more nucleotide in one or more codon such that a particular codon encodes the same or a different amino acid, resulting in either a silent variation (e.g., when the encoded amino acid is not altered by the nucleotide mutation) or non-silent variation; one or more deletion of one or more nucleic acids (or codon) in the sequence; one or more addition or insertion of one or more nucleic acids (or codon) in the sequence; and/or cleavage of, or one or more truncation, of one or more nucleic acid (or codon) in the sequence. Many such changes in the nucleic acid sequence may not substantially alter the enzymatic activity of the resulting encoded polypeptide enzyme compared to the polypeptide enzyme encoded by the original nucleic acid sequence. A nucleic acid sequence described herein can also be modified to include one or more codon that provides for optimum expression in an expression system (e.g., bacterial expression system), while, if desired, said one or more codon still encodes the same amino acid(s).
[0068] Described herein is one or more isolated, non-naturally occurring, or recombinant polynucleotide comprising a nucleic acid sequence that encodes one or more subtilisin variant described herein, or recombinant polypeptide or active fragment thereof. One or more nucleic acid sequence described herein is useful in recombinant production (e.g., expression) of one or more subtilisin variant described herein, typically through expression of a plasmid expression vector comprising a sequence encoding the one or more subtilisin variant described herein or fragment thereof. One embodiment provides nucleic acids encoding one or more subtilisin variant described herein, wherein the variant is a mature form having proteolytic activity. In some embodiments, one or more subtilisin variant described herein is expressed recombinantly with a homologous pro-peptide sequence. In other embodiments, one or more subtilisin variant described herein is expressed recombinantly with a heterologous pro-peptide sequence (e.g., GG36 pro-peptide sequence).
[0069] One or more nucleic acid sequence described herein can be generated by using any suitable synthesis, manipulation, and/or isolation techniques, or combinations thereof. For example, one or more polynucleotide described herein may be produced using standard nucleic acid synthesis techniques, such as solid-phase synthesis techniques that are well-known to those skilled in the art. In such techniques, fragments of up to 50 or more nucleotide bases are typically synthesized, then joined (e.g., by enzymatic or chemical ligation methods) to form essentially any desired continuous nucleic acid sequence. The synthesis of the one or more polynucleotide described herein can be also facilitated by any suitable method known in the art, including but not limited to chemical synthesis using the classical phosphoramidite method (See e.g., Beaucage et al. Tetrahedron Letters 22: 1859-69 (1981)), or the method described in Matthes et al., EMBO J. 3 :801-805 (1984) as is typically practiced in automated synthetic methods. One or more polynucleotide described herein can also be produced by using an automatic DNA synthesizer. Customized nucleic acids can be ordered from a variety of commercial sources (e.g., Midland Certified Reagent Company, Great American Gene Company, Operon
Technologies Inc., and DNA 2.0). Other techniques for synthesizing nucleic acids and related principles are described by, for example, Itakura et al., Ann. Rev. Biochem. 53 :323 (1984) and Itakura et al., Science 198: 1056 (1984).
[0070] Recombinant DNA techniques useful in modification of nucleic acids are well known in the art, such as, for example, restriction endonuclease digestion, ligation, reverse transcription and cDNA production, and polymerase chain reaction (e.g., PCR). One or more polynucleotide described herein may also be obtained by screening cDNA libraries using one or more oligonucleotide probes that can hybridize to or PCR-amplify polynucleotides which encode one or more subtilisin variant described herein, or recombinant polypeptide or active fragment thereof. Procedures for screening and isolating cDNA clones and PCR amplification procedures are well known to those of skill in the art and described in standard references known to those skilled in the art. One or more polynucleotide described herein can be obtained by altering a naturally occurring polynucleotide backbone (e.g., that encodes one or more subtilisin variant described herein or reference subtilisin) by, for example, a known mutagenesis procedure (e.g., site-directed mutagenesis, site saturation mutagenesis, and in vitro recombination). A variety of methods are known in the art that are suitable for generating modified polynucleotides described herein that encode one or more subtilisin variant described herein, including, but not limited to, for example, site-saturation mutagenesis, scanning mutagenesis, insertional mutagenesis, deletion mutagenesis, random mutagenesis, site-directed mutagenesis, and directed-evolution, as well as various other recombinatorial approaches.
[0071] A further embodiment is directed to one or more vector comprising one or more subtilisin variant described herein (e.g., a polynucleotide encoding one or more subtilisin variant described herein); expression vectors or expression cassettes comprising one or more nucleic acid or polynucleotide sequence described herein; isolated, substantially pure, or recombinant DNA constructs comprising one or more nucleic acid or polynucleotide sequence described herein; isolated or recombinant cells comprising one or more polynucleotide sequence described herein; and compositions comprising one or more such vector, nucleic acid, expression vector, expression cassette, DNA construct, cell, cell culture, or any combination or mixtures thereof.
[0072] Some embodiments are directed to one or more recombinant cell comprising one or more vector (e.g., expression vector or DNA construct) described herein which comprises one or more nucleic acid or polynucleotide sequence described herein. Some such recombinant cells are transformed or transfected with such at least one vector, although other methods are available and known in the art. Such cells are typically referred to as host cells. Some such cells comprise bacterial cells, including, but not limited to Bacillus sp. cells, such as B. subtilis cells. Other embodiments are directed to recombinant cells (e.g., recombinant host cells) comprising one or more subtilisin described herein.
[0073] In some embodiments, one or more vector described herein is an expression vector or expression cassette comprising one or more polynucleotide sequence described herein operably linked to one or more additional nucleic acid segments required for efficient gene expression (e.g., a promoter operably linked to one or more polynucleotide sequence described herein). A vector may include a transcription terminator and/or a selection gene (e.g., an antibiotic resistant gene) that enables continuous cultural maintenance of plasmid-infected host cells by growth in antimicrobial-containing media.
[0074] An expression vector may be derived from plasmid or viral DNA, or in alternative embodiments, contains elements of both. Exemplary vectors include, but are not limited to pC194, pJHIOl, pE194, pHP13 (See, Harwood and Cutting [eds.], Chapter 3, Molecular Biological Methods for Bacillus, John Wiley & Sons (1990); suitable replicating plasmids for ?. subtilis include those listed on p. 92). {See also, Perego, "Integrational Vectors for Genetic Manipulations in Bacillus subtilis"; Sonenshein et al., [eds.]; "Bacillus subtilis and Other Gram- Positive Bacteria: Biochemistry, Physiology and Molecular Genetics", American Society for Microbiology, Washington, D.C. (1993), pp. 615-624); and p2JM103BBI).
[0075] For expression and production of a protein of interest (e.g., one or more subtilisin variant described herein) in a cell, one or more expression vector comprising one or more copy of a polynucleotide encoding one or more subtilisin variant described herein, and in some instances comprising multiple copies, is transformed into the cell under conditions suitable for expression of the variant. In some embodiments, a polynucleotide sequence encoding one or more subtilisin variant described herein (as well as other sequences included in the vector) is integrated into the genome of the host cell, while in other embodiments, a plasmid vector comprising a polynucleotide sequence encoding one or more subtilisin variant described herein remains as autonomous extra-chromosomal element within the cell. Some embodiments provide both extrachromosomal nucleic acid elements as well as incoming nucleotide sequences that are integrated into the host cell genome. The vectors described herein are useful for production of the one or more subtilisin variant described herein. In some embodiments, a polynucleotide construct encoding one or more subtilisin variant described herein is present on an integrating vector that enables the integration and optionally the amplification of the polynucleotide encoding the variant into the host chromosome. Examples of sites for integration are well known to those skilled in the art. In some embodiments, transcription of a polynucleotide encoding one or more subtilisin variant described herein is effectuated by a promoter that is the wild-type promoter for the parent subtilisin. In some other embodiments, the promoter is heterologous to the one or more subtilisin variant described herein, but is functional in the host cell. Exemplary promoters for use in bacterial host cells include, but are not limited to the amyE, amyQ, amyL, pstS, sacB, pSPAC, pAprE, pVeg, pHpall promoters; the promoter of the B. stearothermophilus maltogenic amylase gene; the B. amyloliquefaciens (BAN) amylase gene; the B. subtilis alkaline protease gene; the B. clausii alkaline protease gene; the B. pumilis xylosidase gene; the B.
thuringiensis crylllA; and the B. licheniformis alpha-amylase gene. Additional promoters include, but are not limited to the A4 promoter, as well as phage Lambda PR or PL promoters and the E. coli lac, tip or tac promoters.
[0076] One or more subtilisin variant described herein can be produced in host cells of any suitable microorganism, including bacteria and fungi. In some embodiments, one or more subtilisin variant described herein can be produced in Gram-positive bacteria. In some embodiments, the host cells are Bacillus spp., Streptomyces spp., Escherichia spp., Aspergillus spp., Trichoderma spp., Pseudomonas spp., Corynebacterium spp., Saccharomyces spp., or Pichia spp. In some embodiments, one or more subtilisin variant described herein is produced by Bacillus sp. host cells. Examples of Bacillus sp. host cells that find use in the production of the one or more subtilisin variant described herein include, but are not limited to B.
licheniformis, B. lentus, B. subtilis, B. amyloliquefaciens, B. lentus, B. brevis, B.
stearothermophilus, B. alkalophilus, B. coagulans, B. circulans, B. pumilis, B. thuringiensis, B. clausii, and B. megaterium, as well as other organisms within the genus Bacillus. In some embodiments, B. subtilis host cells are used to produce the variants described herein. USPNs 5,264,366 and 4,760,025 (RE 34,606) describe various Bacillus host strains that can be used to produce one or more subtilisin variant described herein, although other suitable strains can be used.
[0077] Several bacterial strains that can be used to produce one or more subtilisin variant described herein include non-recombinant (i.e., wild-type) Bacillus sp. strains, as well as variants of naturally-occurring strains and/or recombinant strains. In some embodiments, the host strain is a recombinant strain, wherein a polynucleotide encoding one or more subtilisin variant described herein has been introduced into the host. In some embodiments, the host strain is a B. subtilis host strain and particularly a recombinant B. subtilis host strain. Numerous B. subtilis strains are known, including, but not limited to for example, 1 A6 (ATCC 39085), 168 (1 A01), SB19, W23, Ts85, B637, PB 1753 through PB 1758, PB3360, JH642, 1A243 (ATCC 39,087), ATCC 21332, ATCC 6051, Mil 13, DE100 (ATCC 39,094), GX4931, PBT 110, and PEP 211strain (See e.g., Hoch et al., Genetics 73 :215-228 (1973); See also, US 4,450,235; US 4,302,544; and EP 0134048). The use of B. subtilis as an expression host cell is well known in the art (See e.g., Palva et al., Gene 19:81-87 (1982); Fahnestock and Fischer, J. Bacterid., 165:796-804 (1986); and Wang et al., Gene 69:39-47 (1988)).
[0078] In some embodiments, the Bacillus host cell is a Bacillus sp. that includes a mutation or deletion in at least one of the following genes: degU, degS, degR and degQ. In some embodiments, the mutation is in a degU gene, and in some embodiments the mutation is degU(Hy)32 (See e.g., Msadek et al., J. Bacteriol. 172:824-834 (1990); and Olmos et al., Mol. Gen. Genet. 253 :562-567 (1997)). In some embodiments, the Bacillus host comprises a mutation or deletion in scoC4 (See e.g., Caldwell et al., J. Bacteriol. 183 :7329-7340 (2001)); spoIIE (See e.g., Arigoni et al., Mol. Microbiol. 31 : 1407-1415 (1999)); and/or oppA or other genes of the opp operon (See e.g., Perego et al., Mol. Microbiol. 5: 173-185 (1991)). Indeed, it is contemplated that any mutation in the opp operon that causes the same phenotype as a mutation in the oppA gene will find use in some embodiments of the altered Bacillus strain described herein. In some embodiments, these mutations occur alone, while in other embodiments, combinations of mutations are present. In some embodiments, an altered Bacillus host cell strain that can be used to produce one or more subtilisin variant described herein is a Bacillus host strain that already includes a mutation in one or more of the above-mentioned genes. In addition, Bacillus sp. host cells that comprise mutation(s) and/or deletion(s) of endogenous protease genes find use. In some embodiments, the Bacillus host cell comprises a deletion of the aprE and the nprE genes. In other embodiments, the Bacillus sp. host cell comprises a deletion of 5 protease genes, while in other embodiments the Bacillus sp. host cell comprises a deletion of 9 protease genes (See e.g., US 2005/0202535).
[0079] Host cells are transformed with one or more nucleic acid sequence encoding one or more subtilisin variant described herein using any suitable method known in the art. Methods for introducing a nucleic acid (e.g., DNA) into Bacillus cells or s, coli cells utilizing plasmid DNA constructs or vectors and transforming such plasmid DNA constructs or vectors into such cells are well known. In some embodiments, the plasmids are subsequently isolated from E. coli cells and transformed into Bacillus cells. However, it is not essential to use intervening
microorganisms such as E. coli, and in some embodiments, a DNA construct or vector is directly introduced into a Bacillus host.
[0080] Exemplary methods for introducing one or more nucleic acid sequence described herein into Bacillus cells are described in, for example, Ferrari et al., "Genetics," in Harwood et al. [eds.], Bacillus, Plenum Publishing Corp. (1989), pp. 57-72; Saunders et al., J. Bacteriol. 157:718-726 (1984); Hoch et al., J. Bacteriol. 93 : 1925-1937 (1967); Mann et al., Current Microbiol. 13 : 131-135 (1986); Holubova, Folia Microbiol. 30:97 (1985); Chang et al., Mol. Gen. Genet. 168: 11-115 (1979); Vorobjeva et al., FEMS Microbiol. Lett. 7:261-263 (1980); Smith et al., Appl. Env. Microbiol. 51 :634 (1986); Fisher et al., Arch. Microbiol. 139:213-217 (1981); and McDonald, J. Gen. Microbiol. 130:203 (1984)). Indeed, such methods as transformation, including protoplast transformation and transfection, transduction, and protoplast fusion are well known and suited for use herein. Methods known in the art to transform Bacillus cells include such methods as plasmid marker rescue transformation, which involves the uptake of a donor plasmid by competent cells carrying a partially homologous resident plasmid {See, Contente et al., Plasmid 2:555-571 (1979); Haima et al., Mol. Gen. Genet. 223 : 185-191 (1990); Weinrauch et al., J. Bacteriol. 154: 1077-1087 (1983); and Weinrauch et al., J. Bacteriol. 169: 1205-1211 (1987)). In this method, the incoming donor plasmid recombines with the homologous region of the resident "helper" plasmid in a process that mimics chromosomal transformation.
[0081] In addition to commonly used methods, in some embodiments, host cells are directly transformed with a DNA construct or vector comprising a nucleic acid encoding one or more subtilisin variant described herein (i.e., an intermediate cell is not used to amplify, or otherwise process, the DNA construct or vector prior to introduction into the host cell). Introduction of a DNA construct or vector described herein into the host cell includes those physical and chemical methods known in the art to introduce a nucleic acid sequence (e.g., DNA sequence) into a host cell without insertion into the host genome. Such methods include, but are not limited to calcium chloride precipitation, electroporation, naked DNA, and liposomes. In additional embodiments, DNA constructs or vector are co-transformed with a plasmid, without being inserted into the plasmid. In further embodiments, a selective marker is deleted from the altered Bacillus strain by methods known in the art {See, Stahl et al., J. Bacteriol. 158:411-418 (1984); and Palmeros et al., Gene 247:255 -264 (2000)).
[0082] In some embodiments, the transformed cells are cultured in conventional nutrient media. The suitable specific culture conditions, such as temperature, pH and the like are known to those skilled in the art and are well described in the scientific literature. Some embodiments provide a culture (e.g., cell culture) comprising one or more subtilisin variant or nucleic acid sequence described herein.
[0083] In some embodiments, host cells transformed with one or more polynucleotide sequence encoding one or more subtilisin variant described herein are cultured in a suitable nutrient medium under conditions permitting the expression of the variant, after which the resulting variant is recovered from the culture. In some embodiments, the variant produced by the cells is recovered from the culture medium by conventional procedures, including, but not limited to, for example, separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt (e.g., ammonium sulfate), and chromatographic purification (e.g., ion exchange, gel filtration, affinity, etc.).
[0084] In some embodiments, one or more subtilisin variant produced by a recombinant host cell is secreted into the culture medium. A nucleic acid sequence that encodes a purification facilitating domain may be used to facilitate purification of the variant. A vector or DNA construct comprising a polynucleotide sequence encoding one or more subtilisin variant described herein may further comprise a nucleic acid sequence encoding a purification facilitating domain to facilitate purification of the variant (See e.g., Kroll et al., DNA Cell Biol. 12:441-53 (1993)). Such purification facilitating domains include, but are not limited to, for example, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (See, Porath, Protein Expr. Purif. 3 :263-281 [1992]), protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system. The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (e.g., sequences available from Invitrogen, San Diego, CA) between the purification domain and the heterologous protein also find use to facilitate purification.
[0085] A variety of methods can be used to determine the level of production of one or more mature subtilisin variant described herein in a host cell. Such methods include, but are not limited to, for example, methods that utilize either polyclonal or monoclonal antibodies specific for the protease. Exemplary methods include, but are not limited to enzyme-linked
immunosorbent assays (ELISA), radioimmunoassays (RIA), fluorescent immunoassays (FIA), and fluorescent activated cell sorting (FACS). These and other assays are well known in the art (See e.g., Maddox et al., J. Exp. Med. 158: 1211 (1983)).
[0086] Some other embodiments provide methods for making or producing one or more mature subtilisin variant described herein. A mature subtilisin variant does not include a signal peptide or a propeptide sequence. Some methods comprise making or producing one or more subtilisin variant described herein in a recombinant bacterial host cell, such as for example, a Bacillus sp. cell (e.g., a B. subtilis cell). Other embodiments provide a method of producing one or more subtilisin variant described herein, wherein the method comprises cultivating a recombinant host cell comprising a recombinant expression vector comprising a nucleic acid sequence encoding one or more subtilisin variant described herein under conditions conducive to the production of the variant. Some such methods further comprise recovering the variant from the culture.
[0087] Further embodiments provide methods of producing one or more subtilisin variant described herein, wherein the methods comprise: (a) introducing a recombinant expression vector comprising a nucleic acid encoding the variant into a population of cells (e.g., bacterial cells, such as B. subtilis cells); and (b) culturing the cells in a culture medium under conditions conducive to produce the variant encoded by the expression vector. Some such methods further comprise: (c) isolating the variant from the cells or from the culture medium.
[0088] Unless otherwise noted, all component or composition levels provided herein are made in reference to the active level of that component or composition, and are exclusive of impurities, for example, residual solvents or by-products, which may be present in commercially available sources. Enzyme components weights are based on total active protein. All percentages and ratios are calculated by weight unless otherwise indicated. All percentages and ratios are calculated based on the total composition unless otherwise indicated. Compositions described herein include cleaning compositions, such as detergent compositions. In the exemplified detergent compositions, the enzyme levels are expressed by pure enzyme by weight of the total composition and unless otherwise specified, the detergent ingredients are expressed by weight of the total compositions.
[0089] In one embodiment, one or more subtilisin variant described herein is useful in cleaning applications, such as, for example, but not limited to, cleaning dishware or tableware items, fabrics, medical instruments and items having hard surfaces (e.g., the hard surface of a table, table top, wall, furniture item, floor, and ceiling). In other embodiments, one or more subtilisin variant described herein is useful in disinfecting applications, such as, for example, but not limited to, disinfecting an automatic dishwashing or laundry machine.
[0090] Another embodiment is directed to a composition comprising one or more subtilisin variant described herein. In some embodiments, the composition is a cleaning composition. In other embodiments, the composition is a detergent composition. In yet other embodiments, the composition is selected from a laundry detergent composition, an automatic dishwashing (ADW) composition, a hand (manual) dishwashing detergent composition, a hard surface cleaning composition, an eyeglass cleaning composition, a medical instrument cleaning composition, a disinfectant (e.g., malodor or microbial) composition, and a personal care cleaning composition. In still other embodiments, the composition is a laundry detergent composition, an ADW composition, or a hand (manual) dishwashing detergent composition. Even still further embodiments are directed to fabric cleaning compositions, while other embodiments are directed to non-fabric cleaning compositions. In some embodiments, the cleaning composition is boron- free. In other embodiments, the cleaning composition is phosphate-free. In still other embodiments, the composition comprises one or more subtilisin variant described herein and one or more of an excipient, adjunct material, and/or additional enzyme.
[0091] In yet still a further embodiment, the composition described herein contains phosphate, is phosphate-free, contains boron, is boron-free, or combinations thereof. In other embodiments, the composition is a boron-free composition. In some embodiments, a boron-free composition is a composition to which a borate stabilizer has not been added. In another embodiment, a boron-free composition is a composition that contains less than 5.5% boron. In a still further embodiment, a boron-free composition is a composition that contains less than 4.5% boron. In yet still another embodiment, a boron-free composition is a composition that contains less than 3.5% boron. In yet still a further embodiment, a boron-free composition is a composition that contains less than 2.5% boron. In even further embodiments, a boron-free composition is a composition that contains less than 1.5% boron. In another embodiment, a boron-free composition is a composition that contains less than 1.0% boron. In still further embodiments, a boron-free composition is a composition that contains less than 0.5% boron. In other embodiments, the composition is a composition free or substantially-free of enzyme stabilizers or peptide inhibitors.
[0092] In another embodiment, one or more composition described herein is in a form selected from gel, tablet, powder, granular, solid, liquid, unit dose, and combinations thereof. In yet another embodiment, one or more composition described herein is in a form selected from a low water compact formula, low water HDL or Unit Dose (UD), or high water formula or HDL. In some embodiments, the cleaning composition described herein is in a unit dose form. In other embodiments, the unit does form is selected from pills, tablets, capsules, gelcaps, sachets, pouches, multi-compartment pouches, and pre-measured powders or liquids. In some embodiments, the unit dose format is designed to provide controlled release of the ingredients within a multi-compartment pouch (or other unit dose format). Suitable unit dose and controlled release formats are described, for example, in EP 2100949; WO 02/102955; US 4,765,916; US 4,972,017; and WO 04/111178. In some embodiments, the unit dose form is a tablet or powder contained in a water-soluble film or pouch.
[0093] Exemplary laundry detergent compositions include, but are not limited to, for example, liquid and powder laundry detergent compositions. Exemplary hard surface cleaning compositions include, but not limited to, for example, compositions used to clean the hard surface of a non-dishware item, non-tableware item, table, table top, furniture item, wall, floor, and ceiling. Exemplary hard surface cleaning compositions are described, for example, in USPNs 6,610,642, 6,376,450, and 6,376,450. Exemplary personal care compositions include, but are not limited to, compositions used to clean dentures, teeth, hair, contact lenses, and skin. Exemplary components of such oral care composition include those described in, for example, US 6,376,450.
[0094] In some embodiments, one or more subtilisin variant described herein cleans at low temperatures. In other embodiments, one or more composition described herein cleans at low temperatures. In other embodiments, one or more composition described herein comprises an effective amount of one or more subtilisin variant described herein as useful or effective for cleaning a surface in need of proteinaceous stain removal
[0095] In some embodiments, adjunct materials are incorporated, for example, to assist or enhance cleaning performance; for treatment of the substrate to be cleaned; or to modify the aesthetics of the cleaning composition as is the case with perfumes, colorants, dyes or the like. One embodiment is directed to a composition comprising one or more adjunct material and one or more subtilisin variant described herein. Another embodiment is directed to a composition comprising one or more adjunct material and one or more subtilisin variant described herein, wherein the adjunct material is selected from a bleach catalyst, an additional enzyme, an enzyme stabilizer (including, for example, an enzyme stabilizing system), a chelant, an optical brightener, a soil release polymer, a dye transfer agent, a dispersants, a suds suppressor, a dye, a perfume, a colorant, a filler, a photoactivator, a fluorescer, a fabric conditioner, a hydrolyzable surfactant, a preservative, an anti-oxidant, an anti-shrinkage agent, an anti-wrinkle agent, a germicide, a fungicide, a color speckle, a silvercare agent, an anti-tarnish agent, an anti- corrosion agent, an alkalinity source, a solubilizing agent, a carrier, a processing aid, a pigment, a pH control agent, a surfactant, a builder, a chelating agent, a dye transfer inhibiting agent, a deposition aid, a dispersant, a catalytic material, a bleach activator, a bleach booster, a hydrogen peroxide, a source of hydrogen peroxide, a preformed peracid, a polymeric dispersing agent, a clay soil removal/anti-redeposition agent, a structure elasticizing agent, a fabric softener, a carrier, a hydrotrope, a processing aid, a pigment, and combinations thereof. Exemplary adjunct materials and levels of use are found in USPNs 5,576,282; 6,306,812; 6,326,348; 6,610,642; 6,605,458; 5,705,464; 5,710, 115; 5,698,504; 5,695,679; 5,686,014 and 5,646, 101. In
embodiments in which one or more cleaning adjunct material is not compatible with one or more subtilisin variant described herein, methods are employed to keep the adjunct material and variant(s) separated (i.e., not in contact with each other) until combination of the two
components is appropriate. Such separation methods include any suitable method known in the art (e.g., gelcaps, encapsulation, tablets, physical separation, etc.).
[0096] Some embodiments are directed to cleaning additive products comprising one or more subtilisin variant described herein. In some embodiments, the additive is packaged in a dosage form for addition to a cleaning process. In some embodiments, the additive is packaged in a dosage form for addition to a cleaning process where a source of peroxygen is employed and increased bleaching effectiveness is desired.
[0097] Exemplary fillers or carriers for granular compositions include, but are not limited to, for example, various salts of sulfate, carbonate and silicate; talc; and clay. Exemplary fillers or carriers for liquid compositions include, but are not limited to, for example, water or low molecular weight primary and secondary alcohols including polyols and diols (e.g., methanol, ethanol, propanol and isopropanol). In some embodiments, the compositions contain from about 5% to about 90% of such filler or carrier. Acidic fillers may be included in such compositions to reduce the pH of the resulting solution in the cleaning method or application.
[0098] In one embodiment, one or more cleaning composition described herein comprises an effective amount of one or more subtilisin variant described herein, alone or in combination with one or more additional enzyme. Typically, a cleaning composition comprises at least about 0.0001 to about 20 wt %, from about 0.0001 to about 10 wt %, from about 0.0001 to about 1 wt %, from about 0.001 to about 1 wt %, or from about 0.01 to about 0.1 wt % of one or more protease. In another embodiment, one or more cleaning composition described herein comprises from about 0.01 to about 10 mg, about 0.01 to about 5 mg, about 0.01 to about 2 mg, about 0.01 to about 1 mg, about 0.05 to about 1 mg, about 0.5 to about 10 mg, about 0.5 to about 5 mg, about 0.5 to about 4 mg, about 0.5 to about 4 mg, about 0.5 to about 3 mg, about 0.5 to about 2 mg, about 0.5 to about 1 mg, about 0.1 to about 10 mg, about 0.1 to about 5 mg, about 0.1 to about 4 mg, about 0.1 to about 3 mg, about 0.1 to about 2 mg, about 0.1 to about 2 mg, about 0.1 to about 1 mg, or about 0.1 to about 0.5 mg of one or more protease per gram of composition.
[0099] The cleaning compositions described herein are typically formulated such that during use in aqueous cleaning operations, the wash water will have a pH of from about 4.0 to about 11.5, or even from about 5.0 to about 11.5, or even from about 5.0 to about 8.0, or even from about 7.5 to about 10.5. Liquid product formulations are typically formulated to have a pH from about 3.0 to about 9.0 or even from about 3 to about 5. Granular laundry products are typically formulated to have a pH from about 8 to about 11. In some embodiments, the cleaning compositions of the present invention can be formulated to have an alkaline pH under wash conditions, such as a pH of from about 8.0 to about 12.0, or from about 8.5 to about 11.0, or from about 9.0 to about 11.0. In some embodiments, the cleaning compositions of the present invention can be formulated to have a neutral pH under wash conditions, such as a pH of from about 5.0 to about 8.0, or from about 5.5 to about 8.0, or from about 6.0 to about 8.0, or from about 6.0 to about 7.5. In some embodiments, the neutral pH conditions can be measured when the cleaning composition is dissolved 1 : 100 (wt:wt) in de-ionised water at 20°C, measured using a conventional pH meter. Techniques for controlling pH at recommended usage levels include the use of buffers, alkalis, acids, etc., and are well known to those skilled in the art.
[00100] In some embodiments, one or more subtilisin variant described herein is encapsulated to protect it during storage from the other components in the composition and/or control the availability of the variant during cleaning. In some embodiments, encapsulation enhances the performance of the variant and/or additional enzyme. In some embodiments, the encapsulating material typically encapsulates at least part of the subtilisin variant described herein. Typically, the encapsulating material is water-soluble and/or water-dispersible. In some embodiments, the encapsulating material has a glass transition temperature (Tg) of 0°C or higher. Exemplary encapsulating materials include, but are not limited to, carbohydrates, natural or synthetic gums, chitin, chitosan, cellulose and cellulose derivatives, silicates, phosphates, borates, polyvinyl alcohol, polyethylene glycol, paraffin waxes, and combinations thereof. When the encapsulating material is a carbohydrate, it is typically selected from monosaccharides, oligosaccharides, polysaccharides, and combinations thereof. In some embodiments, the encapsulating material is a starch (See e.g., EP0922499, US 4,977,252, US 5,354,559, and US 5,935,826). In some embodiments, the encapsulating material is a microsphere made from plastic such as
thermoplastics, acrylonitrile, methacrylonitrile, polyacrylonitrile, polymethacrylonitrile and mixtures thereof. Exemplary commercial microspheres include, but are not limited to
EXPANCEL® (Stockviksverken, Sweden); and PM 6545, PM 6550, PM 7220, PM 7228, EXTE DOSPHERES®, LUXSIL®, Q-CEL®, and SPHERICEL® (PQ Corp., Valley Forge, PA).
[00101] There are a variety of wash conditions including varying detergent formulations, wash water volumes, wash water temperatures, and lengths of wash time to which one or more subtilisin variant described herein may be exposed. A low detergent concentration system is directed to wash water containing less than about 800 ppm detergent components. A medium detergent concentration system is directed to wash containing between about 800 ppm and about 2000 ppm detergent components. A high detergent concentration system is directed to wash water containing greater than about 2000 ppm detergent components. In some embodiments, the "cold water washing" of the present invention utilizes "cold water detergent" suitable for washing at temperatures from about 10°C to about 40°C, from about 20°C to about 30°C, or from about 15°C to about 25°C, as well as all other combinations within the range of about 15°C to about 35°C or 10°C to 40°C.
[00102] Different geographies have different water hardness. Hardness is a measure of the amount of calcium (Ca2+) and magnesium (Mg2+) in the water. Water hardness is usually described in terms of the grains per gallon (gpg) mixed Ca2+/Mg2+. Most water in the United States is hard, but the degree of hardness varies. Moderately hard (60-120 ppm) to hard (121- 181 ppm) water has 60 to 181 ppm (ppm can be converted to grains per U.S. gallon by dividing ppm by 17.1) of hardness minerals.
[00103] Other embodiments are directed to one or more cleaning composition comprising from about 0.00001 % to about 10% by weight composition of one or more subtilisin variant described herein and from about 99.999%) to about 90.0% by weight composition of one or more adjunct material. In another embodiment, the cleaning composition comprises from about 0.0001 % to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5%) by weight composition of one or more subtilisin variant and from about 99.9999%) to about 90.0%, about 99.999 % to about 98%, about 99.995% to about 99.5% by weight composition of one or more adjunct material.
[00104] In other embodiments, the composition described herein comprises one or more subtilisin variant described herein and one or more additional enzyme. The one or more additional enzyme is selected from acyl transferases, alpha-amylases, beta-amylases, alpha- galactosidases, arabinosidases, aryl esterases, beta-galactosidases, carrageenases, catalases, cellobiohydrolases, cellulases, chondroitinases, cutinases, endo-beta-1, 4-glucanases, endo-beta- mannanases, esterases, exo-mannanases, galactanases, glucoamylases, hemicellulases, hyaluronidases, keratinases, laccases, lactases, ligninases, lipases, lipoxygenases, , mannanases, metalloproteases, nucleases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectinases, pentosanases, perhydrolases, peroxidases, phenoloxidases, phosphatases,
phospholipases, phytases, polygalacturonases, polyesterases, additional proteases, pullulanases, reductases, rhamnogalacturonases, beta-glucanases, tannases, transglutaminases, xylan acetyl- esterases, xylanases, xyloglucanases, xylosidases, and any combination or mixture thereof.
Some embodiments are directed to a combination of enzymes (i.e., a "cocktail") comprising conventional enzymes like amylase, lipase, cutinase, mannanase and/or cellulase in conjunction with one or more subtilisin variant described herein and/or one or more additional protease.
[00105] In another embodiment, one or more composition described herein comprises one or more subtilisin variant described herein and one or more additional protease. In one
embodiment, the additional protease is a serine protease. In another embodiment, the additional protease is a metalloprotease, a fungal subtilisin, or an alkaline microbial protease or a trypsin- like protease. Suitable additional proteases include those of animal, vegetable or microbial origin. In some embodiments, the additional protease is a microbial protease. In other embodiments, the additional protease is a chemically or genetically modified mutant. In another embodiment, the additional protease is an alkaline microbial protease or a trypsin-like protease. Exemplary alkaline proteases include subtilisins derived from, for example, Bacillus (e.g., subtilisin, lentus, amyloliquefaciens, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168). Exemplary additional proteases include but are not limited to those described in WO92/21760, W095/23221, WO2008/010925, WO09/149200, WO09/149144, WO09/149145, WO 10/056640, WO10/056653, WO2010/0566356, WOl 1/072099, WO2011/13022,
WOl 1/140364, WO 12/151534, WO2015/038792, WO2015/089447, WO2015/089441, US Publ. No. 2008/0090747, US 5,801,039, US 5,340,735, US 5,500,364, US 5,855,625, RE 34,606, US 5,955,340, US 5,700,676 US 6,312,936, US 6,482,628, US 8,530,219, US Provisional Appl Nos. 62/180673 and 62/161077, and PCT Appl Nos. PCT/US2015/021813,
PCT/US2015/055900, PCT/US2015/057497, PCT/US2015/057492, PCT/US2015/057512, PCT/US2015/057526, PCT/US2015/057520, PCT/US2015/057502, PCT/US2016/022282, and PCT/US16/32514, as well as metalloproteases described in WO1999014341, WO1999033960, WO1999014342, WO1999034003, WO2007044993, WO2009058303, WO 2009058661, WO2014071410, WO2014194032, WO2014194034, WO 2014194054, and WO 2014/194117. Exemplary additional proteases include, but are not limited to trypsin (e.g., of porcine or bovine origin) and the Fusarium protease described in WO89/06270. Exemplary commercial proteases include, but are not limited to MAXATASE®, MAXACAL™, MAXAPEM™, OPTICLEAN®, OPTIMASE®, PROPERASE®, PURAFECT®, PURAFECT® OXP, PURAMAX™,
EXCELLASE™, PREFERENZ™ proteases (e.g. P100, PI 10, P280), EFFECTENZ™ proteases (e.g. PI 000, PI 050, P2000), EXCELLENZ™ proteases (e.g. PI 000), ULTIMASE®, and
PURAFAST™ (DuPont); ALCALASE®, BLAZE®, BLAZE® variants, BLAZE® EVITY®, BLAZE® EVITY® 16L, CORONASE®, SAVINASE®, SAVINASE® ULTRA, SAVINASE® EVITY®, SAVINASE® EVERIS®, PREVIASE®, DURAZYM™, POLARZYME®, OVOZYME®, KANNASE®, LIQUANASE®, LIQUANASE EVERIS®, NEUTRASE®, PROGRESS UNO®, RELASE®, and ESPERASE® (Novozymes); BLAP™ and BLAP™ variants (Henkel);
LAVERGY™ PRO 104 L (BASF), KAP (B. alkalophilus subtilisin (Kao)) and BIOTOUCH® (AB Enzymes).
[00106] Another embodiment is directed to a composition comprising one or more subtilisin variant described herein and one or more lipase. In some embodiments, the composition comprises from about 0.00001 % to about 10%, about 0.0001 % to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5% lipase by weight composition. An exemplary lipase can be a chemically or genetically modified mutant.
Exemplary lipases include, but are not limited to, e.g., those of bacterial or fungal origin, such as, e.g., H. lanuginosa lipase {see, e.g., EP 258068 and EP 305216), T. lanuginosa lipase {see, e.g., WO 2014/059360 and WO2015/010009), Rhizomucor miehei lipase {see, e.g., EP 238023), Candida lipase, such as C. antarctica lipase (e.g., C. antarctica lipase A or B) {see, e.g., EP 214761), Pseudomonas lipases such as P. alcaligenes and P. pseudoalcaligenes lipase {see, e.g., EP 218272), P. cepacia lipase {see, e.g., EP 331376), P. stutzeri lipase {see, e.g., GB 1,372,034), P. fluorescens lipase, Bacillus lipase (e.g., B. subtilis lipase (Dartois et al., Biochem. Biophys. Acta 1131 :253-260 (1993)), B. stearothermophilus lipase {see, e.g., JP 64/744992), and B.
pumilus lipase {see, e.g., WO 91/16422)). Exemplary cloned lipases include, but are not limited to Penicillium camembertii lipase {See, Yamaguchi et al., Gene 103 :61-67 (1991)), Geotricum candidum lipase {See, Schimada et al., J. Biochem., 106:383-388 (1989)), and various Rhizopus lipases, such as, R. delemar lipase {See, Hass et al., Gene 109: 117-113 (1991)), R. niveus lipase (Kugimiya et al., Biosci. Biotech. Biochem. 56:716-719 (1992)) and R. oryzae lipase. Other lipolytic enzymes, such as cutinases, may also find use in one or more composition described herein, including, but not limited to, e.g., cutinase derived from Pseudomonas mendocina {see, WO 88/09367) and/ 'or Fusarium solanipisi {see, WO90/09446). Exemplary commercial lipases include, but are not limited to Ml LIPASE™, LUMA FAST™, and LIPOMAX™ (DuPont);
LIPEX®, LIPOCLEAN®, LIPOLASE® and LIPOLASE® ULTRA (Novozymes); and LIPASE P™ (Amano Pharmaceutical Co. Ltd).
[00107] A still further embodiment is directed to a composition comprising one or more subtilisin variant described herein and one or more amylase. In one embodiment, the
composition comprises from about 0.00001 % to about 10%, about 0.0001 % to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5% amylase by weight composition. Any amylase (e.g., alpha and/or beta) suitable for use in alkaline solutions may be useful to include in such composition. An exemplary amylase can be a chemically or genetically modified mutant. Exemplary amylases include, but are not limited to those of bacterial or fungal origin, such as, for example, amylases described in GB 1,296,839, WO9100353, WO9402597, W094183314, WO9510603, W09526397, W09535382,
WO9605295, W09623873, W09623874, WO 9630481, WO9710342, W09741213,
W09743424, W09813481, WO 9826078, WO9902702, WO 9909183, W09919467, W09923211, W09929876, W09942567, WO 9943793, W09943794, WO 9946399, WO0029560, WO0060058, WO0060059, WO0060060, WO 0114532, WO0134784, WO 0164852, WO0166712, WO0188107, WO0196537, WO02092797, WO 0210355, WO0231124, WO 2004055178, WO2004113551, WO2005001064, WO2005003311, WO 2005018336, WO2005019443, WO2005066338, WO2006002643, WO2006012899, WO2006012902, WO2006031554, WO 2006063594, WO2006066594, WO2006066596, WO2006136161, WO 2008000825, WO2008088493, WO2008092919, WO2008101894, WO2008/112459,
WO2009061380, WO2009061381, WO 2009100102, WO2009140504, WO2009149419, WO 2010/059413, WO 2010088447, WO2010091221, WO2010104675, WO2010115021,
WO10115028, WO2010117511, WO 2011076123, WO2011076897, WO2011080352,
WO2011080353, WO 2011080354, WO2011082425, WO2011082429, WO 2011087836, WO2011098531, WO2013063460, WO2013184577, WO 2014099523, WO2014164777, and WO2015077126. Exemplary commercial amylases include, but are not limited to AMPLIFY®, DURAMYL®, TERMAMYL®, FUNGAMYL®, STAINZYME®, STAINZYME PLUS®, STAINZYME PLUS®, STAINZYME ULTRA® EVITY®, and BAN™ (Novozymes);
EFFECTENZ™ S 1000, POWERASE™, PREFERENZ™ S 100, PREFERENZ™ S 110,
EXCELLENZ™ S 2000, RAPIDASE® and MAXAMYL® P (DuPont).
[00108] Yet a still further embodiment is directed to a composition comprising one or more subtilisin variant described herein and one or more cellulase. In one embodiment, the composition comprises from about 0.00001 % to about 10%, 0.0001 % to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5% cellulase by weight of composition. Any suitable cellulase may find use in a composition described herein. An exemplary cellulase can be a chemically or genetically modified mutant. Exemplary cellulases include but are not limited, to those of bacterial or fungal origin, such as, for example, those described in WO2005054475, WO2005056787, US 7,449,318, US 7,833,773, US
4,435,307; EP 0495257; and US Provisional Appl. No. 62/296,678. Exemplary commercial cellulases include, but are not limited to, CELLUCLEAN®, CELLUZYME®, CAREZYME®, ENDOLASE®, RENOZYME®, and CAREZYME® PREMIUM (Novozymes); REVITALENZ™ 100, REVITALENZ™ 200/220, and REVITALENZ® 2000 (DuPont); and KAC-500(B)™ (Kao Corporation). In some embodiments, cellulases are incorporated as portions or fragments of mature wild-type or variant cellulases, wherein a portion of the N-terminus is deleted (see, e.g., US 5,874,276).
[00109] An even still further embodiment is directed to a composition comprising one or more subtilisin variant described herein and one or more mannanase. In one embodiment, the composition comprises from about 0.00001 % to about 10%, about 0.0001 % to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5%
mannanase by weight composition. An exemplary mannanase can be a chemically or genetically modified mutant. Exemplary mannanases include, but are not limited to, those of bacterial or fungal origin, such as, for example, those described in WO 2016/007929; USPNs 6,566, 114; 6,602,842; and 6,440,991 : and US Provisional Appl. Nos. 62/251516, 62/278383, and
62/278387. Exemplary commercial mannanases include, but are not limited to MANNAWAY® (Novozymes) and EFFECTENZ™ M 1000, EFFECTENZ™ M 2000, PREFERENZ® M 100, MANNASTAR®, and PURABRITE™ (DuPont).
[00110] A yet even still further embodiment is directed to a composition comprising one or more subtilisin variant described herein and one or more peroxidase and/or oxidase enzyme. In one embodiment, the composition comprises from about 0.00001 % to about 10%, about 0.0001 % to about 10%, about 0.001% to about 5%, about 0.001% to about 2%, or about 0.005% to about 0.5% peroxidase or oxidase by weight composition. A peroxidase may be used in combination with hydrogen peroxide or a source thereof (e.g., a percarbonate, perborate or persulfate) and an oxidase may be used in combination with oxygen. Peroxidases and oxidases are used for "solution bleaching" (i.e., to prevent transfer of a textile dye from a dyed fabric to another fabric when the fabrics are washed together in a wash liquor), alone or in combination with an enhancing agent (see, e.g., W094/12621 and WO95/01426). An exemplary peroxidase and/or oxidase can be a chemically or genetically modified mutant. Exemplary
peroxidases/oxidases include, but are not limited to those of plant, bacterial, or fungal origin.
[00111] Another embodiment is directed to a composition comprising one or more subtilisin variant described herein, and one or more perhydrolase, such as, for example, is described in WO2005/056782, WO2007/106293, WO 2008/063400, WO2008/106214, and WO2008/106215.
[00112] In yet another embodiment, the one or more subtilisin variant described herein and one or more additional enzyme contained in one or more composition described herein may each independently range to about 10% by weight composition, wherein the balance of the cleaning composition is one or more adjunct material. [00113] In some embodiments, one or more composition described herein finds use as a detergent additive, wherein said additive is in a solid or liquid form. Such additive products are intended to supplement and/or boost the performance of conventional detergent compositions and can be added at any stage of the cleaning process. In some embodiments, the density of the laundry detergent composition ranges from about 400 to about 1200 g/liter, while in other embodiments it ranges from about 500 to about 950 g/liter of composition measured at 20°C.
[00114] Some embodiments are directed to a laundry detergent composition comprising one or more subtilisin variant described herein and one or more adjunct material selected from surfactants, enzyme stabilizers, builder compounds, polymeric compounds, bleaching agents, additional enzymes, suds suppressors, dispersants, lime-soap dispersants, soil suspension agents, anti-redeposition agents, corrosion inhibitors, and combinations thereof. In some embodiments, the laundry compositions also contain softening agents.
[00115] Further embodiments are directed to manual dishwashing composition comprising one or more subtilisin variant described herein and one or more adjunct material selected from surfactants, organic polymeric compounds, suds enhancing agents, group II metal ions, solvents, hydrotropes, and additional enzymes.
[00116] Other embodiments are directed to one or more composition described herein, wherein said composition is a compact granular fabric cleaning composition that finds use in laundering colored fabrics or provides softening through the wash capacity, or is a heavy duty liquid (HDL) fabric cleaning composition. Exemplary fabric cleaning compositions and/or processes for making are described in USPNs 6,610,642 and 6,376,450. Other exemplary cleaning compositions are described, for example, in USPNs 6,605,458; 6,294,514; 5,929,022; 5,879,584; 5,691,297; 5,565, 145; 5,574,005; 5,569,645; 5,565,422; 5,516,448; 5,489,392; and 5,486,303; 4,968,451; 4,597,898; 4,561,998; 4,550,862; 4,537,706; 4,515,707; and 4,515,705.
[00117] In some embodiments, the cleaning compositions comprise an acidifying particle or an amino carboxylic builder. Examples of an amino carboxylic builder include aminocarboxylic acids, salts and derivatives thereof. In some embodiment, the amino carboxylic builder is an aminopolycarboxylic builder, such as glycine-N,N-diacetic acid or derivative of general formula MOOC-CHR-N(CH2COOM)2 where R is Ci-i2alkyl and M is alkali metal. In some
embodiments, the amino carboxylic builder can be methylglycine diacetic acid (MGDA), GLDA (glutamic-N,N-diacetic acid), iminodisuccinic acid (IDS), carboxymethyl inulin and salts and derivatives thereof, aspartic acid-N-monoacetic acid (ASMA), aspartic acid-N,N-diacetic acid (ASDA), aspartic acid-N-monopropionic acid (ASMP), iminodisuccinic acid (IDA), N-(2- sulfomethyl) aspartic acid (SMAS), N-(2-sulfoethyl)aspartic acid (SEAS), N-(2- sulfomethyl)glutamic acid (SMGL), N-(2-sulfoethyl) glutamic acid (SEGL), IDS (iminodiacetic acid) and salts and derivatives thereof such as N-methyliminodiacetic acid (MID A) , alpha- alanine-N,N-diacetic acid (alpha-ALDA) , serine-N,N-diacetic acid (SEDA), isoserine- N,Ndiacetic acid (ISDA) , phenylalanine-N,N-diacetic acid (PHD A), anthranilic acid-N,N- diacetic acid (AND A), sulfanilic acid-N,N-di acetic acid (SLDA), taurine-N,N-diacetic acid (TUDA) and sulfomethyl-N,N-diacetic acid (SMDA) and alkali metal salts and derivative thereof. In some embodiments, the acidifying particle has a weight geometric mean particle size of from about 400μ to about 1200μ and a bulk density of at least 550 g/L. In some
embodiments, the acidifying particle comprises at least about 5% of the builder.
[00118] In some embodiments, the acidifying particle can comprise any acid, including organic acids and mineral acids. Organic acids can have one or two carboxyls and in some instances up to 15 carbons, especially up to 10 carbons, such as formic, acetic, propionic, capric, oxalic, succinic, adipic, maleic, fumaric, sebacic, malic, lactic, glycolic, tartaric and glyoxylic acids. In some embodiments, the acid is citric acid. Mineral acids include hydrochloric and sulphuric acid. In some instances, the acidifying particle is a highly active particle comprising a high level of amino carboxylic builder. Sulphuric acid has also been found to further contribute to the stability of the final particle.
[00119] Additional embodiments are directed to a cleaning composition comprising one or more subtilisin variant and one or more surfactant and/or surfactant system, wherein the surfactant is selected from nonionic surfactants, anionic surfactants, cationic surfactants, ampholytic surfactants, zwitterionic surfactants, semi-polar nonionic surfactants, and mixtures thereof. In some embodiments, the surfactant is present at a level of from about 0.1 to about 60%, while in alternative embodiments the level is from about 1 to about 50%, while in still further embodiments the level is from about 5 to about 40%, by weight of the cleaning composition.
[00120] In some embodiments, one or more composition described herein comprises one or more detergent builders or builder systems. In one embodiment, the composition comprises from about 1%, from about 0.1% to about 80%, from about 3% to about 60%, from about 5% to about 40%, or from about 10% to about 50% builder by weight composition. Exemplary builders include, but are not limited to alkali metal; ammonium and alkanol ammonium salts of polyphosphates; alkali metal silicates; alkaline earth and alkali metal carbonates;
aluminosilicates; polycarboxylate compounds; ether hydroxypolycarboxylates; copolymers of maleic anhydride with ethylene or vinyl methyl ether, 1, 3, 5-trihydroxy benzene-2, 4, 6- trisulphonic acid, and carboxymethyloxysuccinic acid; ammonium and substituted ammonium salts of polyacetic acids such as ethylenediamine tetraacetic acid and nitrilotriacetic acid;
polycarboxylates such as mellitic acid, succinic acid, citric acid, oxydisuccinic acid, polymaleic acid, benzene 1,3,5-tricarboxylic acid, carboxymethyloxysuccinic acid; and soluble salts thereof. In some such compositions, the builders form water-soluble hardness ion complexes (e.g., sequestering builders), such as citrates and polyphosphates, e.g., sodium tripolyphosphate, sodium tripolyphospate hexahydrate, potassium tripolyphosphate, and mixed sodium and potassium tripolyphosphate. Exemplary builders are described in, e.g., EP 2100949. In some embodiments, the builders include phosphate builders and non-phosphate builders. In some embodiments, the builder is a phosphate builder. In some embodiments, the builder is a non- phosphate builder. In some embodiments, the builder comprises a mixture of phosphate and non-phosphate builders. Exemplary phosphate builders include, but are not limited to monophosphates, di-phosphates, tri-polyphosphates or oligomeric-poylphosphates, including the alkali metal salts of these compounds, including the sodium salts. In some embodiments, a builder can be sodium tripolyphosphate (STPP). Additionally, the composition can comprise carbonate and/or citrate. Other suitable non-phosphate builders include homopolymers and copolymers of polycarboxylic acids and their partially or completely neutralized salts, monomeric
polycarboxylic acids and hydroxycarboxylic acids and their salts. In some embodiments, salts of the above mentioned compounds include the ammonium and/or alkali metal salts, i.e. the lithium, sodium, and potassium salts, including sodium salts. Suitable polycarboxylic acids include acyclic, alicyclic, hetero-cyclic and aromatic carboxylic acids, wherein in some embodiments, they can contain at least two carboxyl groups which are in each case separated from one another by, in some instances, no more than two carbon atoms.
[00121] In some embodiments, one or more composition described herein comprises one or more chelating agent. In one embodiment, the composition comprises from about 0.1% to about 15%) or about 3% to about 10%> chelating agent by weight composition. Exemplary chelating agents include, but are not limited to, e.g., copper, iron, manganese, and mixtures thereof.
[00122] In some embodiments, one or more composition described herein comprises one or more deposition aid. Exemplary deposition aids include, but are not limited to, e.g.,
polyethylene glycol; polypropylene glycol; polycarboxylate; soil release polymers, such as, e.g., polytelephthalic acid; clays such as, e.g., kaolinite, montmorillonite, attapulgite, illite, bentonite, and halloysite; and mixtures thereof.
[00123] In other embodiments, one or more composition described herein comprises one or more anti-redeposition agent or non-ionic surfactant (which can prevent the re-deposition of soils) (see, e.g., EP 2100949). For example, in ADW compositions, non-ionic surfactants find use for surface modification purposes, in particular for sheeting, to avoid filming and spotting and to improve shine. These non-ionic surfactants also find use in preventing the re-deposition of soils. In some embodiments, the non-ionic surfactant can be ethoxylated nonionic surfactants, epoxy-capped poly(oxyalkylated) alcohols and amine oxides surfactants.
[00124] In some embodiments, one or more composition described herein comprises one or more dye transfer inhibiting agent. Exemplary polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinyloxazolidones, polyvinylimidazoles, and mixtures thereof. In one embodiment, the composition comprises from about 0.0001% to about 10%), about 0.01%) to about 5%, or about 0.1%> to about 3% dye transfer inhibiting agent by weight composition.
[00125] In some embodiments, one or more composition described herein comprises one or more silicate. Exemplary silicates include, but are not limited to, sodium silicates, e.g., sodium disilicate, sodium metasilicate, and crystalline phyllosilicates. In some embodiments, silicates are present at a level of from about 1%> to about 20% or about 5% to about 15% by weight of the composition.
[00126] In some still additional embodiments, one or more composition described herein comprises one or more dispersant. Exemplary water-soluble organic materials include, but are not limited to, e.g., homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two carbon atoms. [00127] In some further embodiments, one or more composition described herein comprises one or more enzyme stabilizer. In some embodiments, the enzyme stabilizer is water-soluble sources of calcium and/or magnesium ions. In some embodiments, the enzyme stabilizers include oligosaccharides, polysaccharides, and inorganic divalent metal salts, including alkaline earth metals, such as calcium salts. In some embodiments, the enzymes employed herein are stabilized by the presence of water-soluble sources of zinc (II), calcium (II) and/or magnesium (II) ions in the finished compositions that provide such ions to the enzymes, as well as other metal ions (e.g., barium (II), scandium (II), iron (II), manganese (II), aluminum (III), tin (II), cobalt (II), copper (II), nickel (II), and oxovanadium (IV)). Chlorides and sulfates also find use in some embodiments. Exemplary oligosaccharides and polysaccharides (e.g., dextrins) are described, for example, in WO 07/145964. In some embodiments, reversible protease inhibitors also find use, such as boron-containing compounds (e.g., borate, 4-formyl phenyl boronic acid, and phenyl -boronic acid derivatives (such as for example, those described in W096/41859) and/or a peptide aldehyde, such as, for example, is further described in WO2009/118375 and WO2013004636.
[00128] Peptide aldehydes may be used as protease stabilizers in detergent formulations as previously described (W0199813458, WO2011036153, US20140228274). Examples of peptide aldehyde stabilizers are peptide aldehydes, ketones, or halomethyl ketones and might be 'N- capped' with for instance a ureido, a carbamate, or a urea moiety, or 'doubly N-capped' with for instance a carbonyl, a ureido, an oxiamide, a thioureido, a dithiooxamide, or a thiooxamide moiety (EP2358857B 1). The molar ratio of these inhibitors to the protease may be 0.1 : 1 to 100: 1, e.g. 0.5: 1-50: 1, 1 : 1-25: 1 or 2: 1-10: 1. Other examples of protease stabilizers are benzophenone or benzoic acid anilide derivatives, which might contain carboxyl groups (US 7,968,508 B2). The molar ratio of these stabilizers to protease is preferably in the range of 1 : 1 to 1000: 1 in particular 1 : 1 to 500: 1 especially preferably from 1 : 1 to 100: 1, most especially preferably from 1 : 1 to 20 : 1.
[00129] In some embodiments, one or more composition described herein comprises one or more bleach, bleach activator, and/or bleach catalyst. In some embodiments, one or more composition described herein comprises one or more inorganic and/or organic bleaching compound. Exemplary inorganic bleaches include, but are not limited to perhydrate salts, e.g., perborate, percarbonate, perphosphate, persulfate, and persilicate salts. In some embodiments, inorganic perhydrate salts are alkali metal salts. In some embodiments, inorganic perhydrate salts are included as the crystalline solid, without additional protection, although in some other embodiments, the salt is coated. Bleach activators are typically organic peracid precursors that enhance the bleaching action in the course of cleaning at temperatures of 60°C and below.
Exemplary bleach activators include compounds which, under perhydrolysis conditions, give aliphatic peroxoycarboxylic acids having from about 1 to about 10 carbon atoms or about 2 to about 4 carbon atoms, and/or optionally substituted perbenzoic acid. Exemplary bleach activators ae described, for example, in EP 2100949. Exemplary bleach catalysts include, but are not limited to, manganese triazacyclononane and related complexes, as well as cobalt, copper, manganese, and iron complexes. Additional exemplary bleach catalysts are described, for example, in US 4,246,612; US 5,227,084; US 4,810,410; WO 99/06521; and EP 2100949.
[00130] In some embodiments, one or more composition described herein comprises one or more catalytic metal complexes. In some embodiments, a metal-containing bleach catalyst finds use. In some embodiments, the metal bleach catalyst comprises a catalyst system comprising a transition metal cation of defined bleach catalytic activity (e.g., copper, iron, titanium, ruthenium, tungsten, molybdenum, or manganese cations), an auxiliary metal cation having little or no bleach catalytic activity (e.g., zinc or aluminum cations), and a sequestrate having defined stability constants for the catalytic and auxiliary metal cations, particularly
ethylenediaminetetraacetic acid, ethyl enediaminetetra (methylenephosphonic acid) and water- soluble salts thereof (see, e.g., US 4,430,243). In some embodiments, one or more composition described herein is catalyzed by means of a manganese compound. Such compounds and levels of use are described, for example, in US 5,576,282. In additional embodiments, cobalt bleach catalysts find use and are included in one or more composition described herein. Various cobalt bleach catalysts are described, for example, in USPNs 5,597,936 and 5,595,967.
[00131] In some additional embodiments, one or more composition described herein includes a transition metal complex of a macropolycyclic rigid ligand (MRL). As a practical matter, and not by way of limitation, in some embodiments, the compositions and cleaning processes described herein are adjusted to provide on the order of at least one part per hundred million, from about 0.005 ppm to about 25 ppm, about 0.05 ppm to about 10 ppm, or about 0.1 ppm to about 5 ppm of active MRL in the wash liquor. Exemplary MRLs include, but are not limited to special ultra-rigid ligands that are cross-bridged, such as, e.g., 5,12-diethyl-l,5,8, 12- tetraazabicyclo(6.6.2)hexadecane. Exemplary metal MRLs are described, for example, in WO 2000/32601 and US 6,225,464.
[00132] In another embodiment, one or more composition described herein comprises one or more metal care agent. In some embodiments, the composition comprises from about 0.1% to about 5% metal care agent by weight composition. Exemplary metal care agents include, for example, aluminum, stainless steel, and non-ferrous metals (e.g., silver and copper). Additional exemplary metal care agents are described, for example, in EP 2100949, WO 94/26860, and WO 94/26859. In some compositions, the metal care agent is a zinc salt.
[00133] In some embodiments, the cleaning composition is a heavy duty liquid (HDL) composition comprising one or more subtilisin variant described herein. The HDL liquid laundry detergent can comprise a detersive surfactant (10-40%) comprising anionic detersive surfactant selected from a group of linear or branched or random chain, substituted or unsubstituted alkyl sulphates, alkyl sulphonates, alkyl alkoxylated sulphate, alkyl phosphates, alkyl phosphonates, alkyl carboxylates, and/or mixtures thereof; and optionally non-ionic surfactant selected from a group of linear or branched or random chain, substituted or unsubstituted alkyl alkoxylated alcohol, for example, a Cs-Cisalkyl ethoxylated alcohol and/or C6-Ci2alkyl phenol alkoxylates, optionally wherein the weight ratio of anionic detersive surfactant (with a hydrophilic index (HIc) of from 6.0 to 9) to non-ionic detersive surfactant is greater than 1 : 1. Suitable detersive surfactants also include cationic detersive surfactants (selected from alkyl pyridinium compounds, alkyl quarternary ammonium compounds, alkyl quarternary phosphonium compounds, alkyl ternary sulphonium compounds, and/or mixtures thereof); zwitterionic and/or amphoteric detersive surfactants (selected from alkanolamine sulpho-betaines); ampholytic surfactants; semi-polar non-ionic surfactants; and mixtures thereof.
[00134] In another embodiment, the cleaning composition is a liquid or gel detergent, which is not unit dosed, that may be aqueous, typically containing at least 20% and up to 95% water by weight, such as up to about 70% water by weight, up to about 65% water by weight, up to about 55% water by weight, up to about 45% water by weight, or up to about 35% water by weight. Other types of liquids, including without limitation, alkanols, amines, diols, ethers and polyols may be included in an aqueous liquid or gel. An aqueous liquid or gel detergent may contain from 0-30%) organic solvent. A liquid or gel detergent may be non-aqueous. [00135] The composition can comprise optionally, a surfactancy boosting polymer consisting of amphiphilic alkoxylated grease cleaning polymers selected from a group of alkoxylated polymers having branched hydrophilic and hydrophobic properties, such as alkoxylated polyalkylenimines in the range of 0.05wt%-10wt% and/or random graft polymers typically comprising a hydrophilic backbone comprising monomers selected from the group consisting of: unsaturated Ci-C6carboxylic acids, ethers, alcohols, aldehydes, ketones, esters, sugar units, alkoxy units, maleic anhydride, saturated polyalcohols such as glycerol, and mixtures thereof; and hydrophobic side chain(s) selected from the group consisting of: C4-C25alkyl group, polypropylene, polybutylene, vinyl ester of a saturated C2-C6mono-carboxylic acid, Ci-C6alkyl ester of acrylic or methacrylic acid, and mixtures thereof.
[00136] The composition can comprise additional polymers such as soil release polymers including, for example, anionically end-capped polyesters, for example SRP1; polymers comprising at least one monomer unit selected from saccharide, dicarboxylic acid, polyol and combinations thereof, in random or block configuration; ethylene terephthalate-based polymers and co-polymers thereof in random or block configuration, for example, Repel-o-tex SF, SF-2 and SRP6, Texcare SRA100, SRA300, SRN100, SRN170, SRN240, SRN300 and SRN325, Marloquest SL; anti-redeposition polymers (0.1 wt% to 10wt%, including, for example, carboxylate polymers, such as polymers comprising at least one monomer selected from acrylic acid, maleic acid (or maleic anhydride), fumaric acid, itaconic acid, aconitic acid, mesaconic acid, citraconic acid, methyl enemalonic acid, and any mixture thereof; vinylpyrrolidone homopolymer; and/or polyethylene glycol with a molecular weight in the range of from 500 to 100,000 Da); cellulosic polymer (including, for example, alkyl cellulose; alkyl alkoxyalkyl cellulose; carboxyalkyl cellulose; alkyl carboxyalkyl cellulose, examples of which include carboxymethyl cellulose, methyl cellulose, methyl hydroxyethyl cellulose, methyl
carboxymethyl cellulose; and mixtures thereof); and polymeric carboxylate (such as, for example, maleate/acrylate random copolymer or polyacrylate homopolymer).
[00137] The composition can further comprise saturated or unsaturated fatty acid, preferably saturated or unsaturated Ci2-C24fatty acid (0-10 wt%); deposition aids (including, for example, polysaccharides, cellulosic polymers, polydiallyl dimethyl ammonium halides (DADMAC), and co-polymers of DADMAC with vinyl pyrrolidone, acrylamides, imidazoles, imidazolinium halides, and mixtures thereof, in random or block configuration; cationic guar gum; cationic cellulose such as cationic hydoxyethyl cellulose; cationic starch; cationic polyacylamides; and mixtures thereof.
[00138] The composition can further comprise dye transfer inhibiting agents examples of which include manganese phthalocyanine, peroxidases, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinyloxazolidones and polyvinylimidazoles and/or mixtures thereof; chelating agents examples of which include ethylene-diamine-tetraacetic acid (EDTA); diethylene triamine penta methylene phosphonic acid (DTPMP); hydroxy-ethane diphosphonic acid (HEDP);
ethylenediamine Ν,Ν'-disuccinic acid (EDDS); methyl glycine diacetic acid (MGDA);
diethylene triamine penta acetic acid (DTP A); propylene diamine tetracetic acid (PDT A); 2- hydroxypyridine-N-oxide (HPNO); or methyl glycine diacetic acid (MGDA); glutamic acid N,N- diacetic acid (Ν,Ν-dicarboxymethyl glutamic acid tetrasodium salt (GLDA); nitrilotriacetic acid (NTA); 4,5-dihydroxy-m-benzenedisulfonic acid; citric acid and any salts thereof; N- hydroxyethylethylenediaminetri-acetic acid (HEDTA), triethylenetetraaminehexaacetic acid (TTHA), N-hydroxyethyliminodiacetic acid (HEIDA), dihydroxyethylglycine (DHEG), ethylenediaminetetrapropionic acid (EDTP), and derivatives thereof.
[00139] The composition can further comprise silicone or fatty-acid based suds suppressors; an enzyme stabilizer; hueing dyes, calcium and magnesium cations, visual signaling ingredients, anti-foam (0.001 to about 4.0 wt%), and/or structurant/thickener (0.01- 5 wt%) selected from the group consisting of diglycerides, triglycerides, ethylene glycol distearate, microcrystalline cellulose, cellulose based materials, microfiber cellulose, biopolymers, xanthan gum, gellan gum, and mixtures thereof.
[00140] In some embodiments, the cleaning composition is a heavy duty powder (HDD) composition comprising one or more subtilisin variant described herein. The HDD powder laundry detergent can comprise a detersive surfactant including anionic detersive surfactants (selected from linear or branched or random chain, substituted or unsubstituted alkyl sulphates, alkyl sulphonates, alkyl alkoxylated sulphate, alkyl phosphates, alkyl phosphonates, alkyl carboxylates and/or mixtures thereof), non-ionic detersive surfactant (selected from 1 linear or branched or random chain, substituted or unsubstituted Cs-Cis alkyl ethoxylates, and/or C6-C12 alkyl phenol alkoxylates), cationic detersive surfactants (selected from alkyl pyridinium compounds, alkyl quaternary ammonium compounds, alkyl quaternary phosphonium compounds, alkyl ternary sulphonium compounds, and mixtures thereof); zwitterionic and/or amphoteric detersive surfactants (selected from alkanolamine sulpho-betaines); ampholytic surfactants; semi-polar non-ionic surfactants and mixtures thereof; builders (phosphate free builders, e,g., zeolite builders examples of which include zeolite A, zeolite X, zeolite P and zeolite MAP in the range of 0 to less than 10 wt%); phosphate builders, e.g., sodium tri- polyphosphate in the range of 0 to less than 10 wt%; citric acid, citrate salts and nitrilotriacetic acid or salt thereof in the range of less than 15 wt%; silicate salt (sodium or potassium silicate or sodium meta-silicate in the range of 0 to less than 10 wt% or layered silicate (SKS-6)); carbonate salt (sodium carbonate and/or sodium bicarbonate in the range of 0 to less than 10 wt%); and bleaching agents (photobleaches, e.g., sulfonated zinc phthalocyanines, sulfonated aluminum phthalocyanines, xanthenes dyes, and mixtures thereof); hydrophobic or hydrophilic bleach activators (e.g., dodecanoyl oxybenzene sulfonate, decanoyl oxybenzene sulfonate, decanoyl oxybenzoic acid or salts thereof, 3,5,5-trimethy hexanoyl oxybenzene sulfonate, tetraacetyl ethylene diamine-TAED, and nonanoyloxybenzene sulfonate-NOBS, nitrile quats, and mixtures thereof); hydrogen peroxide; sources of hydrogen peroxide (inorganic perhydrate salts, e.g., mono or tetra hydrate sodium salt of perborate, percarbonate, persulfate, perphosphate, or persilicate); preformed hydrophilic and/or hydrophobic peracids (selected from percarboxylic acids and salts, percarbonic acids and salts, perimidic acids and salts, peroxymonosulfuric acids and salts, and mixtures thereof); and/or bleach catalyst (e.g., imine bleach boosters, such as iminium cations and polyions; iminium zwitterions; modified amines; modified amine oxides; N- sulphonyl imines; N-phosphonyl imines; N-acyl imines; thiadiazole dioxides; perfluoroimines; cyclic sugar ketones and mixtures thereof), metal-containing bleach catalyst (e.g., copper, iron, titanium, ruthenium, tungsten, molybdenum, or manganese cations along with an auxiliary metal cations such as zinc or aluminum and a sequestrate such as ethylenediaminetetraacetic acid, ethylenediaminetetra(methylenephosphonic acid) and water-soluble salts thereof ).
[00141] The composition can further comprise additional detergent ingredients including perfume microcapsules, starch encapsulated perfume accord, an enzyme stabilizer, hueing agents, additional polymers including fabric integrity and cationic polymers, dye lock
ingredients, fabric-softening agents, brighteners (for example C.I. Fluorescent brighteners), flocculating agents, chelating agents, alkoxylated polyamines, fabric deposition aids, and/or cyclodextrin. [00142] In some embodiments, the cleaning composition is an ADW detergent composition comprising one or more subtilisin variant described herein. The ADW detergent composition can comprise two or more non-ionic surfactants selected from ethoxylated non-ionic surfactants, alcohol alkoxylated surfactants, epoxy-capped poly(oxyalkylated) alcohols, and amine oxide surfactants present in amounts from 0-10% by wt; builders in the range of 5-60%by wt.
comprising either phosphate (mono-phosphates, di-phosphates, tri-polyphosphates or oligomeric- poylphosphates), sodium tripolyphosphate-STPP or phosphate-free builders (amino acid based compounds, e.g., MGDA (methyl-glycine-diacetic acid) and salts and derivatives thereof, GLDA (glutamic-N,Ndi acetic acid) and salts and derivatives thereof, IDS (iminodisuccinic acid) and salts and derivatives thereof, carboxy methyl inulin and salts and derivatives thereof and mixtures thereof, nitrilotriacetic acid (NT A), diethylene triamine penta acetic acid (DTP A), and B-alaninediacetic acid (B-ADA) and their salts), homopolymers and copolymers of poly- carboxylic acids and their partially or completely neutralized salts, monomeric polycarboxylic acids and hydroxy carboxylic acids and their salts in the range of 0.5-50% by wt;
sulfonated/carboxylated polymers (provide dimensional stability to the product) in the range of about 0.1 to about 50% by wt; drying aids in the range of about 0.1 to about 10% by wt (selected from polyesters, especially anionic polyesters optionally together with further monomers with 3- 6 functionalities which are conducive to polycondensation, specifically acid, alcohol or ester functionalities, polycarbonate-, polyurethane- and/or polyurea-polyorganosiloxane compounds or precursor compounds thereof of the reactive cyclic carbonate and urea type); silicates in the range from about 1 to about 20% by wt (sodium or potassium silicates, e.g., sodium disilicate, sodium meta-silicate and crystalline phyllosilicates); bleach-inorganic (e.g., perhydrate salts such as perborate, percarbonate, perphosphate, persulfate and persilicate salts) and organic (e.g., organic peroxyacids including diacyl and tetraacylperoxides, especially diperoxydodecanedioc acid, diperoxytetradecanedioc acid, and diperoxyhexadecanedioc acid); bleach activator-organic peracid precursors in the range from about 0.1 to about 10% by wt; bleach catalysts (selected from manganese triazacyclononane and related complexes, Co, Cu, Mn and Fe bispyridylamine and related complexes, and pentamine acetate cobalt(III) and related complexes); metal care agents in the range from about 0.1 -5% by wt (selected from benzatriazoles, metal salts and complexes, and silicates); enzymes in the range from about 0.01-5.0mg of active enzyme per gram of ADW detergent composition (acyl transferases, alpha-amylases, beta-amylases, alpha- galactosidases, arabinosidases, aryl esterases, beta-galactosidases, carrageenases, catalases, cellobiohydrolases, cellulases, chondroitinases, cutinases, endo-beta-1, 4-glucanases, endo-beta- mannanases, esterases, exo-mannanases, galactanases, glucoamylases, hemicellulases, hyaluronidases, keratinases, laccases, lactases, ligninases, lipases, lipoxygenases, mannanases, nucleases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectinases, pentosanases, peroxidases, phenoloxidases, phosphatases, phospholipases, phytases,
polyestersases, polygalacturonases, proteases, pullulanases, reductases, rhamnogalacturonases, beta-glucanases, tannases, transglutaminases, xylan acetyl-esterases, xylanases, xyloglucanases, xylosidases, and mixtures thereof); and enzyme stabilizer components (selected from
oligosaccharides, polysaccharides and inorganic divalent metal salts).
[00143] More embodiments are directed to compositions and methods of treating fabrics (e.g., to desize a textile) using one or more subtilisin variant described herein. Fabric-treating methods are well known in the art (see, e.g., US 6,077,316). For example, the feel and appearance of a fabric can be improved by a method comprising contacting the fabric with a variant described herein in a solution. The fabric can be treated with the solution under pressure.
[00144] One or more subtilisin variant described herein can be applied during or after weaving a textile, during the desizing stage, or one or more additional fabric processing steps. During the weaving of textiles, the threads are exposed to considerable mechanical strain. Prior to weaving on mechanical looms, warp yarns are often coated with sizing starch or starch derivatives to increase their tensile strength and to prevent breaking. One or more subtilisin variant described herein can be applied during or after weaving to remove the sizing starch or starch derivatives. After weaving, the variant can be used to remove the size coating before further processing the fabric to ensure a homogeneous and wash-proof result. One or more subtilisin variant described herein can be used alone or with other desizing chemical reagents and/or desizing enzymes to desize fabrics, including cotton-containing fabrics, as detergent additives, e.g., in aqueous compositions. An amylase also can be used in compositions and methods for producing a stonewashed look on indigo-dyed denim fabric and garments. For the manufacture of clothes, the fabric can be cut and sewn into clothes or garments, which are afterwards finished. In particular, for the manufacture of denim jeans, different enzymatic finishing methods have been developed. The finishing of denim garment normally is initiated with an enzymatic desizing step, during which garments are subjected to the action of proteolytic enzymes to provide softness to the fabric and make the cotton more accessible to the subsequent enzymatic finishing steps. One or more subtilisin variant described herein can be used in methods of finishing denim garments (e.g., a "bio-stoning process"), enzymatic desizing and providing softness to fabrics, and/or finishing process.
[00145] One or more subtilisin variant described herein can be used to remove proteins from animals and their subsequent degradation or disposal, such as, e.g., feathers, skin, hair, and hide. In some instances, immersion of the animal carcass in a solution comprising one or more subtilisin variant described herein can act to protect the skin from damage in comparison to the traditional immersion in scalding water or the defeathering process. In one embodiment, feathers can be sprayed with one or more subtilisin variant described herein under conditions suitable for digesting or initiating degradation of the plumage. In some embodiments, the variant can be used in combination with an oxidizing agent.
[00146] In some embodiments, the removal of the oil or fat associated with raw feathers can be assisted by one or more subtilisin variant described herein. In some embodiments, one or more subtilisin variant described herein is used in compositions for cleaning the feathers as well as to sanitize and partially dehydrate the fibers. In yet other embodiments, one or more subtilisin variant described herein finds use in recovering protein from plumage. In some other embodiments, one or more subtilisin variant described herein is applied in a wash solution in combination with 95% ethanol or other polar organic solvent with or without a surfactant at about 0.5% (v/v). In other embodiments, one or more subtilisin variant described herein may be used alone or in combination in suitable feather processing and proteolytic methods, such as those disclosed in PCT/EP2013/065362, PCT/EP2013/065363, and PCT/EP2013/065364. In some embodiments, the recovered protein can be subsequently used in animal or fish feed.
[00147] In still another embodiment, one or more animal feed composition, animal feed additive and/or pet food comprises one or more subtilisin variant described herein. Other embodiments are directed to methods for preparing such an animal feed composition, animal feed additive composition and/or pet food comprising mixing one or more subtilisin variant described herein with one or more animal feed ingredients and/or animal feed additive ingredients and/or pet food ingredients.
[00148] The term "animal" includes all non-ruminant and ruminant animals. In a particular embodiment, the animal is a non-ruminant animal, such as a horse and a mono-gastric animal. Examples of mono-gastric animals include, but are not limited to, pigs and swine, such as piglets, growing pigs, sows; poultry such as turkeys, ducks, chicken, broiler chicks, layers; fish such as salmon, trout, tilapia, catfish and carps; and crustaceans such as shrimps and prawns. In a further embodiment, the animal is a ruminant animal including, but not limited to, cattle, young calves, goats, sheep, giraffes, bison, moose, elk, yaks, water buffalo, deer, camels, alpacas, llamas, antelope, pronghorn and nilgai.
[00149] In the present context, it is intended that the term "pet food" is understood to mean a food for a household animal such as, but not limited to, dogs, cats, gerbils, hamsters, chinchillas, fancy rats, guinea pigs; avian pets, such as canaries, parakeets, and parrots; reptile pets, such as turtles, lizards and snakes; and aquatic pets, such as tropical fish and frogs.
[00150] The terms "animal feed composition," "feedstuff and "fodder" are used
interchangeably and can comprise one or more feed materials selected from a) cereals, such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS) (particularly corn based Distillers Dried Grain Solubles (cDDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola, fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; and e) minerals and vitamins.
[00151] One or more subtilisin variant described herein finds further use in the enzyme aided bleaching of paper pulps such as chemical pulps, semi-chemical pulps, kraft pulps, mechanical pulps or pulps prepared by the sulfite method. In general terms, paper pulps are incubated with one or more subtilisin variant described herein under conditions suitable for bleaching the paper pulp.
[00152] In some embodiments, the pulps are chlorine free pulps bleached with oxygen, ozone, peroxide or peroxyacids. In some embodiments, one or more subtilisin variant described herein is used in enzyme aided bleaching of pulps produced by modified or continuous pulping methods that exhibit low lignin contents. In some other embodiments, one or more subtilisin variant described herein is applied alone or preferably in combination with xylanase and/or
endoglucanase and/or alpha-galactosidase and/or cellobiohydrolase enzymes. [00153] In other embodiments, one or more subtilisin variant described herein finds further use in the enzyme aided debridement of tissue. This involves the removal of dead or damaged tissue, for example, removal from wounds to aid in healing.
[00154] In even further embodiments, one or more subtilisin variant described herein finds further use in tissue culture. In particular, one or more subtilisin variant described herein can be used to suspend or resuspend cells adherent to a cell culture wall, such as during the process of harvesting cells. In another embodiment, one or more subtilisin variant described herein can be used to cleave protein bonds between cultured cells and the dish, allowing cells to become suspended in solution.
[00155] In yet another embodiment, one or more subtilisin variant described herein finds further use as a food additive, a digestive aide, and/or a food processing aid.
[00156] In still yet another embodiment, one or more subtilisin variant described herein finds further use in leather processing by removing hair from animal hides, soaking, degreasing, or bating, which is a process involving degradation of non- structural proteins during leather making.
[00157] The following examples are provided to demonstrate and illustrate certain preferred embodiments and aspects of the present disclosure and should not be construed as limiting.
EXAMPLE 1
Assays
HPLC Assay for Protein Determination
[00158] The concentration of the sample proteases in culture supernatant was determined by UHPLC using a Zorbax 300 SB-C3 column and linear gradient of 0.1% Trifluoroacetic acid (Buffer A) and 0.07% Trifluoroacetic acid in Acetonitrile (Buffer B) and detection at 220nm. Culture supernatants were diluted in 10 mM NaCl, 0.1 mM CaCh, 0.005% Tween80 for loading onto column. The protein concentration of the samples was calculated using a standard curve of the purified parent enzyme.
Cleaning Performance in Detergent
Creme Briilee
[00159] Cleaning performance of subtilisin variants on creme brulee stain was tested by using DM10 melamine tiles prepared by CFT in Vlaardingen, the Netherlands as set forth herein. Creme brulee on melamine tiles were prepared by CFT according to the IKW method set forth in "Recommendations for the Quality Assessment of the Cleaning Performance of Dishwasher Detergents (Part B, Update 2015)", 9. Creme Brulee, IKW, p46, Sofw Journal - 142 - 06/16. (see, http://www.ikw.org/fileadmin/content/downloads/ Haushaltspflege/ 2016_EQ_
Dishwasher Detergents Part B Update_2015.pdf (last visited December 14, 2016)) using either 1.7 or 2.5 g of material per tile.
[00160] The melamine tiles were used as a lid and tightly pressed onto a microtiter plate (MTP). 3 g/L of GSMB or MGDA detergent (Tables 1 and 2, respectively) adjusted to 374ppm water hardness and each enzyme sample were added to the MTP prior to attaching the melamine tile lid to the MTP. The volume capacity of the MTP, and therefore the volume of solution added thereto, may vary, wherein a minimal volume of solution that enables contact between solution and stain surface should be added to the MTP. In this example, a volume of 300μΙ. of detergent containing enzyme was added to each well of an aluminum 96-well MTP. The MTPs were incubated in an Infors thermal shaker for 45 min at 40°C at 250 rpm. After incubation, the tiles were removed from the MTP and air-dried.
[00161] In some instances, stain removal was quantified using red, green and blue (RGB) measurements taken with a scanner (MiCrotek Scan Maker 900). Images were imported into Photoshop CSII to extract the RGB values from the stain areas using IPTK 5.0 software from Reindeer Graphics. In other instances, stain removal was quantified by photographing the plates and measuring the RGB values from each stain area using custom software.
[00162] Percent Soil removal (%SRI) values of the washed tiles were calculated by using the RGB values in the following formula:
% SRI = (ΔΕ/ΔΕ initial ) * 100
Whe e AE = SQR((Rafter - Rbefore)2 + (Gaiter - Gbefore)2 + (Baiter - Bbefore)2)
Where ΔΕ initial = SQR((Rwhite - Rbefore) +(Gwhite - Gbefoie Y + (BwhSte - Bbefore)2)
[00163] Cleaning performance was obtained by subtracting the value of a blank control (no enzyme) from each sample value (hereinafter "blank subtracted cleaning"). For each condition and subtilisin variant, a performance index (PI) was calculated by dividing the blank subtracted cleaning by that of the parent protease at the same concentration. The value for the parent protease PI was determined from a standard curve of the parent protease which was included in the test and which was fitted to a Langmuir fit or Hill Sigmoidal fit.
Egg Yolk and BMI
[00164] The automatic dishwashing (ADW) cleaning performance of the subtilisin variants described herein was tested relative to parent using GSM-B detergent (see Table 1), pH 10.5 and egg yolk microswatches (PAS-38, Center for Testmaterials BV, Vlaardingen, Netherlands). Prepunched (to fit a MTP), rinsed and unrinsed, PAS-38 swatches were used in this assay. Rinsed PAS38 swatches were prepared by adding 180μί lOmM CAPS buffer, pH 11, to MTPs containing the PAS38 microswatches. The MTPs were sealed and incubated in an iEMS incubator for 30 min at 60°C and 1100 rpm shaking. After incubation, the buffer was removed, the swatches rinsed with deionized water to remove any residual buffer, and the MTPs air dried prior to use in the assay. The microswatch plates were filled prior to enzyme addition with 3 g/1 GSM-B detergent adjusted to 374ppm water hardness.
[00165] The heavy duty liquid laundry (HDL) and heavy duty powder laundry (HDD) detergent cleaning performance of the subtilisin variants described herein relative to parent was tested using BMI microswatches (blood/milk/ink on cotton) (EMPA-116, Center for
Testmaterials BV, Vlaardingen, Netherlands). Pre-punched (to fit on MTP) and filled microswatch-containing plates were used.
[00166] The microswatch plates were filled prior to enzyme addition with 2.7 g/1 Persil Non- Bio (Unilever) HDL detergent adjusted to 250ppm water hardness, 0.95 g/1 heat inactivated Tide (Procter and Gamble) HDL adjusted to 250ppm water hardness, or 6.5 g/1 ECE-2 HDD adjusted to 250ppm water hardness. Persil Non-Bio, which was purchased for use in this test in the United Kingdom in 2014, does not contain boron or enzymes. Tide liquid laundry detergent, which was purchased in the United State in 2014, contained enzymes that were heat-inactivated by heating the liquid detergent in a water bath at 95°C for 16 hours. ECE-2 detergent from wfk Testgewebe is more fully described in Table 3 set forth hereinbelow.
[00167] After incubating the PAS-38 swatches for 30 min at 40°C, absorbance was read at 405nm with a SpectraMax plate reader. After incubating the EMPA-116 swatches for 15 min at 25°C, absorbance was read at 600nm with a SpectraMax plate reader. Absorbance results were obtained by subtracting the value for a blank control (no enzyme) from each sample value (hereinafter "blank subtracted absorbance"). For each condition and subtilisin variant, a performance index (PI) was calculated by dividing the blank subtracted absorbance by that of the parent protease at the same concentration. The value for the parent protease was determined from a standard curve of the parent protease which was included in the test and which was fitted to a Langmuir fit or Hill Sigmoidal fit.
AAPF Assay
[00168] The protease activity of parent and subtilisin variants thereof was tested by measuring hydrolysis of N-suc-AAPF-pNA. The reagent solutions used for the AAPF hydrolysis assay were: 100 mM Tris/HCl pH 8.6, containing 0.005% TWEEN®-80 (Tris dilution buffer); 100 mM Tris buffer pH 8.6, containing 10 mM CaCk and 0.005% TWEEN®-80 (Tris/Ca buffer); and 160 mM suc-AAPF-pNA in DMSO (sue- AAPF -pNA stock solution) (Sigma: S-7388). A substrate working solution was prepared by adding 1 mL suc-AAPF-pNA stock solution to 100 mL Tris/Ca buffer and mixed well. An enzyme sample was added to a MTP (Greiner 781101) containing 1 mg/suc-AAPF-pNA working solution and assayed for activity at 405 nm over 3 min with a SpectraMax plate reader in kinetic mode at room temperature (RT). The absorbance of a blank containing no protease was subtracted from each sample reading. The protease activity was expressed as mOD min"1.
Stability Assay
[00169] The stability of the subtilisin variants described herein was measured by diluting the variants in stress buffer and measuring the proteolytic activity of the variants before and after a heat incubation step using the AAPF assay described above. The temperature and duration of the heat incubation step were chosen such that the reference protease showed -30% residual activity. Stability was measured in Tris-EDTA (50mM Tris pH 9; 1-5 mM EDTA; 0.005% Tween) buffered condition. Percent residual activities were calculated by taking a ratio of the stressed to unstressed activity and multiplying by 100. Stability Pis were obtained by dividing the residual activity of subtilisin variant by that of the parent protease.
Detergents
Sodium disilicate: Protil A (Cognis) 25.0
Linear fatty alcohol ethoxylate 2.0
Sodium carbonate anhydrous add to 100
Table 2: MGDA pH 10.5 ADW Detergent Ingredients
Component Weight %
MGDA 64.6
Plurafac SLF 18-45D 4.4
Bismuthcitrate 0.4
Phosphonates (Bayhibit S) 0.4
Acusol 420 / Acosul 587 1.6
PEG6000 2.4
PEG1500 5.9
Sodium percarbonate 16.1
TAED 4.1
Table 3. ECE-2 HDD
Component Weight %
Linear sodium alkyl benzene sulfonate 9.7
Ethoxylated fatty alcohol CI 2- 18 (7 EO) 5.2
Sodium soap 3.6
Antifoam DC2-4248S 4.5
Sodium aluminium silicate zeolite 4A 32.5
Sodium carbonate 11.8
Sodium salt of a copolymer from acrylic and maleic acid 5.2 (Sokalan CP5)
Sodium silicate (Si02:Na20 = 3,3 : 1) 3.4
Carboxymethylcellulose 1.3
Diethylene triamine penta (methylene phosphonic acid) 0.8
Sodium sulfate 9.8
Water 12.2
EXAMPLE 2
Expression of Parent Subtilisins and Variants Thereof
[00170] DNA manipulations to generate parent subtilisins and variants thereof were carried out using conventional molecular biology techniques (see, e.g., Sambrook et al, Molecular Cloning: Cold Spring Harbor Laboratory Press). A series of artificial DNA sequences were generated that code for mature subtilisin variant sequences with amino acid modifications introduced into the sequence of the parent subtilisin. All subtilisins were expressed and recovered as described hereinbelow. Protease samples for the studies described herein were generated by culturing cells in selective growth medium in a 96-well MTP at 31°C for 68 hours. Culture supernatant was prepared by centrifugation and filtration.
B. lentus Parent Subtilisin (GG36) and Variants Thereof
[00171] B. lentus P29600 parent subtilisin (UnitProtKB SUB S B ACL) (GG36) (SEQ ID NO: 1) and variants thereof were expressed by using a DNA fragment comprising: a 5'AprE flanking region that contains the B. subtilis PI rrnl promoter sequence (SEQ ID NO:2)(the B. subtilis PI rrnl promoter is more fully described in US-2014-0329309), the aprE signal peptide sequence (SEQ ID NO:3), the pro sequence from B. lentus (SEQ ID NO:4), the sequence corresponding to the gene for the B. lentus P29600 subtilisin (SEQ ID NO:5), the BPN' terminator (SEQ ID NO: 6), the chloramphenicol acetyl transferase (CAT) gene expression cassette from S. aureus (SEQ ID NO: 7), and the 3 'AprE flanking sequence (SEQ ID NO: 8), in consecutive order was assembled using standard molecular techniques. The amino acid sequence of the B. subtilis aprE signal peptide encoded by SEQ ID NO: 3 is set forth as SEQ ID NO:9. The amino acid sequence of the pro sequence encoded by SEQ ID NO:4 is set forth as SEQ ID NO: 10. The amino acid sequence of the protein encoded by the B. lentus P29600 subtilisin gene is set forth as SEQ ID NO: l . This linear B. lentus P29600 expression cassette was used to transform 200uL of competent B. subtilis cells of a suitable strain. The transformed cells were incubated at 37°C for 1 hour while shaking at 250 rpm. The transformation mixture was plated onto LA plates containing 1.6% skim milk and 5 ppm chloramphenicol (CMP) and incubated overnight at 37°C. Single colonies were picked and grown in Luria broth + 5ppm CMP at 37°C. Strain samples were frozen at -80°C with 20% glycerol for storage.
[00172] Genomic DNA of the B. subtilis strain expressing the B. lentus P29600 subtilisin was isolated and used as a template to generate variants of the B. lentus P29600 mature protease region. Variants containing single site amino acid substitutions were created using a polymerase chain reaction with appropriate primer pairs, DNA template, and Q5 polymerase (New England Biolabs). These assembled fragments were used to transform competent B. subtilis cells and the transformants were handled as described above.
[00173] The B. lentus P29600 variants that were generated are listed below in Table 7 with the positions of the amino acid substitutions described relative to both BPN' wild-type and the B. lentus P29600 parent. The sequence of each subtilsin variant set forth in Table 7 was confirmed by DNA sequence analysis. B. gibsonii-clade Bgi02446 Parent Subtilisin and Variants Thereof
[00174] B. gibsonii-da.de Bgi02446 parent subtilisin (Bgi02446) (UnitProtKB-S5VEF0) (SEQ ID NO: 11) and variants thereof were expressed by using a DNA fragment comprising: a 5'AprE flanking region that contains the B. subtilis PI rrni promoter sequence (SEQ ID NO:2) (the B. subtilis PI rrni promoter is more fully described in US-2014-0329309), the aprE signal peptide sequence (SEQ ID NO:3), the pro sequence from B. lentus (SEQ ID NO:4), the sequence corresponding to the gene for the B. gibsonii-dade Bgi02446 subtilisin (SEQ ID NO: 12), the BPN' terminator (SEQ ID NO:6), the chloramphenicol acetyl transferase (CAT) gene expression cassette from S. aureus (SEQ ID NO: 7), and the 3 'AprE flanking sequence (SEQ ID NO: 8), in consecutive order was assembled using standard molecular techniques. The amino acid sequence of the B. subtilis aprE signal peptide encoded by SEQ ID NO: 3 is set forth as SEQ ID NO:9. The amino acid sequence of the pro sequence encoded by SEQ ID NO:4 is set forth as SEQ ID NO: 10. The amino acid sequence of the protein encoded by the B. gibsonii-dade Bgi02446 subtilisin gene is set forth as SEQ ID NO: 11. This linear B. gibsonii-dade Bgi02446 expression cassette was used to transform 200uL of competent B. subtilis cells of a suitable strain. The transformed cells were incubated at 37°C for 1 hour while shaking at 250 rpm. The transformation mixture was plated onto LA plates containing 1.6% skim milk and 5 ppm chloramphenicol (CMP) and incubated overnight at 37°C. Single colonies were picked and grown in Luria broth + 5ppm CMP at 37°C. Strain samples were frozen at -80°C with 20% glycerol for storage.
[00175] Genomic DNA of the B. subtilis strain expressing the B. gibsonii-dade Bgi02446 subtilisin was isolated and used as a template to generate variants of the B. gibsonii-dade Bgi02446 mature protease region. Variants containing single site amino acid substitutions were created using a polymerase chain reaction with appropriate primer pairs, DNA template, and Q5 polymerase (New England Biolabs). These assembled fragments were used to transform competent B. subtilis cells and the transformants were handled as described above.
[00176] The B. gibsonii-dade Bgi02446 subtilisin variants that were generated are listed below in Tables 4, 5, 6, and 7 with the positions of the amino acid substitutions described relative to both BPN' wild-type and the B. gibsonii-dade Bgi02446 subtilisin parent. The sequence of each subtilsin variant set forth in Tables 4, 5, 6, and 7 was confirmed by DNA sequence analysis. B. gibsonii-clade DSM14391 Parent Subtilisin and Variants Thereof
[00177] B. gibsonii-dade DSM14391 parent subtilisin (BgiDSM14391) (SEQ ID NO: 13) and variants thereof were expressed by using a DNA fragment comprising: a 5'AprE flanking region that contains the B. subtilis PI rrnl promoter sequence (SEQ ID NO:2) (the B. subtilis PI rrnl promoter is more fully described in US-2014-0329309), the aprE signal peptide sequence (SEQ ID NO:3), the pro sequence from B. lentus (SEQ ID NO: 4), the sequence corresponding to the gene for the B. gibsonii-dade DSM14391 subtilisin (SEQ ID NO: 14), the BPN' terminator (SEQ ID NO: 6), the chloramphenicol acetyl transferase (CAT) gene expression cassette from S. aureus (SEQ ID NO: 7), and the 3 'AprE flanking sequence (SEQ ID NO: 8), in consecutive order was assembled using standard molecular techniques. The amino acid sequence of the B. subtilis aprE signal peptide encoded by SEQ ID NO:3 is set forth as SEQ ID NO:9. The amino acid sequence of the pro sequence encoded by SEQ ID NO:4 is set forth as SEQ ID NO: 10. The amino acid sequence of the protein encoded by the B. gibsonii-dade DSM14391 subtilisin gene is set forth as SEQ ID NO: 13. This linear B. gibsonii-dade DSM14391 expression cassette was used to transform 200uL of competent B. subtilis cells of a suitable strain. The transformed cells were incubated at 37°C for 1 hour while shaking at 250 rpm. The transformation mixture was plated onto LA plates containing 1.6% skim milk and 5 ppm chloramphenicol (CMP) and incubated overnight at 37°C. Single colonies were picked and grown in Luria broth + 5ppm CMP at 37°C. Strain samples were frozen at -80°C with 20% glycerol for storage.
[00178] Genomic DNA of the B. subtilis strain expressing the B. gibsonii-dade DSM14391 subtilisin was isolated and used as a template to generate variants of the B. gibsonii-dade DSM14391 mature protease region. Variants containing single site amino acid substitutions were created using a polymerase chain reaction with appropriate primer pairs, DNA template, and Q5 polymerase (New England Biolabs). These assembled fragments were used to transform competent B. subtilis cells and the transformants were handled as described above.
[00179] The B. gibsonii-dade DSM14391 subtilisin variants that were generated are listed below in Tables 4, 5, 6, and 7 with the positions of the amino acid substitutions described relative to both BPN' wild-type and the B. gibsonii-dade DSM14391 subtilisin parent. The sequence of each subtilisin variant set forth in Tables 4, 5, 6, and 7 was confirmed by DNA sequence analysis. B. licheniformis AprL Parent Subtilisin and Variants Thereof
[00180] B. licheniformis AprL (subtilisin Carlsberg) parent subtilisin (SEQ ID NO: 15) and variants thereof were expressed by using a DNA fragment comprising: a 5'AprE flanking region that contains the B. subtilis PI rrnl promoter sequence (SEQ ID NO:2) (the B. subtilis PI rrnl promoter is more fully described in US-2014-0329309), the aprE signal peptide sequence (SEQ ID NO:3), the pro sequence from B. licheniformis AprL(SEQ ID NO: 19), the sequence corresponding to the gene for the B. licheniformis AprL subtilisin (SEQ ID NO: 16), the BPN' terminator (SEQ ID NO: 6), the chloramphenicol acetyl transferase (CAT) gene expression cassette from S. aureus (SEQ ID NO: 7), and the 3 'AprE flanking sequence (SEQ ID NO: 8), in consecutive order was assembled using standard molecular techniques. The amino acid sequence of the B. subtilis aprE signal peptide encoded by SEQ ID NO: 3 is set forth as SEQ ID NO: 9. The amino acid sequence of the pro sequence encoded by SEQ ID NO: 19 is set forth as SEQ ID NO:20. The amino acid sequence of the protein encoded by the B. licheniformis AprL subtilisin gene is set forth as SEQ ID NO: 15. This linear B. licheniformis AprL expression cassette was used to transform 200uL of competent B. subtilis cells of a suitable strain. The transformed cells were incubated at 37°C for 1 hour while shaking at 250 rpm. The
transformation mixture was plated onto LA plates containing 1.6% skim milk and 5 ppm chloramphenicol (CMP) and incubated overnight at 37°C. Single colonies were picked and grown in Luria broth + 5ppm CMP at 37°C. Strain samples were frozen at -80°C with 20% glycerol for storage.
[00181] Genomic DNA of the B. subtilis strain expressing the B. licheniformis AprL subtilisin was isolated and used as a template to generate variants of the B. licheniformis AprL mature protease region. Variants containing single site amino acid substitutions were created using a polymerase chain reaction with appropriate primer pairs, DNA template, and Q5 polymerase (New England Biolabs). These assembled fragments were used to transform competent B. subtilis cells and the transformants were handled as described above.
[00182] The B. licheniformis AprL subtilisin variants that were generated are listed below in Table 7 with positions of the amino acid substitutions described relative to both BPN' wild-type and the B. licheniformis AprL subtilisin parent. The sequence of each subtilsin variant set forth in Table 7 was confirmed by DNA sequence analysis. B. amyloliquefaciens Parent Subtilisin (ΒΡΝ') and Variants Thereof
[00183] B. amyloliquefaciens parent subtilisin (BPN')(SEQ ID NO: 17) and variants thereof were expressed by using a DNA fragment comprising: a 5'AprE flanking region that contains the B. subtilis PI rrnl promoter sequence (SEQ ID NO:2) (the B. subtilis PI rrnl promoter is more fully described in US-2014-0329309), the aprE signal peptide sequence (SEQ ID NO:3), the pro sequence from BPN' (SEQ ID NO:21), the sequence corresponding to the gene for the BPN' subtilisin (SEQ ID NO: 18), the BPN' terminator (SEQ ID NO:6), the chloramphenicol acetyl transferase (CAT) gene expression cassette from S. aureus (SEQ ID NO: 7), and the 3 'AprE flanking sequence (SEQ ID NO: 8), in consecutive order was assembled using standard molecular techniques. The amino acid sequence of the B. subtilis aprE signal peptide encoded by SEQ ID NO:3 is set forth as SEQ ID NO:9. The amino acid sequence of the pro sequence encoded by SEQ ID NO:21 is set forth as SEQ ID NO:22. The amino acid sequence of the protein encoded by the BPN' gene is set forth as SEQ ID NO: 17. This linear BPN' expression cassette was used to transform 200uL of competent B. subtilis cells of a suitable strain. The transformed cells were incubated at 37°C for 1 hour while shaking at 250 rpm. The transformation mixture was plated onto LA plates containing 1.6% skim milk and 5 ppm chloramphenicol (CMP) and incubated overnight at 37°C. Single colonies were picked and grown in Luria broth + 5ppm CMP at 37°C. Strain samples were frozen at -80°C with 20% glycerol for storage.
[00184] Genomic DNA of the B. subtilis strain expressing the BPN' subtilisin was isolated and used as a template to generate variants of the BPN' mature protease region. Variants containing single site amino acid substitutions were created using a polymerase chain reaction with appropriate primer pairs, DNA template, and Q5 polymerase (New England Biolabs).
These assembled fragments were used to transform competent B. subtilis cells and the transformants were handled as described above.
[00185] The BPN' subtilisin variants that were generated are listed below in Table 7 with the positions of the amino acid substitutions described relative to BPN' wild-type subtilisin parent. The sequence of each subtilsin variant set forth in Table 7 was confirmed by DNA sequence analysis.
EXAMPLE 3
Performance of B. gibsonii-clad Subtilisins in Laundry and Dish Applications
[00186] The cleaning performance of the B. gibsonii-clade subtilisins (Bgi02446 and BgiDSM14391) and variants thereof made in accordance with Example 2 were evaluated in the egg-yolk and BMI assays described in Example 1. The stability of the B. gibsonii-dadt subtilisins (Bgi02446 and BgiDSM14391) and variants thereof made in accordance with Example 2 were evaluated in the stability assay described in Example 1. For the wild-type Bgi02446 subtilisin and variants thereof, the heat incubation step was conducted for 5 mins at a temperature at which the wild-type subtilisin had approximately 30% residual activity. For the wild-type BgiDSM14391 subtilisin and variants thereof, the heat incubation step was conducted for 5 mins at a temperature at which the wild-type subtilisin had approximately 30% residual activity.
[00187] The egg-yolk cleaning performance of the B. gibsonii-clade subtilisins and variants thereof is set forth in Table 4, expressed as PI values versus parent subtilisin. The BMI cleaning performance of the B. gibsonii-clade subtilisins and variants thereof is set forth in Tables 5, expressed as PI values versus parent subtilisin. The stability of the B. gibsonii-dadt subtilisins and variants thereof is set forth in Table 6, expressed as PI values versus parent subtilisin. The PI values were calculated as described above in Example 2, where the parent of the Bgi02446 variants is the wild-type Bgi02446 subtilisin (SEQ ID NO: l 1), and the parent of the
BgiDSM14391 variants is the wild-type BgiDSM14391 subtilisin (SEQ ID NO: 13). Dashes on Tables 4, 5, and 6 indicate samples where results were not determined. Tables 4, 5 and 6 show the corresponding residue in the BPN' sequence (SEQ ID NO: 17) for each Bgi02446 residue according to the alignment shown on Figure 1.
Table 4: ADW EGG Performance of Subtilisin Variants Ex ressed as PI vs Parent
Table 4: ADW EGG Performance of Subtilisin Variants Ex ressed as PI vs Parent
Table 4: ADW EGG Performance of Subtilisin Variants Ex ressed as PI vs Parent
Table 4: ADW EGG Performance of Subtilisin Variants Ex ressed as PI vs Parent
Table 5: Laundry BMI Performance of Subtilisin Variants, Expressed as PI vs Parent
Table 5: Laundry BMI Performance of Subtilisin Variants, Expressed as PI vs Parent
ib seqence nmernguu
ib seqence nmernguu
EXAMPLE 4
Creme Brulee Cleaning Performance of Various Subtilisins
The creme brulee cleaning performance of the subtilisins made in accordance with Example 2 was evaluated in the creme brulee assay described in Example 1. The creme brulee cleaning performance of the subtilisin variants is set forth in Table 7, expressed as PI values versus parent subtilisin. The PI values were calculated as described above in Example 2, where the parent of the BPN' variants is the wild-type BPN' subtilisin (SEQ ID NO: 17), the parent of the GG36 variants is the wild-type GG36 subtilisin (SEQ ID NO: 1), the parent of the AprL variants is the wild-type AprL subtilisin (SEQ ID NO: 15), the parent of the Bgi02446 variants is the wild-type Bgi02446 subtilisin (SEQ ID NO: 1 1), and the parent of the BgiDSM14391 variants is the wild-type BgiDSM14391 subtilisin (SEQ ID NO: 13). Dashes denote instances where results were not determined. Table 7 shows the corresponding residue in the BPN' sequence (SEQ ID NO: 17) for each residue of the other subtilisin backbones according to the alignment shown on Figure 1.
EXAMPLE 5
Stability, Laundry and ADW Cleaning Performance of Bgi02446-S39E Variants
[00189] The Bgi02446-S39E subtilisin (the designation S39E indicates a substitution of serine (S) at position 39 of the mature protein to glutamic acid (E)) and variants thereof described in this example were made in accordance with Example 2. The Bgi02446-S39E subtilisin and variants therof were studied using methods described in Example 1. Stability, laundry and automatic dish (ADW) cleaning performance were measured in accordance to methods described in Example 1 and results are shown on Table 8 as compared to the parent Bgi02446-S39E. ND indicates instances where results were Not Determined. Table 8 shows the corresponding residue in the BPN' sequence (SEQ ID NO: 17) for each Bgi02446-S39E residue according to the alignment shown on Figure 1.
[00190] The stability of the Bgi02446-S39E subtilisin variants was evaluated using the stability assay described in Example 1, where the heat incubation step was conducted for 5 mins in Tris buffer pH 9 containing 5 mM EDTA at a temperature at which the parent Bgi02446-S39E subtilisin had approximately 45% residual activity. The stability is expressed as percent residual activity (Residual activity in EDTA (%)) as compared to the parent Bgi02446-S39E.
[00191] The laundry cleaning performance of the Bgi02446-S39E subtilisin and variants thereof was evaluated on egg-yolk (PAS-38 stain) and BMI assays as described in Example 1. The BMI cleaning performance of the Bgi02446-S39E variants, tested using Persil Non-Bio HDL detergent and ECE-2 HDD detergent is set forth in Table 8, expressed as PI values versus parent subtilisin. The egg-yolk cleaning performance of the Bgi02446-S39E subtilisin variants tested using GSM-B detergent in unrinsed or rinsed PAS-38 swatches is set forth in Table 8, expressed as PI values versus parent subtilisin. The PI values were calculated as described above in Example 1, where the parent is the Bgi02446-S39E subtilisin.
[00192] The ADW creme brulee cleaning performance of the subtilisins made in accordance with Example 2 was evaluated in the creme brulee assay described in Example 1. The creme brulee cleaning performance of the subtilisin variants tested on DM10 tiles using either GSM-B or MGDA detergents is set forth in Table 8, expressed as PI values versus parent subtilisin. The PI values were calculated as described above in Example 1, where the parent is the Bgi02446-S39E subtilisin. 21 S 41 1.1 0.9 0.9 1.0 1.0 0.9
21 T 40 1.0 0.9 1.0 1.1 1.0 1.0
21 W 40 1.0 0.9 1.1 1.0 1.0 0.8
21 Y 44 1.1 0.9 0.9 1.0 1.1 1.0
47 D 41 1.0 0.7 0.9 0.7 1.3 1.4
47 E 44 1.1 0.7 1.0 1.0 1.4 1.4
47 K 42 0.9 1.0 1.0 1.1 0.7 0.6
47 M 45 1.1 1.1 0.9 1.2 1.1 0.9
47 N 38 1.0 0.9 0.9 0.6 1.1 0.9
47 Q 41 1.0 1.0 1.0 1.0 1.1 0.9
47 R 40 0.8 1.2 0.9 1.0 0.7 0.5
47 V 43 1.0 1.0 1.0 1.1 0.8 0.9
56 C 46 1.0 0.7 1.0 1.0 1.1 1.3
56 D 41 1.1 0.8 1.0 0.7 1.4 1.7
56 E 44 1.2 0.8 ND 0.5 1.3 1.6
56 H 43 1.1 0.9 1.0 1.0 0.9 1.0
56 I 41 1.0 ND 1.0 1.1 1.0 1.1
56 K 37 1.1 0.7 0.9 0.9 1.2 1.6
56 M 43 1.0 1.0 1.0 1.0 0.9 1.3
56 N 42 1.0 0.9 1.1 ND 1.0 1.2
56 P 44 1.0 1.0 1.1 1.0 0.9 1.0
56 Q 41 1.2 1.1 1.0 0.7 1.1 1.5
56 s 43 1.0 1.0 1.1 0.9 1.0 1.2
56 w 46 1.1 0.9 1.0 0.9 0.8 0.9
74 D 76 1.1 0.8 1.1 0.9 1.2 1.3
80 L 61 1.0 0.9 0.9 1.0 0.9 1.1
85 A 40 0.9 1.1 0.9 1.0 1.1 1.0
85 C 46 1.2 1.4 1.2 2.1 1.9 1.7
85 D 64 1.1 0.8 0.9 1.1 1.1 1.3
85 E 64 1.1 0.7 1.0 0.9 1.1 1.3
85 M 39 1.0 1.0 1.0 1.0 1.0 1.1
85 V 43 1.0 0.9 0.9 1.0 1.0 1.1
87 A 38 0.8 1.2 1.0 1.0 1.1 1.0
87 D 43 1.0 0.9 1.0 0.9 1.2 1.1
87 G 36 0.9 1.0 1.1 0.6 0.9 0.7
87 H 36 0.9 1.3 1.0 0.9 0.9 0.9
87 M 36 1.0 1.5 1.0 0.9 1.1 1.0
87 N 36 1.0 1.8 1.1 1.0 1.2 0.9
87 Q 36 0.9 1.2 1.0 1.0 0.8 0.8
87 s 41 0.9 1.1 1.0 0.9 0.8 0.7
87 w 35 0.9 1.3 1.1 0.8 0.8 0.8 99 97 A 46 1.1 1.0 1.0 0.8 1.0 1.1
99 97 D 42 1.1 0.7 1.1 1.4 1.4 1.8
99 97 G 43 1.0 0.8 0.9 0.9 0.9 1.1
99 97 S 44 1.0 1.1 1.0 1.0 1.0 1.1
101 99 E 36 1.3 0.5 1.0 1.5 1.5 1.7
101 99 F 46 0.7 0.8 1.0 1.3 0.7 0.5
101 99 G 41 1.2 0.8 0.8 0.3 1.0 0.9
101 99 I 43 0.7 0.9 1.1 1.5 0.6 0.6
101 99 K 44 0.8 0.7 1.2 1.5 0.6 0.7
101 99 L 45 1.0 0.8 1.1 1.7 1.3 0.8
101 99 M 44 1.1 1.0 0.9 1.4 0.9 1.3
101 99 N 44 1.2 1.3 0.9 1.1 1.1 1.1
101 99 Q 43 1.2 1.0 1.1 1.1 1.0 1.0
101 99 V 45 0.7 0.9 1.0 1.4 0.9 0.7
101 99 w 43 0.5 0.4 0.8 1.3 0.5 0.4
101 99 Y 45 0.7 0.5 1.0 1.4 0.8 0.5
103 101 A 43 0.8 ND 0.8 0.6 0.8 0.9
116 114 A 46 0.9 1.1 0.9 0.9 1.0 1.1
116 114 D 47 1.1 0.7 1.0 1.1 1.2 1.5
116 114 E 54 1.0 0.8 1.0 1.0 1.2 1.3
116 114 F 40 1.1 1.2 0.9 0.7 0.9 1.0
116 114 K 42 0.9 1.1 1.1 1.1 0.7 1.0
116 114 L 44 1.0 1.0 1.1 1.1 1.0 1.5
116 114 M 47 1.0 1.0 1.0 1.0 0.9 1.1
116 114 N 45 1.0 1.2 1.1 1.2 1.0 1.3
116 114 Q 45 1.0 1.0 1.1 1.0 1.0 1.2
116 114 s 43 1.1 1.1 1.0 1.1 0.9 1.2
118 116 D 45 1.0 0.8 0.9 0.9 1.2 1.4
118 116 R 42 0.7 1.1 0.8 0.9 0.7 0.8
128 126 I 40 1.0 0.5 1.1 1.4 0.6 0.9
128 126 L 43 1.7 1.6 1.4 2.9 1.4 1.7
128 126 T 46 1.0 0.8 1.1 1.1 0.9 1.0
129 127 E 42 0.9 1.0 ND 0.9 1.1 1.2
130 128 A 39 1.2 1.0 1.1 1.2 1.3 2.4
130 128 H 41 0.9 0.8 0.9 1.1 1.4 0.1
130 128 I 44 1.1 0.8 0.9 1.2 1.3 1.0
130 128 K 38 1.0 0.9 1.0 1.2 0.9 0.8
130 128 L 43 1.0 0.9 1.0 1.2 1.6 1.3
130 128 N 41 1.1 1.0 1.1 1.2 1.3 1.9
130 128 Q 41 1.3 1.1 1.1 1.3 1.6 0.1
130 128 R 37 1.0 1.8 1.0 2.0 1.4 1.4 130 128 S 39 1.1 0.8 1.2 1.1 1.4 0.0
130 128 T 37 1.3 0.7 1.1 1.2 1.6 0.0
130 128 V 42 1.0 0.8 1.0 1.2 1.4 1.2
130 128 Y 45 0.9 0.6 1.0 1.3 1.4 0.0
159 157 s 45 1.1 1.0 1.1 1.1 1.0 1.0
170 164 s 37 1.3 0.3 0.9 0.5 1.5 2.1
194 188 P 48 1.0 1.1 0.9 1.0 0.9 0.8
205 199 I 45 D 0.7 1.0 1.0 0.7 1.3
206 200 C 60 0.9 0.3 0.9 0.9 1.2 1.3
206 200 L 69 0.8 0.8 0.8 0.9 0.9 1.1
218 212 D 41 1.3 0.4 1.1 1.1 2.0 1.5
245 239 R 42 0.8 1.1 1.0 0.9 0.7 0.9
248 242 C 44 1.1 0.6 0.9 0.9 0.9 1.5
248 242 E 44 1.1 0.8 1.0 1.0 0.9 1.3
248 242 G 40 1.0 0.9 1.0 0.8 0.7 1.1
248 242 H 42 0.9 0.9 1.0 0.9 0.7 1.2
248 242 I 43 1.1 1.0 1.0 1.0 0.8 1.2
248 242 K 36 0.8 0.9 1.0 1.1 0.6 0.7
248 242 L 48 0.9 0.9 1.0 1.0 0.7 1.4
248 242 M 48 1.0 0.9 0.9 1.1 0.6 1.0
248 242 Q 44 1.1 1.1 1.0 1.0 0.7 1.0
248 242 s 44 1.1 0.9 0.9 1.0 0.8 1.1
248 242 T 43 1.1 0.9 0.9 1.0 0.7 1.2
248 242 V 44 1.0 0.9 1.0 1.0 0.7 1.2
248 242 w 44 0.8 0.8 0.9 0.9 0.6 1.1
248 242 Y 42 0.8 0.8 0.7 0.9 0.7 1.3
255 249 R 40 0.8 1.3 0.9 0.9 0.5 0.4

Claims

Claims We claim:
1. A subtilisin variant comprising an amino acid sequence comprising one or more amino acid substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from:
(i) 1A/C/D/E/G/H/I/K/M/N/R/S/T/V, 9R, 15T,
21 A C/D/E/F/G/H/K/L/M/N/P/Q/R/S/T/VAV/Y, 38 A/C/D/E/F/G/H/I/L/M/N/P/Q/R/V, 40A/C/D/E/F/G/M/N/P/Q/R/T/Y, 48C/D/E/I/K/M/N/P/Q/R/S/T/V/Y,
58C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/VAV/Y, 76 A/C/D/E/F/G/H/I/K/L/M/Q/T/V/Y,
82 A/ C/E/F/ G/H/K/L/M/N/P/ Q/R/ S/T/W /Y, 87A/C/D/E/F/G/H/I/L/M/Q/T/V/W,
89A/C/D/F/G/H/L/M/N/P/Q/R/S/V/W, 99A D/G/S,
101A D/E/F/G/H/I/K/L/M/N/Q/S/T/VAV/Y, 116A/C/D/E/F/G/H/K/L/M/N/Q/R/S/V, 118D/R, 128A/D/E/H/I/L/M/N/Q/T/V/Y, 129C/E, 130A/C/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 163S, 170S, 194P, 2051, 206C/L, 218D, 245R, 248A/C/E/F/G/H/I/K/L/M/Q/S/T/V/W/Y, and 255R;
(ii) I S, 21E/F/G/M/N/P/Q/R/S/T, 38C/D/F/G/L/P, 40A/C/D/G/M/N, 48P/Q/T, 58C/D/F/M/Q/R, 76A/D/F/G/H/I/K/L/M/Q/T/V/Y, 82C/M/R/T/Y, 87D/Q, 89C/R, 101D/E/M, 116D/E/H/N/R, 128D/E/N/Q/V, 129C, 130D/E/G/V, and 248T;
(iii) 1D/E/M/N/S, 21A/C/D/F/G/L/M/N/P/Q/R/S/V/W/Y, 38A D/F/G/L/M/N/P/Q/R, 40A/C/D/F/G/M/N/P/Q/R, 48K, 58L/M/P/Q/R/S/W/Y, 76A/D/F/K/M/Q,
82A/C/F/K/M/N/R/T/Y, 87A/C/D/E/F/G/H/M/Q, 89C/F/H/L/N/P/Q/R/S/V/W, 101M, 116A/C/D/E/F/H/M/N/R, 128A, 129E, 130G, and 248A/F/H/Q/T;
(iv) 21F/M/N/P/Q/R/S, 38D/F/G/P, 40G/M, 58R, 76A/D/F, 82M/R, 89C/R, and 116H/N/R;
(v) 1C/E/S/T/V, 21E/G/Q/S/T/V, 38C/D/E/G/H/I/L/V, 40A/C/D/E/G/N/Q/T/Y, 48C/D/E/I/N/P/Q/S/T/V/Y, 58C/D/E/F/G/I/K/M/Q/V, 76A/C/D/E/F/G/H/I/L/M/T/V/Y, 82C/E/ G/H/N/P/ Q/R/ S/T/W /Y, 87A/C/D/I/L/M/Q/T/V/W, 89C,
lOlA/D/E/G/H/I/K/L/M/N/Q/S/T/V, 116C/D/E/G/H/N/V, 128D/E/H/L/M/N/Q/T/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V/Y, and 248A/C/E/G/Q/S/T/V; (vi) 21E/T, 38C/D/G/L, 40D/G, 48P/Q/T, 58D/F, 76D/G/H/I, 82T/Y, 87D/Q, 89C, 101D/E, 116D/E/H/N, 128D/E/N/Q/V, 129C, 130D/E/G/V, and 248T;
(vii) 1C/D/E/F/I/K/L/M/N/P/V/Y, 21A/E/G/H/K/L/M/N/P/S/T/V/W/Y,
38C/D/E/H/I/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/G/H/I/T/Y,
58 A/C/D/E/F/G/H/I/K/M/S/V, 76 A/C/D/E/G/H/I/K/L/M/P/S/T/V/W/Y,
82A/C/E/G/H/K/M/N/P/Q/R/S/T/W/Y, 87A/C/D/F/H/I/K/L/M/P/Q/T/V/W/Y, 89C/H/K/N/P/V, 101D/E/F/I/K/L/M/N/Q/T/V/Y, 116A/C/D/E/G/K/L/N/R/S/V,
128A/D/F/H/I/K/L/M/N/Q/T/V/W/Y, 129C, 130D/E/G/H/I/K/M/N/Q/S/T/W/Y, and
48A/E/G/L/Q/T/V;
(viii) IK, 21K/M/T, 38D/V, 58G/K/V, 76C/I/K, 82G/M/P/S/T/Y, 87C, 89C, 116A/D, 128A/D/I/K/L/N/Q/V, 129C, and 130E/S/T;
(ix) 1C/D/E/I/L/M/T/Y, 21A/C/D/E/G/L/M/N/R/W/Y,
38 A/C/D/E/G/H/I/L/M/N/P/S/T/VAV/Y, 40A/C/D/E/G/I/K/L/M/T/V/W/Y,
8C/D/E/G/H/I/M/N/P/Q/S/T/V/Y, 58 A/C/D/E/G/I/K/L/M/N/P/Q/R/S/V/Y,
76A/C/D/E/G/H/L/M/P/Q/S/T/V/Y, 82C/D/E/F/H/K/L/M/N/P/Q/S/T/V/Y,
87 A/ C/D/E/F/ G/H/K/L/M/N/P/ Q/ S/T/V/W / Y, 89A/C/D/E/M/N/Y,
101 A/D/E/F/G/H/I/K/L/M/N/Q/S/T/V/Y, 116 A/C/D/E/G/H/I/K/L/M/N/Q/S/V/Y,
128A/D/K/N/Q/T/W/Y, 129C, 130C/D/E/G/H/I/K/L/M/N/P/Q/S/T/V/W/Y, and
48A/C/D/E/G/H/I/K/L/Q/S/T/V/Y;
(x) IT, 21C/D/E/L, 38C/D/E/G/I/L/M/V, 40D/E/I/L/V, 48C/D/E/P/V/Y,
58C/D/G/I/K/V/Y, 76C/D/E/P/T/Y, 82S/T/V/Y, 87C/D/E/G/P, 89C, 101A/D/E/L/M/N/T/V, 116A/D/E/H/I/L/N/Y, 128D/T, 129C, 130/D/E/G/L/Q/S/T/V, and 248G/T;
(xi) 1C/D/E, 21C/D/E/R, 38C/D/E/G/I/M/S/T, 40C/D/E/L, 48C/D/E/I/S/V/Y,
58A/C/D/E/K, 76A/C/D/E/T, 82E/S, 87C/D/E/N, 89C, lOlA/D/E/G/H/I/L/M/N/Q/S/T/V, 116A/C/D/E, 128D/T/W/Y, 129C, 130C/D/E/G/H/I/K/L/N/S/T/V/W/Y, and
48C/D/E/G/H/I/K/L/Q/T/V/Y;
(xii) 21D, 38C/D/E, 40D, 48E, 58C, 76D/E/T, 87C/D, 89C, 101D/E, 116D/E, and 130D/E/G;
(xiii) 1C/H/K/L/S/T/Y, 38D/E/G/H/I/K/L/M/N/P/V, 40A/C/D/E/F/I/M/P/R,
8C/G/I/M/N/Q/T/W/Y, 58I/P/S/V, 76A/C/D/F/P/Q/S, 87A/C/D/L/M/T, 89C/F/G/M/N/Q/S, 101C/E/F/HZM/N/P/S/T, 116D/E/F/G/H/I/L/N/S/V/W/Y, 128F/I/M, 129C,
130C/D/E/G/H/M/N/P/Q/R/S/T/V, and 248C/D/G/L/S/W;
(xiv) 38D/E/P, 40C/M, 76P, 89C/G/M, 101E/N, 116H/I, 128M, and 130G;
(xv) 21E/L, 38C/D/E/G/H/V, 40D, 48C/E, 58K, 76A/C/D/E/G/T, 82S, 87C, 89C, 101D/e/M/N, 116A/C/D/E, 128K/T/W/Y, 130D/G/H/I/K/L/N/S/Y, and 248E/G/I/K/Q/T/Y
(xvi) 87C, 89C, 1 16A/D, and 130G;
(xvii) 38D/E/G/H, 48C, 76A/C, 87C, 89C, 101D/E/N, 116D/E, 130G, 130H, 130N, 130S, and 248G;
(xviii) 38D/E/G/I/M, 40C/D/E, 48C, 76A/C/D, 87C/D, 89C, 101E/M/N/S/T, 116D/E, 128T, 130C/D/E/G /H/N/S/T, and 248C; or
(xix) combination of (i) to (xviii);
wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
2. A subtilisin variant comprising an amino acid sequence comprising one or more amino acid substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from:
(i) 1 C/H/K/L/T/Y, 38D/E/G/H/I/K/L/M/P, 40C/F/M, 48C/G/I/M/N/Q/T/W/Y, 58I/P,
76A/C/F/P, 87A/D, 87L/M/T, 89C/F/G/M/N/Q/S, 101E/H/N, 116E/F/H/I/N/S/V/W, 128F/M, 130C/G/HZM/N/P/R/S/T, and 248C/S;
(ii) I S, 38D/E/N/P/V, 40A/C/D/E/I/M/P/R, 58S/V, 76D/P/Q/S, 87C, 89C/G/M,
101C/E/F/M/N/P/ST, 116D/G/H/I/L/Y, 128I/M, 130D/E/G/Q/V, and 248D/G/L/W;
(iii) IK, 76D, 82L, 87D/E, 116E, and 206C/L;
(iv) 1C/E, 21E/T, 38C/D/G, 40C/D/G/N, 48D/E/I/P/S/T, 58C/D/F/G/I/K/Q/V,
76C/D/E/F/G/H/I/L/T/V/Y, 82G/H/N/P/Q/R/S/T/W/Y, 87C/D/L/Q/T/V, 89C, 101D/E, 116C/D/E/H/N, 128D/E/L/Q/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V, and 248A/E/Q/T/V;
(v) 1 S/T/V, 21E/G/Q/S/T, 38C/D/E/G/I/L/V, 40D/E/G/T, 48P/T/V, 58C/D/E, 76D/G/H/I, 82 Y, 87D, 89C, 101A/D/E/G/H/I/K/L/M/N/Q/S/T/V, 116D/E/G/N, 128D/E/N/Q/T/V, 129C, 130D/E/G/V, and 248G/S/T; 1G/I, 15T, 21D/E/F/G/H/M/P/Q/S/Y, 48E/M, 58D/E/H/K/Q/W, 76D, 87C/D/E, 101E/G/M/N/Q, 116D/F/S, 128L, 130A/I/N/Q/S/T, 159S, 170S, 218D, and
248C/E/I/Q/S/T;
21E, 58D, 76D, 87D, 101E, 116D, and 248T;
1D/E/N/S, 21 F/ G/L/M/N/P/ Q/R/ S/ V/W / Y, 38D/F/G/L/N/P/Q, 40D/G/M/Q, 58P/R, 76A/D/F/K/M, 82K/M/N/R/T/Y, 87A/C/D/F/G/H/M/Q, 89C/H/L/R/W, 101M,
116A/C/D/E/F/H/N/R, 128A, 129E, 130G, and 248A/F/H/Q/T;
1M, 21A/C/D/F/M/N/P/Q/R/S, 38A/D/F/G/M/P/R, 40A/C/F/G/M/N/P/R, 48K, 58L/M/Q/R/S, 58W, 58Y, 76 A, 76D, 76F, 76Q, 82 A, 82C, 82F, 82M, 82R, 87E, 89C, 89F, 89N, 89P, 89Q, 89/S/V, and 116H/M/N/R;
1A/G/K/M/R, 9R, 21M/N/P, 48M/R, 58I/Q, 87A/C, 89A/H/M/N/Q/S/W, 101N, 116A/F/K/N/S, 128L, 130Q/R,194P, 245R 248Q, and 255R;
21M/N/P and 116N;
IC/D/E/F/I/K/L/M/N/V/Y, 21A/E/G/H/K/L/M/N/P/S/T/VAV/Y, 38C/D/H/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/H/I/T/Y, 58C/F/G/I/K/M/V,
76A/C/D/E/G/I/K/L/M/P/T/VAV/Y, 82E/G/H/K/M/N/P/Q/R/S/T/W/Y,
87A/C/D/F/H/I/K/L/M/T/VAV/Y, 89C/H/N, 101D/E/F/I/K/L/Mm/Q/T/V/Y,
116A/C/D/E/G/K/L/N/R/S/V, 128A/D/I/K/L/M/N/Q/V/W, 129C,
130D/E/G/H/I/K/M/N/S/T/W/Y, and 248A/E/L/Q/TV;
1K/P, 21K/M/Q/T, 38D/E/I/V, 48G, 58A/D/E/G/H/K/S/V, 76C/H/I/K/S,
82A/C/G/M/P/S/T/Y, 87C/P/Q, 89C/K/P/V, 116A/D, 128A/D/F/H/I/K/L/N/Q/T/V/Y, 129C, 130E/Q/S/T, and 248 G;
lA/H/K/M/R/V, 15T, 21D/G/H/K/L/M/T/W, 48K/M/V, 58E/I/N/P/S, 76D, 87C/D, 89G/N/W, 101E/F/I/K/L/M/N/Q/V/W/Y, 116D/K/L/N/Q/S, 128I/L/T, 129E,
130A/H/I/K/L/N/Q/R/S/T/V/Y, 159S, 218D, and 248K/M;
IK, 21K/M/T, 87C, 116D, 128I/L, and 130S/T;
1T/Y, 21C/D/E/L/R, 38C/D/E/G/H/I/L/M/S/T/V/W, 40D/E/I/K/L/T/V/W,
48C/D/E/M/N/P/Q/V/Y, 58A/C/D/G/I/K/M/N/P/Q/R/S/V/Y, 76A/C/D/E/L/M/P/T/V/Y, 82C/D/E/K/M/N/P/Q/S/T/V/Y, 87 A/ C/D/E/F/ G/H/K/L/M/P/ S/T/V/W / Y,
89A/C/D/M/N/Y, 101A/D/E/L/M/N/T/V/Y, 116A/C/D/E/H/I/K/L/N/S/V/Y, 128D/K/T/W/Y, 129C, 130C/D/E/G/H/I/K/L/N/P/Q/S/T/V/W/Y, and
248A/C/D/E/G/H/I/K/L/Q/T/V/Y;
(xvii) 1 C/D/E/I/L/M/T, 21 A/C/D/E/G/L/M/N/W/Y, 38 A/C/D/E/G/I/L/M/N/P/V/Y,
40A/C/D/E/G/I/L/M/V/Y, 48C/D/E/G/H/I/P/S/T/V/Y, 58C/D/E/G/I/K/L/V/Y,
76C/D/E/G/H/P/Q/S/T/Y, 82F/H/L/S/T/V/Y, 87C/D/E/G/N/P/Q, 89C/E,
101A/D/E/F/G/H/I/K/L/M/N/Q/S/T/V, 116A/D/E/G/H/I/L/M/N/Q/Y, 128A/D/N/Q/T, 129C, 130D/E/G/L/M/Q/S/T/V, and 248G/S/T;
(xviii) IM, 21A/C/D/E/H/M/N/P/Y, 48D/E/M/N/Q, 58C/D/E/I/K/M/N/Q/S, 76D, 82L,
87A/C/D/E/M/V, 89A/D/M/N, 101E/L/M/N, 116A/D/E/L/M/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, 170S, 2051, 206C/L, 218D, and
248C/E/G/H/I/L/S/T/V/W/Y;
(xix) 21C/D/E, 48D/E, 58C/D/I/K, 76D, 87C/D/E, 101E/L/M/N, 116A/D/E/L/N,
130L/Q/S/T/V, and 248G/T;
(xx) 1Y, 21E/L, 38C/D/H/L/V, 40D/I/T/V, 48E/Y, 58C/G/I/K/M/V,
76A/C/D/E/L/M/P/T/V/Y, 82E/K/M/N/P/Q/S/T/Y, 87A/C/D/F/H/K/L/M/T/V/W/Y, 89C/N, 101D/E/L/M/N/T/V/Y, 116A/C/D/E/K/L/N/S/V, 128D/K/W, 129C,
130D/E/G/H/I/K/N/S/T/W/Y, and 248A/E/L/Q/T/V;
(xxi) 21M, 38D/E/I/V, 48G, 58D/E/G/K/V, 76C/H/S, 82S/T/Y, 87C/P/Q, 89C, 116A/D, 128A/D/N/Q/T, 129C, 130E/Q/S/T, and 248 G;
(xxii) IM, 21D/H/M, 48M, 58E/I/N/S, 76D, 87C/D, 89N, 101E/L/M/N, 116D/L/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, and 218D;
(xxiii) 87C, 116D, and 130S/T;
(xxiv) 1Y, 38D/H/L, 48Y, 581, 76A/C/P, 87A/D/L/M/T, 89C/N, 101E/N, 116E/N/S/V, and 130G/H/N/S/T;
(xxv) 38D/E/V, 58V, 76S, 87C, 89C, 116D, 130E/Q, and 248G;
(xxvi) 76D and 87D;
(xxvii) 1T/Y, 38D/E/G/H/I/L/M, 48C/M/N/Q/Y, 58I/P, 76A/C/P, 87A/D/L/M/T, 89C/M/N, 101E/N, 116E/H/I/N/S/V, 130C/G/H/N/P/S/T, and 248C;
(xxviii) 38D/E/N/P/V, 40A/C/D/E/I/M, 58V, 76D/P/Q/S, 87C, 89C, 101E/F/M/N/S/T,
116D/G/H/I/L/Y, 130D/E/G/Q/V, and 248G; or
(xxix) 76D, 82L, 87D/E, 116E, and 206C/L, wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
3. The subtilisin variant according to Claim 1 or 2, wherein said variant
(i) is a member of the Bacillus gibsonii-clade;
(ii) is isolated;
(iii) has proteolytic activity; or
(iv) comprises a combination of (i) to (iii).
4. The subtilisin variant according to any preceding claim, wherein said variant is derived from a parent or reference polypeptide with
(i) 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%), 98%), 99%), or 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13; or
(ii) 100%) amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or
13.
5. The subtilisin variant of any preceding claim, wherein said variant comprises an amino acid sequence with
(i) 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%), 98%), 99%) or less than 100%) amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13;
(ii) 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or less than 100%> amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13; or
(iii) 95%, 96%, 97%, 98%, 99%, or less than 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 11 or 13.
6. The subtilisin variant of any preceding claim, wherein said variant has one or more improved property when compared to a parent or reference subtilisin; wherein the improved property is selected from improved cleaning performance in detergent, improved stability; and combinations thereof.
7. The subtilisin variant of any preceding claim, wherein the parent subtilisin comprises an amino acid sequence of SEQ ID NO: 11 or 13.
8. The subtilisin variant of claim 6 or 7, wherein the improved property is
(i) improved cleaning performance in detergent, wherein said variant has a BMI, creme brulee and/or egg stain cleaning PI >1; and/or
(ii) improved stability, wherein said variant has a stability PI > 1 or >50% residual activity when measured in accordance with the stability assay of Example 1.
9. The subtilisin variant of any one of claims 6-8, wherein said
(i) cleaning performance in detergent is measured in accordance with the cleaning performance in laundry (HDL) and ADW detergents assay of Example 1; and/or
(ii) stability is measured in accordance with the stability assay of Example 1.
10. A composition comprising one or more subtilisin variant according to any preceding Claim.
11. The composition according to Claim 10, wherein said composition is selected from an enzyme composition and a detergent composition.
12. The composition according to Claim 11, wherein said detergent composition is selected from a laundry detergent, a fabric softening detergent, a dishwashing detergent, and a hard- surface cleaning detergent.
13. The composition according to any one of Claims 10-12, further comprising (i) one or more other enzymes selected acyl transferases, amylases, alpha-amylases, beta-amylases, alpha- galactosidases, arabinases, arabinosidases, aryl esterases, beta-galactosidases, beta-glucanases, carrageenases, catalases, chondroitinases, cutinases, endo-beta-mannanases, exo-beta- mannanases, esterases, exo-mannanases, galactanases, glucoamylases, hemicellulases, hyaluronidases, keratinases, laccases, lactases, ligninases, lipases, lipolytic enzymes,
lipoxygenases, mannanases, metalloproteases, nucleases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectinases, pentosanases, perhydrolases, peroxidases,
phenoloxidases, phosphatases, phospholipases, phytases, polyesterases, polygalacturonases, additional proteases, pullulanases, reductases, rhamnogalacturonases, cellulases, beta-glucanases, tannases, transglutaminases, xylan acetyl-esterases, xylanases, and xylosidases; (ii) one or more surfactants; (iii) one or more ions selected from calcium and zinc; (iv) one or more adjunct material; (v) one or more stabilizers; (vi) from about 0.001% to about 1.0 weight % of the variant of any one of Claims 1-9; (vii) one or more bleaching agents; and/or (viii) combinations thereof.
14. The composition of any one of Claims 10-13, wherein said composition is phosphate-free or contains phosphate and/or is boron free or contains boron.
15. The composition of any one of Claims 10-14, wherein said composition is a granular, powder, solid, bar, liquid, tablet, gel, paste and/or unit dose composition.
16. A method of cleaning, comprising contacting a surface or an item in need of cleaning with an effective amount of a variant of any one of Claims 1-9 or the composition of any one of claims 10-15; and optionally further comprising the step of rinsing said surface or item after contacting said surface or item with said variant or composition.
17. The method according to Claim 16, wherein said method is a method of cleaning a creme brulee stain.
18. The method of Claim 16 or 17, wherein said item is dishware or fabric.
19. A polynucleotide comprising a nucleic acid sequence encoding a variant of any one of Claims 1-9, wherein said polynucleotide is, optionally, isolated.
20. The polynucleotide of claim 19, wherein the nucleic acid sequence is operably linked to a promoter.
21. An expression vector or cassette comprising the polynucleotide of Claim 19 or 20.
22. A recombinant host cell comprising the polynucleotide of Claim 19 or 20 or the vector or cassette of Claim 21.
23. A composition comprising a variant of any one of Claims 1-9, wherein said composition is a disinfectant, medical instrument cleaning, animal feed, contact lens cleaning, wound cleaning, or textile, leather or feather processing composition.
24. A method of cleaning a creme brulee stain comprising contacting a surface or an item in need of cleaning with an effective amount of a subtilisin variant or composition containing a subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from:
(i) 1, 21, 38, 40, 48, 58, 76, 82, 87, 89, 101, 116, 128, 129, 130, and 248;
(ii) 1C/D/E/F/H/I/K/L/M/N/P/R/S/T/VAV/Y,
21 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y, 38 A/C/D/E/F/G/H/I/L/M/N/P/Q/R/S/T/V/W/Y, 40A/C/D/E/F/G/H/I/K/L/M/N/Q/R/S/T/VAV/Y, 48C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 58 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y, 76A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
82A/C/D/E/F/H/I/K/L/M/N/P/Q/R/S/T/V/W/Y,
87A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
89A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/T/VAV/Y, 101 A/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/V/Y, 116A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/V/Y, 128A/C/D/E/F/H/I/K/L/M/N/Q/S/T/VAV/Y, 129 A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y,
130A/C/D/E/F/G/H/I/K/L/M/N/P/Q/R/S/T/VAV/Y, and
248A/C/D/E/F/G/H/I/K/L/M/P/Q/R/S/T/VAVAr;
(iii) 1I/M/N/T/Y, 21 A/C/D/E/L/M/N/R/W / Y, 38A/C/D/E/G/H/I/L/M/N/P/Q/VAV/Y, 40A/D/G/H/I/K/L/S/T/V/Y, 48C/D/E/F/G/I/M/N/P/Q/V/Y, 58A/C/D/G/I/K/M/Q/S/V/Y, 76C/D/E/F/G/H/L/M/P/Q/S/T/V/W/Y, 82F/K/M/T/V/Y, 87C/D/E/F/ G/H/L/M/N/P/ Q/T/V/W / Y, 89A/C/D/M/N, 101A/D/E/F/G/L/M/N/Q/T/V, 116A/C/D/E/G/H/I/K/L/M/N/Q/Y, 128D/N/T, 129C/M, 130A/D/E/G/K/L/M/N/P/Q/T/V, and 248G/T;
(iv) IT, 21A/C/M/N/W, 38A/H/I/L/M/V/Y, 40D/I/L/V, 48C/D/E/M/V/Y, 58C/D/G/K/V, 76C/E/M/Q/S/T/V/Y, 82K/Y, 87C/D/E/M/N/P, 89C, 101A/D/E/M/N/T, 116A/C/D/I/M/N/Q, 128T, 129C, and 130G/L;
(vi) 38I/L/V, 401, 48V, 76T, 89C, 101 A/N, and 130G; or
(vii) combinations of (i) to (vi);
wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
25. The method according to Claim 24, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from:
(i) 1C/D/E/F/K/H/T/V/W, 21C/D/E/F/H/K/R, 38C/D/E/F/G/H/I/M/N/P/R/S/T,
40C/D/E/F/G/H/I/K/L/R/S, 48C/D/E/I/M/R/S/V/Y, 58A/C/D/E/K,
76A/C/D/E/F/G/K/M/N/R/T/W, 82E/K/M/R/S, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V,
89A/C/D/F/K/M/N/P/Q/R, 101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 116A/C/D/E/F/M/N/P/Q/R, 128A/D/H/N/Q/S/T/W/Y, 129C/D/E/G/M/Q/R, OC/D/E/G/H/I/K/L/M/N/P/R/S/T/VAVA^, and 248C/D/E/G/H/I/K/L/Q/T/V/Y; (ii) 21, 38, 40, 48, 76, 87, 89, 101, 1 16, 128, 129, and 130;
(iii) 21C/D/E/F/H/K/R, 38C/D/E/F/G/H/I/M/N/P/R/S/T, 40C/D/E/F/G/H/I/K/L/R/S, 48C/D/E/I/M/R/S/V/Y, 76 A/C/D/E/F/ G/K/M/N/R/T/W, 87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V, 89A/C/D/F/K/M/N/P/Q/R, 101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 1 16A/C/D/E/F/M/N/P/Q/R, 128A/D/H/N/Q/S/T/W/Y, 129C/D/E/G/M/Q/R, and 130C/D/E/G/H/I/K/L/M/N/P/R/S/T/VAV/Y;
(iv) 48, 76, 87, 89, 101, 1 16, and 130;
(v) 48C/D/E/I/M/R/S/V/Y, 76 A/C/D/E/F/ G/K/M/N/R/T/W,
87A/C/D/E/F/H/I/K/L/M/N/P/Q/R/V, 89A/C/D/F/K/M/N/P/Q/R,
101A/D/E/G/H/I/K/L/M/N/P/Q/R/S/T/V, 1 16A/C/D/E/F/M/N/P/Q/R, and
13 OC/D/E/G/H/I/K/L/M/N/P/R/S/T/V/W/Y;
(vi) 38E, 40D, 48E, 76C/E, 87C/D/M/N, 89C, 101D/E/M/N, 1 16C/D/E/M, and 130D/G;
(vii) 76E, 89C, and 130G;
(viii) IK, 38D/E/G/I/M/T, 40C/D/E, 48C/I, 58D, 76A/C/D/E, 87C/D/E/L/M/Q/R, 89A/C/K/M, 101A/D/E/K/M/N/Q/R/S/T, 1 16D/E/P, 128Q/S/T, 129C/D/E,
130C/D/E/G/H/N/R/S/T, and 248C/D/E/H;
(ix) 38E, 89C, and 130G; or
(x) combinations of (i) to (ix).
26. The method according to Claim 24 or 25, wherein said variant comprises an amino acid sequence with70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%), 97%), 98%), 99% or less than 100% amino acid sequence identity to the amino acid sequence of SEQ ID NO: l, 1 1, 13, 15, or 17.
27. The method according to any one of claims 24-26, wherein said variant has a creme brulee stain, BMI stain, or egg stain cleaning PI >1 when compared to SEQ ID NO: 1, 1 1, 13, 15, and/or 17.
28. The method according to Claim 27, wherein the creme brulee stain, BMI stain, or egg stain cleaning performance of said variant is measured in accordance with the creme brulee, BMI stain, or egg stain assay described in Example 1.
29. The method according to any one of claims 24-28, with the proviso that said variant comprises one or more non-naturally occurring substitutions.
30. The method according to any one of claims 24-29, wherein said variant
(i) is isolated; (ii) has proteolytic activity; or
(iii) comprises a combination of (i) and (ii).
31. A method of cleaning comprising contacting a surface or an item in need of cleaning with an effective amount of a subtilisin variant or composition containing a subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from:
(i) 1 C/H/K/L/T/Y, 38D/E/G/H/I/K/L/M/P, 40C/F/M, 48C/G/I/M/N/Q/T/W/Y, 58I/P,
76A/C/F/P, 87A/D, 87L/M/T, 89C/F/G/M/N/Q/S, 101E/H/N, 116E/F/H/I/N/S/V/W, 128F/M, 130C/G/HZM/N/P/R/S/T, and 248C/S;
(ii) I S, 38D/E/N/P/V, 40A/C/D/E/I/M/P/R, 58S/V, 76D/P/Q/S, 87C, 89C/G/M,
101C/E/F/M/N/P/ST, 116D/G/H/I/L/Y, 128I/M, 130D/E/G/Q/V, and 248D/G/L/W;
(iii) IK, 76D, 82L, 87D/E, 116E, and 206C/L;
(iv) 1C/E, 21E/T, 38C/D/G, 40C/D/G/N, 48D/E/I/P/S/T, 58C/D/F/G/I/K/Q/V,
76C/D/E/F/G/H/I/L/T/V/Y, 82G/H/N/P/Q/R/S/T/W/Y, 87C/D/L/Q/T/V, 89C, 101D/E, 116C/D/E/H/N, 128D/E/L/Q/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V, and 248A/E/Q/T/V;
(v) 1 S/T/V, 21E/G/Q/S/T, 38C/D/E/G/I/L/V, 40D/E/G/T, 48P/T/V, 58C/D/E, 76D/G/H/I, 82 Y, 87D, 89C, lOlA/D/E/G/H/I/K/L/M/N/Q/S/T/V, 116D/E/G/N, 128D/E/N/Q/T/V, 129C, 130D/E/G/V, and 248G/S/T;
(vi) 1G/I, 15T, 21D/E/F/G/H/M/P/Q/S/Y, 48E/M, 58D/E/H/K/Q/W, 76D, 87C/D/E,
101E/G/M/N/Q, 116D/F/S, 128L, 130A/I/N/Q/S/T, 159S, 170S, 218D, and
248C/E/I/Q/S/T;
(vii) 21E, 58D, 76D, 87D, 101E, 116D, and 248T;
(viii) 1D/E/N/S, 21F/G/L/M/N/P/Q/R/S/VAV/Y, 38D/F/G/L/N/P/Q, 40D/G/M/Q, 58P/R, 76A/D/F/K/M, 82K/M/N/R/T/Y, 87A/C/D/F/G/H/M/Q, 89C/H/L/R/W, 101M,
116A/C/D/E/F/H/N/R, 128A, 129E, 130G, and 248A/F/H/Q/T;
(ix) 1M, 21A/C/D/F/M/N/P/Q/R/S, 38A/D/F/G/M/P/R, 40A/C/F/G/M/N/P/R, 48K,
58L/M/Q/R/S, 58W, 58Y, 76 A, 76D, 76F, 76Q, 82 A, 82C, 82F, 82M, 82R, 87E, 89C, 89F, 89N, 89P, 89Q, 89/S/V, and 116H/M/N/R;
(x) 1A/G/K/M/R, 9R, 21M/N/P, 48M/R, 58I/Q, 87A/C, 89A/H/M/N/Q/S/W, 101N,
116A/F/K/N/S, 128L, 130Q/R,194P, 245R 248Q, and 255R; (xi) 21M/N/P and 116N;
(xii) 1 C/D/E/F/I/K/L/M/N/V/Y, 21 A/E/G/H/K/L/M/N/P/S/T/VAV/Y, 38C/D/H/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/H/I/T/Y, 58C/F/G/I/K/M/V,
76A/C/D/E/G/I/K/L/M/P/T/VAV/Y, 82E/G/H/K/M/N/P/Q/R/S/T/W/Y,
87A/C/D/F/H/I/K/L/M/T/VAV/Y, 89C/H/N, 101D/E/F/I/K/L/Mm/Q/T/V/Y,
116A/C/D/E/G/K/L/N/R/S/V, 128A/D/I/K/L/M/N/Q/V/W, 129C,
130D/E/G/H/I/K/M/N/S/T/W/Y, and 248A/E/L/Q/TV;
(xiii) 1K/P, 21K/M/Q/T, 38D/E/I/V, 48G, 58A/D/E/G/H/K/S/V, 76C/H/I/K/S,
82A/C/G/M/P/S/T/Y, 87C/P/Q, 89C/K/P/V, 116A/D, 128A/D/F/H/I/K/L/N/Q/T/V/Y, 129C, 130E/Q/S/T, and 248 G;
(xiv) 1A/HZK/MZR/V, 15T, 21D/G/H/K/L/M/T/W, 48K/M/V, 58E/I/N/P/S, 76D, 87C/D, 89G/N/W, 101E/F/I/K/L/M/N/Q/VAV/Y, 116D/K/L/N/Q/S, 128I/L/T, 129E,
130A/H/I/K/L/N/Q/R/S/T/V/Y, 159S, 218D, and 248K/M;
(xv) IK, 21K/M/T, 87C, 116D, 128I/L, and 130S/T;
(xvi) 1 T/Y, 21 C/D/E/L/R, 38C/D/E/G/H/I/L/M/S/T/V/W, 40D/E/I/K/L/T/V/W,
48C/D/E/M/N/P/Q/V/Y, 58A/C/D/G/I/K/M/N/P/Q/R/S/V/Y, 76A/C/D/E/L/M/P/T/V/Y, 82C/D/E/K/M/N/P/Q/S/T/V/Y, 87 A/ C/D/E/F/ G/H/K/L/M/P/ S/T/V/W / Y,
89A/C/D/M/N/Y, 101A/D/E/L/M/N/T/V/Y, 116A/C/D/E/H/I/K/L/N/S/V/Y,
128D/K/TAV/Y, 129C, 130C/D/E/G/H/I/K/L/N/P/Q/S/T/VAV/Y, and
248A/C/D/E/G/H/I/K/L/Q/T/V/Y;
(xvii) 1 C/D/E/I/L/M/T, 21 A/C/D/E/G/L/M/N/W/Y, 38 A/C/D/E/G/I/L/M/N/P/V/Y,
40A/C/D/E/G/I/L/M/V/Y, 48C/D/E/G/H/I/P/S/T/V/Y, 58C/D/E/G/I/K/L/V/Y,
76C/D/E/G/H/P/Q/S/T/Y, 82F/H/L/S/T/V/Y, 87C/D/E/G/N/P/Q, 89C/E,
101A/D/E/F/G/H/I/K/L/M/N/Q/S/T/V, 116A/D/E/G/H/I/L/M/N/Q/Y, 128A/D/N/Q/T, 129C, 130D/E/G/L/M/Q/S/T/V, and 248G/S/T;
(xviii) 1M, 21A/C/D/E/H/M/N/P/Y, 48D/E/M/N/Q, 58C/D/E/I/K/M/N/Q/S, 76D, 82L,
87A/C/D/E/M/V, 89A/D/M/N, 101E/L/M/N, 116A/D/E/L/M/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, 170S, 2051, 206C/L, 218D, and
248C/E/G/H/I/L/S/T/V/W/Y;
(xix) 21C/D/E, 48D/E, 58C/D/I/K, 76D, 87C/D/E, 101E/L/M/N, 116A/D/E/L/N,
130L/Q/S/T/V, and 248G/T; (xx) 1Y, 21E/L, 38C/D/H/L/V, 40D/I/T/V, 48E/Y, 58C/G/I/K/M/V,
76A/C/D/E/L/M/P/T/V/Y, 82E/K/M/N/P/Q/S/T/Y, 87A/C/D/F/H/K/L/M/T/V/W/Y, 89C/N, 101D/E/L/M/N/T/V/Y, 116A/C/D/E/K/L/N/S/V, 128D/K/W, 129C,
130D/E/G/H/I/K/N/S/T/W/Y, and 248A/E/L/Q/T/V;
(xxi) 21M, 38D/E/I/V, 48G, 58D/E/G/K/V, 76C/H/S, 82S/T/Y, 87C/P/Q, 89C, 116A/D, 128A/D/N/Q/T, 129C, 130E/Q/S/T, and 248 G;
(xxii) 1M, 21D/H/M, 48M, 58E/I/N/S, 76D, 87C/D, 89N, 101E/L/M/N, 116D/L/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, and 218D;
(xxiii) 87C, 116D, and 130S/T;
(xxiv) 1Y, 38D/H/L, 48Y, 581, 76A/C/P, 87A/D/L/M/T, 89C/N, 101E/N, 116E/N/S/V, and 130G/H/N/S/T;
(xxv) 38D/E/V, 58V, 76S, 87C, 89C, 116D, 130E/Q, and 248G;
(xxvi) 76D and 87D;
(xxvii) 1T/Y, 38D/E/G/H/I/L/M, 48C/M/N/Q/Y, 58I/P, 76A/C/P, 87A/D/L/M/T, 89C/M/N, 101E/N, 116E/H/I/N/S/V, 130C/G/H/N/P/S/T, and 248C;
(xxviii) 38D/E/N/P/V, 40A/C/D/E/I/M, 58V, 76D/P/Q/S, 87C, 89C, 101E/F/M/N/S/T,
116D/G/H/I/L/Y, 130D/E/G/Q/V, and 248G; or
(xxix) 76D, 82L, 87D/E, 116E, and 206C/L, wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
32. The method of claim 31, wherein the method cleans a stain selected from a BMI stain, creme brulee stain, egg stain, or combinations thereof, wherein the one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions are selected from:
(i) 1C/E, 21E/T, 38C/D/G, 40C/D/G/N, 48D/E/I/P/S/T, 58C/D/F/G/I/K/Q/V,
76C/D/E/F/G/H/I/L/T/V/Y, 82G/H/N/P/Q/R/S/T/W/Y, 87C/D/L/Q/T/V, 89C, 101D/E, 116C/D/E/H/N, 128D/E/L/Q/V/Y, 129C, 130C/D/E/G/H/I/L/M/N/P/Q/S/T/V, and 248A/E/Q/T/V;
(ii) 1 S/T/V, 21E/G/Q/S/T, 38C/D/E/G/I/L/V, 40D/E/G/T, 48P/T/V, 58C/D/E, 76D/G/H/I, 82 Y, 87D, 89C, 101A/D/E/G/H/I/K/L/M/N/Q/S/T/V, 116D/E/G/N, 128D/E/N/Q/T/V, 129C, 130D/E/G/V, and 248G/S/T; 1G/I, 15T, 21D/E/F/G/H/M/P/Q/S/Y, 48E/M, 58D/E/H/K/Q/W, 76D, 87C/D/E, 101E/G/M/N/Q, 116D/F/S, 128L, 130A/I/N/Q/S/T, 159S, 170S, 218D, and
248C/E/I/Q/S/T;
21E, 58D, 76D, 87D, 101E, 116D, and 248T;
1D/E/N/S, 21 F/ G/L/M/N/P/ Q/R/ S/ V/W / Y, 38D/F/G/L/N/P/Q, 40D/G/M/Q, 58P/R, 76A/D/F/K/M, 82K/M/N/R/T/Y, 87A/C/D/F/G/H/M/Q, 89C/H/L/R/W, 101M,
116A/C/D/E/F/H/N/R, 128A, 129E, 130G, and 248A/F/H/Q/T;
1M, 21A/C/D/F/M/N/P/Q/R/S, 38A/D/F/G/M/P/R, 40A/C/F/G/M/N/P/R, 48K, 58L/M/Q/R/S, 58W, 58Y, 76 A, 76D, 76F, 76Q, 82 A, 82C, 82F, 82M, 82R, 87E, 89C, 89F, 89N, 89P, 89Q, 89/S/V, and 116H/M/N/R;
1A/G/K/M/R, 9R, 21M/N/P, 48M/R, 58I/Q, 87A/C, 89A/H/M/N/Q/S/W, 101N, 116A/F/K/N/S, 128L, 130Q/R,194P, 245R 248Q, and 255R;
) 21M/N/P and 116N;
IC/D/E/F/I/K/L/M/N/V/Y, 21A/E/G/H/K/L/M/N/P/S/T/VAV/Y, 38C/D/H/L/P/Q/V/Y, 40A/C/D/G/H/I/M/P/Q/T/V/Y, 48E/H/I/T/Y, 58C/F/G/I/K/M/V,
76A/C/D/E/G/I/K/L/M/P/T/VAV/Y, 82E/G/H/K/M/N/P/Q/R/S/T/W/Y,
87A/C/D/F/H/I/K/L/M/T/VAV/Y, 89C/H/N, 101D/E/F/I/K/L/Mm/Q/T/V/Y,
116A/C/D/E/G/K/L/N/R/S/V, 128A/D/I/K/L/M/N/Q/V/W, 129C,
130D/E/G/H/I/K/M/N/S/T/W/Y, and 248A/E/L/Q/TV;
1K/P, 21K/M/Q/T, 38D/E/I/V, 48G, 58A/D/E/G/H/K/S/V, 76C/H/I/K/S,
82A/C/G/M/P/S/T/Y, 87C/P/Q, 89C/K/P/V, 116A/D, 128A/D/F/H/I/K/L/N/Q/T/V/Y, 129C, 130E/Q/S/T, and 248 G;
lA/H/K/M/R/V, 15T, 21D/G/H/K/L/M/T/W, 48K/M/V, 58E/I/N/P/S, 76D, 87C/D, 89G/N/W, 101E/F/I/K/L/M/N/Q/V/W/Y, 116D/K/L/N/Q/S, 128I/L/T, 129E,
130A/H/I/K/L/N/Q/R/S/T/V/Y, 159S, 218D, and 248K/M;
IK, 21K/M/T, 87C, 116D, 128I/L, and 130S/T;
) 1 T/Y, 21 C/D/E/L/R, 38C/D/E/G/H/I/L/M/S/T/V/W, 40D/E/I/K/L/T/V/W,
48C/D/E/M/N/P/Q/V/Y, 58A/C/D/G/I/K/M/N/P/Q/R/S/V/Y, 76A/C/D/E/L/M/P/T/V/Y, 82C/D/E/K/M/N/P/Q/S/T/V/Y, 87 A/ C/D/E/F/ G/H/K/L/M/P/ S/T/V/W / Y,
89A/C/D/M/N/Y, 101A/D/E/L/M/N/T/V/Y, 116A/C/D/E/H/I/K/L/N/S/V/Y, 128D/K/T/W/Y, 129C, 130C/D/E/G/H/I/K/L/N/P/Q/S/T/VAV/Y, and
248A/C/D/E/G/H/I/K/L/Q/T/V/Y;
(xiv) 1 C/D/E/I/L/M/T, 21 A/C/D/E/G/L/M/N/W/Y, 38 A/C/D/E/G/I/L/M/N/P/V/Y,
40A/C/D/E/G/I/L/M/V/Y, 48C/D/E/G/H/I/P/S/T/V/Y, 58C/D/E/G/I/K/L/V/Y,
76C/D/E/G/H/P/Q/S/T/Y, 82F/H/L/S/T/V/Y, 87C/D/E/G/N/P/Q, 89C/E,
101A/D/E/F/G/H/I/K/L/M/N/Q/S/T/V, 116A/D/E/G/H/I/L/M/N/Q/Y, 128A/D/N/Q/T, 129C, 130D/E/G/L/M/Q/S/T/V, and 248G/S/T;
(xv) 1M, 21A/C/D/E/H/M/N/P/Y, 48D/E/M/N/Q, 58C/D/E/I/K/M/N/Q/S, 76D, 82L,
87A/C/D/E/M/V, 89A/D/M/N, 101E/L/M/N, 116A/D/E/L/M/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, 170S, 2051, 206C/L, 218D, and
248C/E/G/H/I/L/S/T/V/W/Y;
(xvi) 21C/D/E, 48D/E, 58C/D/I/K, 76D, 87C/D/E, 101E/L/M/N, 116A/D/E/L/N,
130L/Q/S/T/V, and 248G/T;
(xvii) 1Y, 21E/L, 38C/D/H/L/V, 40D/I/T/V, 48E/Y, 58C/G/I/K/M/V,
76A/C/D/E/L/M/P/T/V/Y, 82E/K/M/N/P/Q/S/T/Y, 87A/C/D/F/H/K/L/M/T/V/W/Y, 89C/N, 101D/E/L/M/N/T/V/Y, 116A/C/D/E/K/L/N/S/V, 128D/K/W, 129C,
130D/E/G/H/I/K/N/S/T/W/Y, and 248A/E/L/Q/T/V;
(xviii) 21M, 38D/E/I/V, 48G, 58D/E/G/K/V, 76C/H/S, 82S/T/Y, 87C/P/Q, 89C, 116A/D, 128A/D/N/Q/T, 129C, 130E/Q/S/T, and 248 G;
(xix) 1M, 21D/H/M, 48M, 58E/I/N/S, 76D, 87C/D, 89N, 101E/L/M/N, 116D/L/N/Q/S, 128L, 129E, 130A/H/I/L/N/Q/R/S/T/V/Y, and 218D;
(xx) 87C, 116D, and 130S/T;
(xxi) 1Y, 38D/H/L, 48Y, 581, 76A/C/P, 87A/D/L/M/T, 89C/N, 101E/N, 116E/N/S/V, and 130G/H/N/S/T;
(xxii) 38D/E/V, 58V, 76S, 87C, 89C, 116D, 130E/Q, and 248G;
(xxiii) 76D and 87D;
(xxiv) 1T/Y, 38D/E/G/H/I/L/M, 48C/M/N/Q/Y, 58I/P, 76A/C/P, 87A/D/L/M/T, 89C/M/N, 101E/N, 116E/H/I/N/S/V, 130C/G/H/N/P/S/T, and 248C;
(xxv) 38D/E/N/P/V, 40A/C/D/E/I/M, 58V, 76D/P/Q/S, 87C, 89C, 101E/F/M/N/S/T,
116D/G/H/I/L/Y, 130D/E/G/Q/V, and 248G; or
(xxvi) 76D, 82L, 87D/E, 116E, and 206C/L, wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
33. A method of improving the stability of a subtilisin variant, wherein said variant comprises an amino acid sequence comprising one or more substitutions at one or more positions corresponding to SEQ ID NO: 17 positions selected from:
(i) 1 C/H/K/L/T/Y, 38D/E/G/H/I/K/L/M/P, 40C/F/M, 48C/G/I/M/N/Q/T/W/Y, 58I/P,
76A/C/F/P, 87A/D, 87L/M/T, 89C/F/G/M/N/Q/S, 101E/H/N, 116E/F/H/I/N/S/V/W, 128F/M, 130C/G/HZM/N/P/R/S/T, and 248C/S;
(ii) I S, 38D/E/N/P/V, 40A/C/D/E/I/M/P/R, 58S/V, 76D/P/Q/S, 87C, 89C/G/M,
101C/E/F/M/N/P/ST, 116D/G/H/I/L/Y, 128I/M, 130D/E/G/Q/V, and 248D/G/L/W; or
(iii) IK, 76D, 82L, 87D/E, 116E, and 206C/L
wherein the amino acid positions of the variant are numbered by correspondence with the amino acid sequence of SEQ ID NO: 17.
EP17832644.3A 2016-12-21 2017-12-19 Protease variants and uses thereof Pending EP3559227A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437171P 2016-12-21 2016-12-21
PCT/US2017/067312 WO2018118917A1 (en) 2016-12-21 2017-12-19 Protease variants and uses thereof

Publications (1)

Publication Number Publication Date
EP3559227A1 true EP3559227A1 (en) 2019-10-30

Family

ID=61007800

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17832644.3A Pending EP3559227A1 (en) 2016-12-21 2017-12-19 Protease variants and uses thereof

Country Status (4)

Country Link
US (2) US20200392477A1 (en)
EP (1) EP3559227A1 (en)
CN (1) CN110312795B (en)
WO (1) WO2018118917A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312794B (en) * 2016-12-21 2024-04-12 丹尼斯科美国公司 Bacillus gibsonii clade serine protease
CN111373039A (en) 2017-11-29 2020-07-03 丹尼斯科美国公司 Subtilisin variants having improved stability
CN112189052A (en) 2018-06-19 2021-01-05 宝洁公司 Automatic dishwashing detergent composition
CN112204138A (en) 2018-06-19 2021-01-08 宝洁公司 Automatic dishwashing detergent composition
US20210363470A1 (en) * 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
CA3207822A1 (en) 2018-06-20 2019-12-26 The Procter & Gamble Company A fabric care or home care product comprising polysaccharide derivatives
WO2020112599A1 (en) 2018-11-28 2020-06-04 Danisco Us Inc Subtilisin variants having improved stability
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same
WO2020242858A1 (en) * 2019-05-24 2020-12-03 Danisco Us Inc Subtilisin variants and methods of use
US20220403359A1 (en) 2019-10-24 2022-12-22 Danisco Us Inc Variant maltopentaose/maltohexaose-forming alpha-amylases
CN110846299B (en) * 2019-11-22 2021-09-24 江南大学 Leader peptide mutant and application thereof in keratinase production
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
WO2023114988A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
WO2024163695A1 (en) 2023-02-01 2024-08-08 The Procter & Gamble Company Detergent compositions containing enzymes
WO2024163584A1 (en) 2023-02-01 2024-08-08 Danisco Us Inc. Subtilisin variants and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008165A1 (en) * 1987-04-06 1988-10-20 Genex Corporation Computer based method for protein engineering
WO2016001450A2 (en) * 2014-07-04 2016-01-07 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016205755A1 (en) * 2015-06-17 2016-12-22 Danisco Us Inc. Bacillus gibsonii-clade serine proteases

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296839A (en) 1969-05-29 1972-11-22
GB1372034A (en) 1970-12-31 1974-10-30 Unilever Ltd Detergent compositions
GB2048606B (en) 1979-02-28 1983-03-16 Barr & Stroud Ltd Optical scanning system
US4302544A (en) 1979-10-15 1981-11-24 University Of Rochester Asporogenous mutant of B. subtilis for use as host component of HV1 system
DK187280A (en) 1980-04-30 1981-10-31 Novo Industri As RUIT REDUCING AGENT FOR A COMPLETE LAUNDRY
GR76237B (en) 1981-08-08 1984-08-04 Procter & Gamble
US4450235A (en) 1982-04-21 1984-05-22 Cpc International Inc. Asporogenic mutant of bacillus subtilis useful as a host in a host-vector system
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
EP0134048B2 (en) 1983-07-06 1996-08-14 Gist-Brocades N.V. Molecular cloning and expression in industrial microorganism species
JPS60165486A (en) 1984-02-08 1985-08-28 三洋電機株式会社 Heat-insulating box body
US5972682A (en) 1984-05-29 1999-10-26 Genencor International, Inc. Enzymatically active modified subtilisins
US5700676A (en) 1984-05-29 1997-12-23 Genencor International Inc. Modified subtilisins having amino acid alterations
DK154572C (en) 1985-08-07 1989-04-24 Novo Industri As ENZYMATIC DETERGENT ADDITIVE, DETERGENT AND METHOD FOR WASHING TEXTILES
JPH0697997B2 (en) 1985-08-09 1994-12-07 ギスト ブロカデス ナ−ムロ−ゼ フエンノ−トチヤツプ New enzymatic detergent additive
DK122686D0 (en) 1986-03-17 1986-03-17 Novo Industri As PREPARATION OF PROTEINS
ES2058119T3 (en) 1986-08-29 1994-11-01 Novo Nordisk As ENZYMATIC DETERGENT ADDITIVE.
GB8629837D0 (en) 1986-12-13 1987-01-21 Interox Chemicals Ltd Bleach activation
US4972017A (en) 1987-03-24 1990-11-20 The Clorox Company Rinse soluble polymer film composition for wash additives
US4765916A (en) 1987-03-24 1988-08-23 The Clorox Company Polymer film composition for rinse release of wash additives
ATE113070T1 (en) 1987-05-29 1994-11-15 Genencor Int DETERGENT COMPOSITIONS CONTAINING CUTINASE.
DE3854249T2 (en) 1987-08-28 1996-02-29 Novonordisk As Recombinant Humicola Lipase and Process for the Production of Recombinant Humicola Lipases.
JP2624859B2 (en) 1988-01-07 1997-06-25 ノボ‐ノルディスク アクティーゼルスカブ Enzyme detergent
JP3079276B2 (en) 1988-02-28 2000-08-21 天野製薬株式会社 Recombinant DNA, Pseudomonas sp. Containing the same, and method for producing lipase using the same
US4977252A (en) 1988-03-11 1990-12-11 National Starch And Chemical Investment Holding Corporation Modified starch emulsifier characterized by shelf stability
WO1990009446A1 (en) 1989-02-17 1990-08-23 Plant Genetic Systems N.V. Cutinase
DK0410498T3 (en) 1989-06-29 1999-03-22 Genencor Int Mutant microbial alpha-amylases with increased thermal, acid and / or alkaline stability
JP3112937B2 (en) 1990-04-14 2000-11-27 カリ―ヒエミー アクチエンゲゼルシヤフト Alkaline Bacillus lipase, DNA sequence encoding the same and Bacillus producing this lipase
US5354559A (en) 1990-05-29 1994-10-11 Grain Processing Corporation Encapsulation with starch hydrolyzate acid esters
SG52693A1 (en) 1991-01-16 1998-09-28 Procter & Gamble Detergent compositions with high activity cellulase and softening clays
GB9108136D0 (en) 1991-04-17 1991-06-05 Unilever Plc Concentrated detergent powder compositions
US5340735A (en) 1991-05-29 1994-08-23 Cognis, Inc. Bacillus lentus alkaline protease variants with increased stability
PT717778E (en) * 1992-07-17 2008-01-16 Genencor Int High alkaline serine proteases.
ATE444356T1 (en) 1992-07-23 2009-10-15 Novozymes As MUTATED -G(A)-AMYLASE, DETERGENT AND DISHWASHING DETERGENT
EP0679183B1 (en) 1992-12-01 2003-04-16 Novozymes A/S Enhancement of enzyme reactions
PL310326A1 (en) 1993-02-11 1995-12-11 Genencor Int Novel oxidation-stable mutants of alpha-amylase as well as detergent and starch liquefaction compositions containing them
ATE182615T1 (en) 1993-05-08 1999-08-15 Henkel Kgaa SILVER CORROSION PROTECTION AGENT II
WO1994026859A1 (en) 1993-05-08 1994-11-24 Henkel Kommanditgesellschaft Auf Aktien Silver-corrosion protection agent (i)
DK77393D0 (en) 1993-06-29 1993-06-29 Novo Nordisk As ENZYMER ACTIVATION
EP0722490B2 (en) 1993-10-08 2013-10-23 Novozymes A/S Amylase variants
DE4342680A1 (en) 1993-12-15 1995-06-22 Pfeiffer Erich Gmbh & Co Kg Discharge device for media
US5861271A (en) 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
US5691295A (en) 1995-01-17 1997-11-25 Cognis Gesellschaft Fuer Biotechnologie Mbh Detergent compositions
ES2364776T3 (en) 1994-02-24 2011-09-14 HENKEL AG & CO. KGAA IMPROVED AND DETERGENT ENZYMES THAT CONTAIN THEM.
ES2302330T3 (en) 1994-02-24 2008-07-01 Henkel Kommanditgesellschaft Auf Aktien IMPROVED AND DETERGENT ENZYMES THAT CONTAIN THEM.
US5824531A (en) 1994-03-29 1998-10-20 Novid Nordisk Alkaline bacilus amylase
NZ289115A (en) 1994-06-17 1999-02-25 Genencor Int Laundry compositions with cellulase and pectinase enzymes suitable for degrading cell walls of vegetable origin
ATE301719T1 (en) 1994-06-17 2005-08-15 Genencor Int AMYLOLYTIC ENZYMES DERIVED FROM ALPHA-AMYLASE FROM B. CHENIFORMIS WITH IMPROVED PROPERTIES
KR970704872A (en) 1994-08-11 1997-09-06 혼 마가렛 에이 Improved cleaning composition
AR000862A1 (en) 1995-02-03 1997-08-06 Novozymes As VARIANTS OF A MOTHER-AMYLASE, A METHOD TO PRODUCE THE SAME, A DNA STRUCTURE AND A VECTOR OF EXPRESSION, A CELL TRANSFORMED BY SUCH A DNA STRUCTURE AND VECTOR, A DETERGENT ADDITIVE, DETERGENT COMPOSITION, A COMPOSITION FOR AND A COMPOSITION FOR THE ELIMINATION OF
BR9607013B1 (en) 1995-02-03 2011-03-09 process of constructing a variant of an original bacillus alpha-amylase derived from a strain of b. licheniformis, from b. amyloliquefaciens, by b. stearothermophilus or a bacillus sp. alkalophilic.
KR19980702783A (en) 1995-03-24 1998-08-05 혼 마가렛 에이 Improved Laundry Detergent Composition Including Amylase
CA2222329C (en) 1995-06-13 2007-10-23 Novo Nordisk A/S 4-substituted-phenyl-boronic acids as enzyme stabilizers
AU6513096A (en) 1995-07-19 1997-02-18 Novo Nordisk A/S Treatment of fabrics
US5576282A (en) 1995-09-11 1996-11-19 The Procter & Gamble Company Color-safe bleach boosters, compositions and laundry methods employing same
CA2231843A1 (en) 1995-09-13 1997-03-20 Genencor International, Inc. Alkaliphilic and thermophilic microorganisms and enzymes obtained therefrom
AU2692897A (en) 1996-04-30 1997-11-19 Novo Nordisk A/S Alpha-amylase mutants
US5763385A (en) 1996-05-14 1998-06-09 Genencor International, Inc. Modified α-amylases having altered calcium binding properties
US6211134B1 (en) 1996-05-14 2001-04-03 Genecor International, Inc. Mutant α-amylase
BR9713470A (en) 1996-09-24 2000-04-11 Procter & Gamble Liquid detergents containing proteolytically enzyme and protease inhibitors
CN1231693A (en) 1996-09-26 1999-10-13 诺沃挪第克公司 An enzyme with amylase activity
WO1998026078A1 (en) 1996-12-09 1998-06-18 Genencor International, Inc. H mutant alpha-amylase enzymes
BR9808657A (en) 1997-03-07 2000-05-23 Procter & Gamble Improved methods of producing cross-linked macropolicycles
US6229678B1 (en) 1997-03-18 2001-05-08 Seagate Technology Llc Magnetoresistive read sensor
US6008026A (en) 1997-07-11 1999-12-28 Genencor International, Inc. Mutant α-amylase having introduced therein a disulfide bond
GB2327947A (en) 1997-08-02 1999-02-10 Procter & Gamble Detergent tablet
US6080568A (en) 1997-08-19 2000-06-27 Genencor International, Inc. Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis
GB9719636D0 (en) 1997-09-15 1997-11-19 Genencor Int Bv Proteases from gram-positive organisms
GB9719637D0 (en) 1997-09-15 1997-11-19 Genencor Int Bv Proteases from gram-positive organisms
DE69840577D1 (en) 1997-10-13 2009-04-02 Novozymes As MUTANTS OF alpha-AMYLASE
MA24811A1 (en) 1997-10-23 1999-12-31 Procter & Gamble WASHING COMPOSITIONS CONTAINING MULTISUBSTITUTED PROTEASE VARIANTS
AU9737398A (en) 1997-10-30 1999-05-24 Novo Nordisk A/S Alpha-amylase mutants
US5935826A (en) 1997-10-31 1999-08-10 National Starch And Chemical Investment Holding Corporation Glucoamylase converted starch derivatives and their use as emulsifying and encapsulating agents
CN101440360A (en) 1997-11-21 2009-05-27 诺沃奇梅兹有限公司 Ease variants and compositions
DK1042501T3 (en) 1997-12-24 2007-08-13 Genencor Int Method for analyzing the washability of an enzyme
GB9727471D0 (en) 1997-12-30 1998-02-25 Genencor Int Bv Proteases from gram positive organisms
GB9727464D0 (en) 1997-12-30 1998-02-25 Genencor Int Bv Proteases from gram positive organisms
CA2320759A1 (en) 1998-02-18 1999-08-26 Novo Nordisk A/S Alkaline bacillus amylase
DK1066374T3 (en) 1998-02-27 2006-09-18 Novozymes As Amylolytic enzyme variants
DK2305799T3 (en) 1998-02-27 2016-07-25 Novozymes As Maltogenic alpha-amylase variants
AU2612499A (en) 1998-03-09 1999-09-27 Novo Nordisk A/S Enzymatic preparation of glucose syrup from starch
EP2287318B1 (en) 1998-06-10 2014-01-22 Novozymes A/S Mannanases
US6376450B1 (en) 1998-10-23 2002-04-23 Chanchal Kumar Ghosh Cleaning compositions containing multiply-substituted protease variants
US6197565B1 (en) 1998-11-16 2001-03-06 Novo-Nordisk A/S α-Amylase variants
CA2348893A1 (en) 1998-11-30 2000-06-08 The Procter & Gamble Company Process for preparing cross-bridged tetraaza macrocycles
ATE428773T1 (en) * 1998-12-18 2009-05-15 Novozymes As SUBTILASE ENZYMES OF THE I-S2 SUBGROUP, WITH AN ADDITIONAL AMINO ACID RESIDUE IN AN ACTIVE LOOP REGION
BRPI0009362B8 (en) 1999-03-30 2019-08-20 Novozymes As variant of a precursor alpha amylase, and use of an alpha amylase variant
EP2889375B1 (en) 1999-03-31 2019-03-20 Novozymes A/S Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
WO2000060058A2 (en) 1999-03-31 2000-10-12 Novozymes A/S Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
CN1240832C (en) 1999-08-20 2006-02-08 诺维信公司 Alkaline bacillus amylase
EP1230351A1 (en) 1999-11-10 2002-08-14 Novozymes A/S Fungamyl-like alpha-amylase variants
AU3724801A (en) 2000-03-03 2001-09-12 Novozymes A/S Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
CN101532001A (en) 2000-03-08 2009-09-16 诺维信公司 Variants with altered properties
WO2001088107A2 (en) 2000-05-12 2001-11-22 Novozymes A/S Alpha-amylase variants with altered 1,6-activity
WO2001096537A2 (en) 2000-06-14 2001-12-20 Novozymes A/S Pre-oxidized alpha-amylase
JP4855632B2 (en) 2000-08-01 2012-01-18 ノボザイムス アクティーゼルスカブ Α-Amylase mutants with altered properties
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
AU2002210380A1 (en) 2000-10-13 2002-04-22 Novozymes A/S Alpha-amylase variant with altered properties
EP2264160A3 (en) 2001-05-15 2011-08-31 Novozymes A/S Alpha-amylase variant with altered properties
GB0114847D0 (en) 2001-06-18 2001-08-08 Unilever Plc Water soluble package and liquid contents thereof
DK200101090A (en) * 2001-07-12 2001-08-16 Novozymes As Subtilase variants
EP1576152B1 (en) 2002-12-17 2006-12-06 Novozymes A/S Thermostable alpha-amylases
CN1768137A (en) * 2003-01-30 2006-05-03 诺和酶股份有限公司 Novel subtilases
US7449318B2 (en) 2003-04-30 2008-11-11 Danisco A/S, Genencor Division Bacillus mHKcel cellulase
EP1479755B1 (en) 2003-05-23 2008-02-27 The Procter & Gamble Company Cleaning composition for use in a laundry or dishwashing machine
WO2005001064A2 (en) 2003-06-25 2005-01-06 Novozymes A/S Polypeptides having alpha-amylase activity and polypeptides encoding same
WO2005003311A2 (en) 2003-06-25 2005-01-13 Novozymes A/S Enzymes for starch processing
ES2425351T3 (en) 2003-06-25 2013-10-14 Novozymes A/S Polypeptides that have alpha-amylase activity and polynucleotides that encode them
EP1657981A1 (en) 2003-08-22 2006-05-24 Novozymes A/S Process for preparing a dough comprising a starch-degrading glucogenic exo-amylase of family 13
EP1664285A2 (en) 2003-08-22 2006-06-07 Novozymes A/S Fungal alpha-amylase variants
JP4843497B2 (en) 2003-11-06 2011-12-21 ジェネンコー・インターナショナル・インク Bacterial expression of protease inhibitors and their variants
US7754460B2 (en) 2003-12-03 2010-07-13 Danisco Us Inc. Enzyme for the production of long chain peracid
EP2295554B1 (en) 2003-12-03 2012-11-28 Danisco US Inc. Perhydrolase
CN1902315B (en) 2003-12-03 2012-05-02 明治制果药业株式会社 Endoglucanase STCE and cellulase preparation containing the same
ES2539955T3 (en) 2003-12-08 2015-07-07 Meiji Seika Pharma Co., Ltd. Surfactant-tolerant cellulase and its modification procedure
US7666650B2 (en) 2004-01-08 2010-02-23 Novozymes A/S Amylase
CA2571864C (en) 2004-07-05 2014-09-23 Novozymes A/S Alpha-amylase variants with altered properties
CA2575878A1 (en) 2004-08-02 2006-02-09 Novozymes A/S Creation of diversity in polypeptides
CA2575875A1 (en) 2004-08-02 2006-02-09 Novozymes A/S Maltogenic alpha-amylase variants
CN102919273B (en) 2004-09-10 2016-03-16 诺维信北美公司 Prevent, remove, reduce or the method for disrupting biofilm
US7659101B2 (en) 2004-12-15 2010-02-09 Novozymes A/S Alkaline Bacillus amylase
JP2008523830A (en) 2004-12-22 2008-07-10 ノボザイムス アクティーゼルスカブ Hybrid enzyme
US20090275078A1 (en) 2004-12-23 2009-11-05 Novozymes A/S Alpha-Amylase Variants
JP2008546396A (en) 2005-06-24 2008-12-25 ノボザイムス アクティーゼルスカブ Amylase for pharmaceutical use
CN101243182B (en) * 2005-08-16 2014-08-06 诺维信公司 Subtilases
AR055444A1 (en) 2005-10-12 2007-08-22 Procter & Gamble USE AND PRODUCTION OF NEUTRAL METALOPRETASE STABLE TO STORAGE
JP4627086B2 (en) * 2005-10-21 2011-02-09 株式会社島津製作所 Protein or peptide C-terminal modification method, C-terminal immobilization method, and analysis method
MX2008011092A (en) 2006-03-02 2008-09-10 Genencor Int Surface active bleach and dynamic ph.
CA2652678A1 (en) 2006-06-05 2007-12-21 The Procter & Gamble Company Detergent compositions comprising polysaccharides as enzyme stabilizers
WO2008000825A1 (en) 2006-06-30 2008-01-03 Novozymes A/S Bacterial alpha-amylase variants
NZ573467A (en) 2006-07-18 2012-02-24 Danisco Us Inc Genencor Div Subtilisin variants active over a broad temperature range
US8097444B2 (en) 2006-12-21 2012-01-17 Danisco Us Inc. Compositions and uses for an alpha-amylase polypeptide of bacillus species 195
EP2121910A1 (en) 2007-02-01 2009-11-25 Novozymes A/S Alpha-amylase and its use
US8021863B2 (en) 2007-02-19 2011-09-20 Novozymes A/S Polypeptides with starch debranching activity
US20100151542A1 (en) 2007-02-27 2010-06-17 Mcauliffe Joseph C Cleaning Enzymes and Fragrance Production
CN102604753A (en) 2007-02-27 2012-07-25 丹尼斯科美国公司 Cleaning enzymes and malodor prevention
DE102007011236A1 (en) 2007-03-06 2008-09-11 Henkel Ag & Co. Kgaa Carboxyl-bearing benzophenone or benzoic acid anilide derivatives as enzyme stabilizers
RU2009137386A (en) 2007-03-09 2011-04-20 ДАНИСКО ЮЭс ИНК., ДЖЕНЕНКОР ДИВИЖН (US) AMILASE VARIANTS OF BACILLUS ALKALYPHIC SPECIES, COMPOSITIONS CONTAINING AMILASE OPTIONS AND METHODS OF APPLICATION
DK2205731T3 (en) 2007-10-31 2013-03-11 Danisco Us Inc Use and preparation of citrate-stable, neutral metalloproteases
MX2010004326A (en) 2007-11-01 2010-05-20 Danisco Us Inc Production of thermolysin and variants thereof and use in liquid detergents.
EP2215201A2 (en) 2007-11-05 2010-08-11 Danisco US Inc. Alpha-amylase variants with altered properties
AU2008325250B2 (en) 2007-11-05 2013-06-13 Danisco Us Inc. Variants of Bacillus sp. TS-23 alpha-amylase with altered properties
CA2713582C (en) 2008-02-04 2017-02-21 Danisco Us Inc. Ts23 alpha-amylase variants with altered properties
US20090209447A1 (en) * 2008-02-15 2009-08-20 Michelle Meek Cleaning compositions
EP2100947A1 (en) 2008-03-14 2009-09-16 The Procter and Gamble Company Automatic dishwashing detergent composition
RU2510662C2 (en) 2008-03-26 2014-04-10 Новозимс А/С Stabilised liquid enzyme compositions
WO2009140504A1 (en) 2008-05-16 2009-11-19 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
RU2541786C2 (en) 2008-06-06 2015-02-20 ДАНИСКО ЮЭс ИНК. Compositions and methods including versions of microbial proteases
PL2297313T3 (en) 2008-06-06 2015-08-31 Danisco Us Inc Variant alpha-amylases from bacillus subtilis and methods of use, thereof
BR122013014156A2 (en) 2008-11-11 2015-07-14 Danisco Us Inc Cleaning composition comprising subtilisin variants as well as cleaning process
AR074311A1 (en) 2008-11-11 2011-01-05 Danisco Us Inc BACILLUS ISOLATED SUBTILISIN VARIANTS, WITH PROTEOLITICAL ACTIVITY
CA2742992A1 (en) 2008-11-11 2010-05-20 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
CN102209776B (en) 2008-11-13 2013-11-27 诺维信公司 Detergent composition
US20100122864A1 (en) 2008-11-17 2010-05-20 Allan Rosman Hybrid hydraulic drive system for all terrestrial vehicles, with the hydraulic accumulator as the vehicle chassis
EP2857515B1 (en) 2008-11-20 2018-02-21 Novozymes Inc. Polypeptides having amylolytic enhancing activity and polynucleotides encoding same
WO2010088447A1 (en) 2009-01-30 2010-08-05 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2010091221A1 (en) 2009-02-06 2010-08-12 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
BRPI1009263A2 (en) 2009-03-10 2015-10-06 Danisco Us Inc alpha-amylases related to bacillus megaterium dsm90 strain and methods of their use.
US8852912B2 (en) 2009-04-01 2014-10-07 Danisco Us Inc. Compositions and methods comprising alpha-amylase variants with altered properties
US8877479B2 (en) 2009-04-08 2014-11-04 Danisco Us Inc. Halomonas strain WDG195-related alpha-amylases, and methods of use, thereof
EP2279804A1 (en) 2009-07-28 2011-02-02 Koninklijke Philips Electronics N.V. Washing and sterilizing unit
US20120149625A1 (en) 2009-09-25 2012-06-14 Novozymes A/S Detergent Composition
EP4159833A3 (en) * 2009-12-09 2023-07-26 The Procter & Gamble Company Fabric and home care products
EP2510094B1 (en) 2009-12-09 2016-11-30 Danisco US Inc. Compositions and methods comprising protease variants
US20130071913A1 (en) 2009-12-22 2013-03-21 Novozymes A/S Use of amylase variants at low temperature
WO2011087836A2 (en) 2009-12-22 2011-07-21 Novozymes A/S Pullulanase variants and uses thereof
EP2521774B1 (en) 2010-01-04 2016-07-27 Novozymes A/S Alpha-amylase variants with improved stability
CN105039284B (en) 2010-02-10 2021-04-13 诺维信公司 Variants and compositions comprising variants with high stability in the presence of chelating agents
HUE034524T2 (en) 2010-05-06 2018-02-28 Procter & Gamble Consumer products with protease variants
DK2705146T3 (en) 2011-05-05 2019-03-04 Danisco Us Inc COMPOSITIONS AND PROCEDURES INCLUDING SERINE PROTEASE VARIABLES
BR112013028440A2 (en) * 2011-05-05 2016-11-29 Procter & Gamble compositions and methods comprising serine protease variants
CN103649292B (en) 2011-07-01 2017-11-28 诺维信公司 Stabilized subtilisin composition
EP2726590B1 (en) 2011-07-01 2017-10-18 Novozymes A/S Liquid detergent composition
AU2012328562A1 (en) 2011-10-28 2014-03-13 Danisco Us Inc. Variant maltohexaose-forming alpha-amylase variants
WO2013086219A1 (en) 2011-12-09 2013-06-13 Danisco Us Inc. Ribosomal promotors from b. subtilis for protein production in microorganisms
EP2814956B1 (en) * 2012-02-17 2017-05-10 Novozymes A/S Subtilisin variants and polynucleotides encoding same
HUE057894T2 (en) 2012-06-08 2022-06-28 Danisco Us Inc Variant alpha amylases with enhanced activity on starch polymers
EP2906691B1 (en) 2012-10-12 2021-01-27 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
BR112015010104A2 (en) 2012-11-05 2017-08-22 Danisco Us Inc THERMOLYSIN ENZYME VARIANT, COMPOSITION AND CLEANING METHOD
EP2935575B1 (en) 2012-12-21 2018-04-18 Danisco US Inc. Alpha-amylase variants
EP2970931B1 (en) 2013-03-11 2017-12-06 Danisco US Inc. Alpha-amylase combinatorial variants
EP3260538B1 (en) 2013-05-29 2021-04-14 Danisco US Inc. Novel metalloproteases
US20160160202A1 (en) 2013-05-29 2016-06-09 Danisco Us Inc. Novel metalloproteases
JP2016526880A (en) 2013-05-29 2016-09-08 ダニスコ・ユーエス・インク Novel metalloprotease
EP3004342B1 (en) 2013-05-29 2023-01-11 Danisco US Inc. Novel metalloproteases
MX371497B (en) 2013-07-19 2020-01-31 Danisco Us Inc Compositions and methods comprising a lipolytic enzyme variant.
EP3653707A1 (en) 2013-09-12 2020-05-20 Danisco US Inc. Compositions and methods comprising lg12-clade protease variants
JP6560214B2 (en) 2013-11-20 2019-08-14 ダニスコ・ユーエス・インク Mutant α-amylase with reduced sensitivity to protease cleavage and method of use thereof
EP3080262B1 (en) 2013-12-13 2019-02-06 Danisco US Inc. Serine proteases of bacillus species
DK3553173T3 (en) * 2013-12-13 2021-08-23 Danisco Us Inc SERINE PROTEASES OF BACILLUS GIBSONII-CLADE
US10550381B2 (en) * 2014-07-04 2020-02-04 Novozymes A/S Variant proteases and amylases having enhanced storage stability
CN107072250A (en) 2014-07-11 2017-08-18 丹尼斯科美国公司 Series bacillus and Bacillus spec mannase
US20180002642A1 (en) * 2014-10-27 2018-01-04 Danisco Us Inc. Serine proteases
EP3310913A1 (en) 2015-06-17 2018-04-25 Danisco US Inc. Proteases with modified propeptide regions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008165A1 (en) * 1987-04-06 1988-10-20 Genex Corporation Computer based method for protein engineering
WO2016001450A2 (en) * 2014-07-04 2016-01-07 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016205755A1 (en) * 2015-06-17 2016-12-22 Danisco Us Inc. Bacillus gibsonii-clade serine proteases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS registry [online] 20 October 1988 (1988-10-20), PANTOLIANO MICHAEL: "Subtilisin (Bacillus amyloliquefaciens strain ATCC 23844), 22-L-cysteine-87-L-cysteine", XP055837681, Database accession no. 121479729 *
See also references of WO2018118917A1 *

Also Published As

Publication number Publication date
US20230257728A1 (en) 2023-08-17
CN110312795B (en) 2024-07-23
WO2018118917A1 (en) 2018-06-28
CN110312795A (en) 2019-10-08
US20200392477A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
US20230257728A1 (en) Protease variants and uses thereof
US20240368573A1 (en) Bacillus gibsonii-clade serine proteases
US11946081B2 (en) Bacillus gibsonii-clade serine proteases
US11661567B2 (en) Protease variants and uses thereof
EP3212780B1 (en) Serine protease
EP3212781B1 (en) Serine proteases
US20180010074A1 (en) Serine proteases of bacillus species
US20240182880A1 (en) Protease variants and uses thereof
US20210087546A1 (en) Protease variants and uses thereof
US12146122B2 (en) Protease variants and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190627

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210923

B565 Issuance of search results under rule 164(2) epc

Effective date: 20210923

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/54 20060101ALI20210920BHEP

Ipc: C12N 9/64 20060101AFI20210920BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANISCO US INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240913